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BACKGROUND. Prostatic secretory protein of 94 amino acids (PSP94), also called p_ 
microseminoprotein, is a small and non-glycosylated protein, rich in cysteine residues. It 
was first isolated as a major protein from the human seminal plasma. Subsequently, its 
homologous proteins were identified and also their cDNAs or genes have been cloned in 
primates, pig and rodents. 
METHODS. The present study investigated the expression of PSP94 in the normal 
Noble rat prostate gland by non-radioactive in-situ hybridization, Northern blotting, RT-
PCR, Westem blotting and immunohistochemistry. The hormonal regulation ofPSP94 is 
also investigated by in-situ hybridization and semi-quantitative RT-PCR assay. Probasin 
and SVSII (seminal vesicle secretion II) are two major secretory proteins specifically 
expressed in and synthesised by the lateral lobe (LP) of rat prostate gland. For 
comparison, both probasin and SVSII transcripts are also investigated in parallel with 
PSP94. Their gene expressions in the premalignant dysplastic lesions (or prostatic 
intraepithelial neoplasia) induced in the rat lateral prostate by combined androgen and 
estrogen treatments, and in two rat prostatic tumors (an androgen-dependent Dunning 
tumor line, R3327-H and an androgen-independent tumor, AIT, which was derived 
originally from an estrone-treated Noble rat) were also studied by in-situ hybridization 
and RT-PCR. 
RESULTS. The results of in-situ hybridization, Northern and Westem blot analyses 
showed that the expression of rat PSP94 was highly prostate-specific. It was intensely 
expressed in the lateral prostatic lobe, moderately in the dorsal lobe, weakly in the 
coagulating gland but negative in the ventral lobe and seminal vesicle. Its specific 
expression in the rat prostate gland was further confirmed by RT-PCR analysis of 
prostatic and non-prostatic organ tissues. Its mRNA transcripts were not detected in the 
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urinary, digestive and respiratory tracts, male and female reproductive organs, muscles, 
brain and kidney. Its molecular mass was estimated to be 14.5 kDa by Westem blotting. 
By in-situ hybridization, the hybridization signals of PSP94 and probasin in the lateral 
prostate were significantly weakened after 30 days post-castration and became 
completely lost in 60-days post-castration. For SVSII, its mRNA signals became totally 
lost after 14 days post-castration. Androgen replacement for 3 weeks to the castrated rats 
could restore the hybridization signals of all three proteins to normal intact levels. By 
semi-quantitative RT-PCR assays, significant drops of PSP94 mRNA expression were 
observed after 30 and 60 days post-castration. There was no significant decrease in the 
probasin transcripts following 60 days of castration. For SVSII, its mRNA expression 
dropped significantly after 14 days post-castration. Besides androgen, treatments with 
synthetic glucocorticoid (DEX) and synthetic progestin (MPA) to the castrated rats could 
increase significantly the mRNA expression of PSP94 and probasin. However, only the 
androgen treatment but not other steroids could increase the mRNA expression of SVSII. 
The hybridization signals of these three secretory proteins became reduced in the 
epithelial cells in the low-grade PIN and became lost or significantly weakened in the 
high-grade PIN in the lateral prostate. No hybridization signals of PSP94, probasin and 
SVSII were detected in both Dunning R3327-H and AIT tumors. By RT-PCR, a new and 
smaller form ofPCR product ofPSP94 was detected in both Dunning R3327-H and AIT 
tumors. The probasin mRNA was expressed weakly in Dunning R3327-H and absent in 
AIT. For SVSII, its mRNA was weakly expressed in both Dunning R3327-H and AIT 
tumors. 
CONCLUSIONS. The present study shows that rat PSP94 is a secretory protein highly 
expressed and mainly synthesised by the lateral lobe of rat prostate gland, moderately 
expressed in the dorsal lobe. The lobe-specific expressions ofPSP94, probasin and SVSII 
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in the normal rat prostate is dependent on androgen. Comparing their responsiveness to 
castration, SVSII is the most sensitive protein to androgen withdrawal than PSP94 and 
probasin. Besides androgen, glucocorticoid and progesterone can also up-regulate the 
mRNA expression of PSP94 and probasin in the castrates. SVSII is solely regulated by 
androgen. Their expression became reduced in the low- and high-grade PIK and lost in 
two rat prostate tumors, suggesting that these secretory proteins were down-regulated or 
dys-regulated during the malignant transformation of the prostate gland. 
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摘 要 
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Chapter 1: Introduction 
1.1 Prostatic Secretory Proteins 
The contents of secretion of the prostate gland are variable among species. In 
most mammals, the prostatic secretion is a slightly acidic (pH 6.5) and colorless fluid 
devoid ofreducing sugars. It is rich in citric acid and is the main source ofZn�+ and Ca^^ 
ions in the semen. The protein content is less than 1% in man and contains all the amino 
acids. Several secretory proteins of the prostate gland have been identified in many 
mammals and studied in considerable detail. Some of them are currently being used as 
markers to monitor hormonal regulation of gene expression [Shivaji et al., 1989]. In this 
Chapter, I am going to review the secretory proteins ofthe rat and human prostate glands. 
Some of the secretory proteins in human prostate, which are being used as diagnostic 
markers for human prostatic cancer [Gao et al., 1997], will also be reviewed. 
1.2 Rat Prostatic Secretory Proteins 
The rat prostate gland develops from the embryonic urogenital sinus in response 
to androgens and is composed of discrete lobes at sexual maturity. The rat prostate gland 
consists ofpaired (defined as right and left) subdivisions or lobes: ventral prostate (VP), 
lateral prostate (LP), dorsal prostate (DP) and the coagulating gland, which is sometimes 
referred to as the anterior prostate. Similar to other male accessory sex glands, the rat 
prostate gland complex secretes a variety of substances, which enter the urethra to form 
the prostatic portion of the semen during ejaculation. In spite of their common 
developmental origin and similarity in glandular structure, these lobes show different 
biochemical characteristics. The diverse nature and specificity of these secretory products 
illustrates the biochemical heterogeneity among prostate lobes. For example, the rat 
dorsal prostate and coagulating gland are the major sites of fructose secretions. The 
ventral prostate secretes high amounts of citrate, spermine and spermidine, and a specific 
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protein, referred to as prostatic binding protein (PBP) or prostatein. The lateral prostate is 
the only major zinc-secreting portion of the rat prostate [Wilson and French, 1980]. 
1.2.1 Prostatic Secretory Proteins in Ventral Prostate 
1.2.1.1 Prostatic Binding Protein (PBP) 
Heyns and colleagues [Heyns et al., 1976; Heyns and DeMoor, 1977] have 
isolated a steroid-binding protein, naming it as "prostatic binding protein" (PBP), from 
the cytosol of rat prostate. This protein is shown to bind to 5a-dihydrotestosterone, 
testosterone, androstenedione, epitestosterone, pre-5-en-3-P-ol-20-one, progesterone, 
cholesterol and other steroids, indicating that its binding to steroids is non-specific, with a 
slight preference for non-polar steroids. The binding activity of PBP increases on 
delipidation and the bound steroid remains unmetabolized. PBP is shown to lose its 
steroid-binding activity when treated with trypsin, but not with ribonuclease or 
deoxyribonuclease [Heyns and DeMoor, 1977]. Immunochemical measurements of PBP 
using a monospecific antiserum indicated that this protein is specific to prostate and 
constitutes 50% of the prostatic cytosol protein [Heyns, 1977]. This protein is shown to 
be a secretory protein of the prostate since the prostatic fluid binds as much steroid as the 
prostatic cytosol. 
Prostatic binding protein is the first steroid-binding protein isolated from and 
characterized in the rat ventral prostate cytosol [Heyns et al., 1976; Heyns and DeMoor, 
1977]. Subsequently, proteins with similar steroid-binding properties have been isolated 
from the rat prostate. They were designated "prostatein" [Lea et al., 1979], prostate a -
protein [Chen et al., 1982; Liao et al., 1982], and a protein that bind steroid [Forsgren et 
a l , 1979]. All these three proteins isolated by different groups appear to be identical to 
PBP in regard to their molecular weight, isoelectric point, subunit structure (including the 
components in each subunit), glycosylation, steroid-binding capacity, and presence in the 
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prostate. This protein is a tetramer which consists of two units, S and F [Heyns and 
DeMoor, 1977; Heyns et al , 1978] or A and B [Chen et a l , 1982; Lea et al., 1979], one 
containing the polypeptides C1 (or I) and C3 (or III) and the other containing the 
polypeptides C2 (or II) and C3 (or III) [Heyns et al., 1978]. The tetrameric native protein 
is a compact structure consisting of a core unit of I and II which is linked to III by 
disulfide linkage [Chen et al., 1982]. Moreover, pure prostatein dimer binds steroid with 
affinity inversely related to steroid polarity: progesterone> androstenedione> 
dihydrotestosterone> androsterone> estradiol> testosterone> hydrocortisone. Binding of 
dihydrotestosterone to the monomer is only 1/15 of the dimer. Specific antisera to 
prostatein dimer and monomer have been raised in rabbits. Quantitation by rocket 
immunoelectrophoresis of cytosol extraction from various organs shows that prostatein is 
present only in ventral prostate, with a concentration of 25 to 30% of total soluble 
proteins. Immunohistochemical localization in ventral prostate has shown that prostatein 
is localized to the epithelial cells and secretions in the glandular lumen [Lea et al., 1979]. 
Because of its abundant production in the ventral prostate, prostatein/PBP is 
useful for the studies on androgen regulation of its mRNA synthesis and translation, and 
for the investigation of secretory processes in prostate epithelial cells. Castration can 
decrease the content of PBP in the rat ventral prostate. This effect can be reversed by the 
administration of androgen, implying that PBP synthesis is under androgen control 
[Heyns et al., 1977]. This control probably functions at the level of availability of mRNA 
specific for PBP since it was observed that the total RNA from rat ventral prostate, when 
translated in a wheat germ cell-free system, can yield translation products, 30% of which 
could be immunoprecipitated with a monospecific antiserum to PBP. Moreover, when 
total RNA obtained from the ventral prostate of 6-day-castrated rats is translated, only 
3% of the newly synthesized proteins could be immunoprecipitated, indicating that the 
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levels ofPBP-specific mRNA decrease on castration [Mous et al., 1977]. Administration 
of androgens to the castrated rats for 3 days can lead to a partial recovery of PBP 
synthesis. In an identical study, using poly A+ RNA from ventral prostate instead of the 
total RNA, Peeters and colleagues [Peeters et al., 1980] have shown that the mRNA 
activity related to PBP synthesis decrease from 54 to 16% of the total mRNA activity 
after 6 days of castration. However, its level increases to 42% after androgen treatment 
for 3 days. This further confirms that the synthesis and/or activity of PBP mRNA are 
under androgen control. 
Parker et al. [1980] later confirmed that androgen regulates the synthesis of PBP 
by controlling the synthesis of corresponding mRNA. The subunits of this tetrameric 
protein are encoded by three separate genes, all of which are androgen dependent for 
their expression [Parker et al., 1978]. 
The regulation by androgens of the synthesis of PBP was studied by measuring 
the rate of incorporation of [^]-leucine into total proteins and into PBP by prostatic 
tissue in vitro [Bossyns et al., 1986]; PBP-specific synthesis drops to 30% of the intact 
level after 3 days and 5.5% after 7 days of castration. Administration of androgens to 7-
day-castrated rats reverses these changes: 36% of the control value is reached after 3 days 
of treatment and 70% after 5 days. The mRNA of PBP is measured under similar 
conditions by dot-blot hybridization, using C1-, C2-, and C3-specific cDNA clones ofrat 
PBP. The three mRNAs followed a parallel course. They decrease to about 18% on the 
third day after castration and to about 2% after 7 days. Androgen treatment of 7 day-
castrated rats produces a small increase over these levels after 1 day. After three days, 
150/0 of the intact level is reached. The general similarity of the time course of PBP 
synthesis and PBP mRNA levels in castrated and androgen treated rat supports that it is 
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regulated by androgen at level of transcription, although there is also evidence for an 
influence by androgen on the level of protein synthesis. 
The androgen response elements (AREs) in the promoter region of the rat prostate 
C3 gene have been characterized [Parker et al., 1987; Claessens et al., 1989; Zhang et al., 
1990; Claessens et al., 1990; Tan et al., 1992]. Some proteins, such as octamer 
transcription factor 1 (0TF-1) and nuclear factor I (NF-I), can interact with androgen 
response elements in the C3 gene [Vos et al., 1991; Celis et al., 1993]. Besides androgen, 
the PBP-C1 mRNA is upregulated by progesterone [Pelletier et a l , 1988] and the PBP-
C3 mRNA level is also upregulated by the synthetic progestins [Labrie et al., 1990]. 
Takeda et al. [1990] reported that the transcription o fPBP gene is induced by epithelial-
mesenchymal interaction. The results indicate that the ventral prostate mesenchyme is a 
potent inducer for ventral prostate cytodifferentiation including the secretory activity of 
PBP. 
On the other hands, some reports showed that the C3 component of prostatic 
binding protein (C3) is synthesized in vivo under androgen control in the lacrimal gland 
and ventral prostate of adult male rat [Windericjx et al., 1990; Aumuller et al., 1995]. 
Vanaken et al. [1996] reported that addition ofandrogens to the culture medium results in 
the synthesis and secretions of C3 component ofPBP in a time- and dose-dependent way. 
They also showed that a synthetic glucocorticoid, dexamethasone, seems to play a similar 
role as androgens in C3 regulation. Moreover, the expression of the C3 component of 
prostatic binding protein (PBP) during postnatal development of the rat prostate was 
studied by Northern blotting, dot blot, in situ hybridization, radioimmunoassay and 
immunoblotting. In male intact rats, very little or no PBP-C3 is detected in the prostate at 
10 days, but its expression becomes strong at 20 days. By in situ hybridization, the first 
expression of C3 mRNA is observed at 13 days in the prostate and at 22 days in the 
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lacrimal gland. Androgen treatment of intact male animals can advance the expression of 
PBP-C3 in the prostate at day 22 and in the lacrimal gland at day 19 [Vercaeren et al., 
1998]. 
The function ofprostatein in seminal fluid remains unclear. Immunocytochemical 
studies indicate that it binds to the plasma membrane of spermatozoa. Recently, Maccioni 
et al. [1998] have purified one of the prostatic autoantigens which can be recognized by 
the autoantibodies developed in an experimental model of autoimmune prostatitis (EAP). 
Amino acid sequence analysis has confirmed that the purified prostatein or prostatic 
binding protein belongs to a member of the uteroglobin superfamily. Prostatein is 
recognized not only by the human autoimmune response, but also by the cellular 
autoimmune response. Prostatein is not only the target of the autoimmune response in 
animals immunized with the whole extract, but also an inducing antigen of the disease. 
Purified prostatein, when incorporated to an adequate adjuvant, can elicit cellular and 
humoral autoimmune response and lesion in the prostate gland. 
Interestingly, lipophilin components A, B and C are shown to be the human 
homologues of the rat prostatein. The gene for lipophilin C (also called mammaglobin b) 
is located on chromosome l lql2-ql3.1 near the mammaglobin gene, a homologue 
overexpressed in many breast cancers. The lipophilin B gene resides on chromosome 
10q23, a region deleted in many tumors, and the lipophilin A gene is on chromosome 
15ql2-ql3 [Lehrer et al., 1998; Zhao et al., 1999]. 
1.2.1.2 Androgen-Suppressed Proteins ofRat Ventral Prostate 
In castrated rats, administration of androgens is known to increase the levels of 
mRNA of androgen-dependent proteins in the ventral prostate, such as PBP [Parker et al., 
1980; Peeters et al., 1980]. Parallel to these changes, the levels of mRNA for certain 
other proteins are also suppressed. In vitro translation of mRNA from ventral prostate of 
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castrated rat also shows a reduction in the level of PBP on castration. On the other hand, 
a dramatic increase in translated proteins o f M W 29,000, 37,000, 46,000 and 49,000 was 
observed within a day of castration; with the increase ranging from 4-fold for the 45-kD 
protein to 12-fold for the 37-kD protein [Saltzman et al., 1987]. Leger et al. [1987] also 
observed similar changes in the castrated ventral prostate in a dot blot analysis using a 
cDNA probe for the mRNA of the 29-kD protein, it reveals that the mRNA specific to 
this protein increase by 10-fold after 2 days of castration. This increase was not observed 
after administration of androgen, 5a-dihydrotestosterone [Saltzman et al., 1987]. 
Pervious studies using two dimensional-electrophoresis o f the rat ventral prostate 
fluid also indicate that the levels of several proteins increase in castrated rat and decrease 
after androgen treatment [Anderson et al., 1983]. However, it is not established whether 
these changes are at the level of the mRNA or translation. Rennie et al. [1984] showed 
that the level of plasminogen activator in the rat ventral prostate increases 10-fold 7 days 
after castration and DHT treatment can reduce the activity. It is known that the levels of 
two classes of mRNAs (1 and 2 kb long) increase following castration, but this increase 
occurs only after 8 and 4 days of castration, respectively. This means that the 29-kD 
protein, which increases to peak levels on 2-3 days after castration, is not coded by any of 
the above two RNAs and is a different protein that is suppressed by androgens. 
A protein o f M W 46,000 and pI 5.9-6.3，named "TRPM-2" also shows increased 
levels in the rat ventral prostate following castration and it reaches a maximum level at 6 
days after castration [Leger et al., 1987]. The gene for this protein is not expressed in 
other organs. The cellular function of these androgen-suppressed proteins is unknown; 
they may be involved in the regulation of the growth and function of the prostate 
following castration. 
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1.2.1.3 The 20-kDa Protein 
Besides PBP, another protein of molecular weight 20-kDa has been isolated and 
characterized from the cytosol of the rat ventral prostate by ammonium sulfate 
precipitation, DNA-cellulose chromatography and gel filtration [Chamberlin et al., 1983]. 
This protein is probably identical to another protein, named as "a-protein", isolated 
earlier by Parker and coworkers [Parker et al., 1978]. Besides PBP, 20-kDa protein is one 
of the major proteins in the rat ventral prostate, constituting 5-8% of the total tissue 
protein [Parker et al., 1978]. It is a glycoprotein and contains hexose (11% by weight) but 
no fucose, hexosamine, or sialic acid [Parker et al., 1978; Chamberlin et al., 1983]. 
Amino acid composition of the 20-kDa protein indicates that it is rich in acidic amino 
acids. The size or Stokes radius of the protein is 1SA. 
The synthesis of the 20-kDa protein, like that of the three polypeptides ofPBP, is 
regulated by androgen [Parker et al., 1978]. This androgen regulation occurs at the level 
of mRNA, which decreases on castration and responds to androgen replacement [Parker 
and Scrace, 1979]. This is confirmed by using a cDNA probe specific for the mRNA of 
20-kDa protein. On withdrawal of androgen, it shows a 30-fold decrease in mRNA and 
its mRNA is restored to the original level 4 hours after administration of testosterone 
[Chamberlin et al., 1983; Parker et al., 1980]. 
Immunodiffusion studies using antibodies against the 20-kDa protein indicate that 
this protein is absent in lateral and dorsal prostates, seminal vesicles, epididymis, 
coagulating gland, spleen and kidney. It is present only in the ventral prostate and 
secretion of prostate [Chamberlin et al., 1983]. The 20-kDa protein is not a sperm-
binding protein as it does not bind to spermatozoa, and its function remains unknown. 
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1.2.1.4 Spermine-Binding Proteins 
In cell-free systems, polyamines can stimulate the activity of enzymes involved in 
the synthesis of nucleic acids and proteins. Many of these effects are mediated by the 
binding of polyamines to nucleic acids and proteins. The rat ventral prostate is rich in 
polyamines and may contain proteins that bind to polyamines [Pegg et al., 1970]. 
Attempts have been made to identify these polyamine-binding proteins in the rat ventral 
prostate by binding of the isotope-labeled spermine to cytosolic proteins [Liang et al., 
1978]. When the cytosol fraction of rat ventral prostate obtained by homogenization and 
subsequent centrifugation, is allowed to incubate with [^]-spermine followed by 
gradient centrifugation, it yields a distinct radioactive proteinaceous peak sedimenting at 
3S. This 3S-protein is most predominant in the ventral prostate. This 3S-protein is also 
detected in the cytosol fractions of rat spleen, adrenal, muscle, liver, heart and lung, but 
not in thymus, pancreas and blood serum [Liang et al., 1978]. Pure spermine-binding 
protein is identified to be a glycoprotein containing fucose, galactose, mannose and N-
acetyglucosamine. The molecular weight of the protein was estimated to be a 30 kDa by 
SDS-PAGE and gel filtration. 
This spermine-binding protein appears to be regulated by androgen since 
castration can reduce the quantity of this protein in the cytosol of rat ventral prostate 
[Liang et al., 1978]. The castration effect can be reversed by androgen replacement. 
These results were confirmed subsequently by Hiipakka et al [1984], who measured the 
levels of spermine-binding protein and immunological related proteins in the cytosol of 
rat ventral prostate, using antibodies to the spermine-binding protein. The cytosol of the 
ventral prostate of normal rats consists of three major fractions. One corresponds to the 
spermine-binding protein; the other two cross-react with antibodies to the spermine-
binding proteins. In rats castrated for 48 hours, the spermine-binding protein fraction is 
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absent while the quantity of the other cross-reacting fractions remaining unchanged. 
Injection o f D H T immediately after castration can prevent the decrease in the quantity of 
the protein. Castrated rats injected with DHT for 2 days after castration can regain the 
normal levels of spermine-binding protein with 4-5 days [Hiipakka et al., 1984]. 
The gene expression of spermine-binding protein has been investigated. The level 
o fmRNA for the spermine-binding protein in the ventral prostate of normal and castrated 
rats has been measured using ^^P-labelled cDNA for the spermine-binding protein as the 
hybridization probe. It is shown that castration reduces the level of mRNA by 80% within 
2 days. However, injection of DHT on day 2 after castration can restore the level of the 
mRNA for the spermine-binding protein to normal within 5 days. The rapid decrease in 
mRNA levels in castrated rats within 2 days is not due to a decline in the number of cells 
in the prostate since such changes manifest only after prolonged periods of castration 
[Lesser and Bruchovsky, 1973; Parker et al., 1980]. Hence, it appears that androgen 
regulates the synthesis of mRNA for secretory proteins in rat ventral prostate. 
However, the physiological function of this protein is unknown. Spermine-
binding protein is shown to serve as a substrate in vitro for a protease from rat ventral 
prostate. However, this proteolysis can be inhibited by spermine. Spermine also 
stimulates the phosphorylation of the spermine-binding protein [Goueli et al., 1985] and 
the phosphorylated protein can bind more spermine than the unphosphorylated species 
[Liang et al.，1978]. All these processes related to spermine-binding protein are under 
androgen control. Therefore, this protein can serve as a convenient marker for the study 
of androgen action in rat prostate. 
1.2.1.5 Prostatic Acid Phosphatase (PAP) 
The rat ventral prostate contains two different types of acid phosphatase (AP), a 
lysosomal enzyme and a secretory one. The secretory enzyme is called prostatic acid 
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phosphatase (PAP) due to its tissue specificity [Solin et al., 1990]. Contrariwise, 
lysosomal acid phosphatase is distributed throughout the tissues [Helminen et al., 1975; 
Solin et al., 1990]. Moreover, the secretory form ofacid phosphatase in the rat prostate is 
regulated by androgen, as the enzyme disappears after castration and reappears after 
androgen treatment [Helminen et al., 1975; Tenniswood et al., 1978]. In contrast, the 
lysosomal enzyme does not seem to be directly androgen regulated [Tenniswood et al., 
1976]. Furthermore, the three dimensional structure of rat prostatic acid phosphatase and 
the active site of the enzyme has been studied [Schneider et al., 1993; Porvari et a l , 
1994]. 
The primary structure of rat secretory acid phosphatase has also been studied 
[Roiko et al., 1990]. The deduced Mr of the mature rat PAP is 40,599. RNA blot analysis 
indicates the presence of three mRNA species (4.9, 2.3 and 1.5 kb in size) in the rat 
prostate. The deduced amino acid sequences of rat PAP and human PAP show 75% 
identity, whereas the similarity between rat PAP and human lysosomal acid phosphatase 
is only 45%. Furthermore, the sequence similarity between rat PAP and rat lysosomal 
acid phosphatase is 46% at amino acid level. Similar to human PAP, the rat PAP 
sequence lacks a membrane-anchoring domain indicating the secretory character of this 
phosphatase. The promoters of human and rat PAP genes have also been compared 
[Virkkunen et al., 1994]. The report showed that five putative androgen response 
elements are localized in both the human and rat PAP genes, one of which is conserved in 
location and sequence between the two genes. Two of these elements in both genes, the 
conserved one in the proximal promoter region and another one in intron 1，are shown to 
bind androgen receptor efficiently in vitro. 
Recently, the differential androgen regulation of rat PAP transcripts has been 
investigated [Porvari et al., 1995]. Steady-state levels of mRNAs encoding rat PAP are 
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measured from the rat ventral prostate after castration and testosterone replacement. The 
longest and the most abundant mRNA molecule (4.9 kb) of the rat PAP gene is quite 
resistant to the hormonal status of the prostate, whereas its medium-size transcript (2.3 
kb) and the shortest one (1.5 kb) are up-regulated by androgens. However, the prostatic 
mRNA levels of rat lysosomal acid phosphatase are shown to be not hormonal dependent. 
Only modest variation is observed in the rat lysosomal acid phosphatase transcript after 
androgen withdrawal and replacement. 
1.2.2 Prostatic Secretory Proteins in Dorsal Prostate 
Although the proteins secreted by the ventral prostate (PBP, 20-kDa and PAP) 
have been studied in great detail, there have been very few attempts to characterize the 
proteins of the dorsal lobes of the rat prostate. The ventral and dorsal prostates exhibit a 
number of differences in biochemical properties. The dorsal prostate is rich in zinc-
binding proteins. The uptake of zinc in the dorsal prostate is higher than the ventral lobe 
[Habib, 1978]. On the other hand, the activities of the enzymes, acid and alkaline 
phosphatases, are extremely low in the dorsal lobes as compared to that in the ventral 
prostate. Prostatic binding protein, which represents 50% of the rat ventral prostatic 
cytosol protein, is not a major component of the dorsal lobes [Forsgren et al., 1979; 
Heyns et al., 1978; Wilson and French, 1980]. 
1.2.2.1 Dorsal Proteins I and II (DP I and DP II) 
By SDS-PAGE electrophoresis, Wilson and French [1980] have demonstrated the 
presence of two major and a number of minor proteins in dorsal lobe secretions. They 
named the two major proteins as "dorsal proteins I and 11". Dorsal protein I (DP I) has 
been purified and accounts for 25% of the total tissue protein. It is a dimer of about 130 
kDa and consists of two identical subunits of 71 kDa each. The dimer dissociates at high 
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ionic strength and is partially reconstituted upon the removal of salt. It is glycosylated 
and highly basic (pI, 9). 
Immunological studies indicate that dorsal protein I is absent in ventral prostate, 
lateral prostate, seminal vesicles and the other organs of rats but is present in the dorsal 
lobe ofthe prostate. It is also prominent in the coagulating gland, where it appears to be a 
major protein, constituting 25% of the total soluble protein of the gland. Because ofthis, 
dorsal prostate and coagulating gland are suggested to be homologous [Wilson and 
French, 1980]. The synthesis of dorsal protein I appears to be under androgen control. It 
increases with the onset of puberty and decreases in castrated rat. Therefore, dorsal 
protein I displays an androgen dependency, which is a characteristic of secretory proteins 
of the prostate or other accessory sex glands. This protein is useful for studies on the 
androgen regulation of specific gene expression and prostatic secretory mechanism 
[Wilson and French, 1980]. 
The cDNA coding for dorsal protein 1 (DPI) was isolated by molecular cloning 
[Ho et al., 1992]. The amino acid sequence deduced from the cDNA contains sequences, 
which are identical to several DPI cyanogen bromide cleavage fragments. Northern blot 
hybridization of poly(A) RNAs isolated from intact rat dorsal prostate and coagulating 
gland reveals a predominant mRNA species of approximately 3.2 kb. Expression o f D P l 
mRNA is tissue-specific as indicated by its absence in the ventral prostate and other rat 
tissues. Its expression is androgen-dependent, as its mRNA decreases approximately 80% 
in 7 days after castration and increases rapidly following androgen replacement. Southern 
blot analysis of restriction enzyme-digested rat DNA indicated that DP 1 is encoded by a 
single gene. Moreover, there is no evidence on genomic rearrangements, which may 
account for its lack of expression in the dorsal prostate-derived rat Dunning tumor. 
Sequence comparisons revealed that DPI shares sequence identity with Factor XIIIa and 
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tissue transglutaminase, including the active center, GQCWVF, indicating that DPI is a 
member of the transglutaminase gene family. 
Dorsal protein II, unlike dorsal protein I, has not been purified. Its molecular 
weight appears to be 80,000. Its presence in the tissue is much lesser than dorsal protein 
I. Dorsal protein II is also prominent in the coagulating glands [Wilson and French, 
1980]. 
The distribution of dorsal protein I and II in the cytosol and secretory fluid differ 
markedly. Dorsal protein I comprises approximately 25% of cytosol, whereas it 
constitutes only 5% of fluid total proteins, suggesting that it may be compartmentalized 
within the cell. On the other hand, dorsal protein II represents a smaller proportion of 
predominant proteins of the fluid of coagulating gland [Wilson and French, 1980]. DP I 
and DP II are also compared by in vitro translation of total poly(A) RNA and by pulse-
chase techniques using [^^]methionine and tissue minces of coagulating gland [Bartlett 
et al., 1984]. Their results show that DP I enters a rapid secretion which is enhanced by 
the absence of core glycosylation, whereas DP II follows a slower pathway through the 
Golgi and it involves extensive glycosylation. 
Recently, immunocytochemical studies with an antibody to DP-1 reveal that its 
secretory function initiates at approximately 30 days after birth in the coagulating gland, 
the dorsal prostate, and lateral type 1 prostate. DP-1 is absent in lateral type 2 prostate. 
By Westem blotting, DP-1 is detected in the secretion of coagulating gland, lateral type 1 
prostate and dorsal prostate, but not in the ventral and lateral type 2 prostate [Hayashi et 
al., 1991; Kinbara and Cunha, 1996]. 
1.2.2.2 Seminal Vesicle Secretion II (SVSII) 
Another secretory protein, seminal vesicle secretion II (SVSII) protein has been 
identified in the dorsal prostate by molecular cloning [Dodd et al., 1983]. The androgen 
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dependence of a highly abundant mRNA found in the rat dorsolateral prostate and 
seminal vesicles has been investigated using a cDNA clone obtained from a rat dorsal 
prostate library. The 1.5 kb mRNA codes for a 52 kDa translation product and is 
processed to 49 kDa protein in the presence of microsomal membrane. This product 
appears to correspond to a previously described seminal vesicle protein II (SVSII), 
secreted by the rat seminal vesicles. This SVSII protein isolated from dorsal prostate can 
be immunoprecipitated with an anti-SVSII antiserum. Dot blot hybridization assay shows 
that its mRNA is abundant in the dorsal and lateral prostate glands and in seminal 
vesicles but not in the ventral prostate, coagulating gland or the non-accessory sex tissue. 
Castration ofmature rats can reduce the 1.5 kb mRNA 10-fold in the seminal vesicles and 
7-fold in the dorsolateral prostate in 9 days. Androgen administration to one-week 
castrates can restore the mRNA level to normal in both tissues within 48 hours. The 
levels of the 1.5 kb mRNA are very similar in the dorsolateral prostate and seminal 
vesicles at maturity. A distinct pattern of developmental regulation of this gene has been 
observed in these two tissues. Between 3 and 6 weeks of age, the level of the 1.5 kb 
mRNA increases approximately 3-fold in the dorsolateral prostate while the increase in 
the seminal vesicles is more than 600-fold [Dodd et al.，1986]. 
The gene encoding rat seminal vesicle secretion II (SVSII) protein has been 
cloned from a rat genome DNA library using a cDNA probe generated from rat dorsal 
prostate androgen-dependent mRNA. The mature protein contains 392 amino acids and 
has a molecular weight of 43,116 [Harris et al., 1990]. Based on its size, solubility, and 
amino acid composition, SVSII is identified to be a major clottable protein of the seminal 
secretion [Wagner and Kistler, 1987]. SVSII is disulfide-linked both to itselfand to SVSI 
and SVSII. Several smaller secretory proteins are the substrates for transglutaminase 
action [Williams-Ashman et al., 1980], the covalently crosslinked matrix of clotted rat 
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semen is a complex network that includes contributions by all the major vesicular 
proteins. 
Recently, Horton and Getzenberg [1999] have suggested that in addition to the 
known functions of SVSII, it may also bind extraneous DNA in seminal fluid. 
Additionally, SVSII may participate as a structural component in the organization of a 
tissue-specific seminal vesicle nuclear matrix. 
1.2.2.3 Probasin 
M-40 is the name designated for the mRNA of a major product isolated from the 
rat dorsolateral prostate [Dodd et al., 1983]. The M-40 specific mRNA codes for two 
protein products of molecular sizes, 23 and 21 kDa, indicating that the cDNA clone has 
close homology with two separate mRNAs [Dodd et al.，1983]. M-40 mRNAs have been 
demonstrated to be specific to male accessory sex gland and are not detected in the other 
rat tissues. By in situ hybridization, M-40 mRNAs have been shown to express 
abundantly in the epithelium of the lateral tip of the dorsolateral prostate [Matusik et al., 
1986]. The level o f the M-40 mRNAs is highest in the lateral lobes of prostate. However, 
M-40 mRNA is expressed at a low level in the immature ventral prostate and then 
decreases with sexual maturation. This apparent developmental switch in which the M-40 
gene is expressed in the ventral prostate of prepubertal animals and in the dorsolateral 
prostate ofpost-pubertal animals suggests that androgens alone are not responsible for M-
40 gene expression. This is confirmed by studies of the mRNA levels in mature male rats 
following castration, the M-40 mRNAs decrease initially in response to androgen 
removal but then retum to normal levels between 9 and 12 days following castration. 
Since the effect of androgen removal on M-40 is only short term, the presence of another 
inducer is suggested. Zinc has been examined as a possible candidate. Zinc levels are 25-
fold higher in the lateral lobe of rat prostate than any other tissues. In addition, the zinc 
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content of the prostate increases between 3 and 6 weeks of age which is in parallel to the 
increase in M-40 gene expression. On day 7 after castration, the rats were injected with 
either androgen or zinc and tissue was removed 48 hours later. The level of the M-40 
mRNAs is shown to retum to normal by both androgen treatment and by zinc treatment. 
Therefore, in the castrated rats, zinc can specifically induce the M-40 mRNAs 
expression. The high level of zinc in the lateral prostatic lobe correlates well with the 
high expression of M-40 mRNAs. Therefore, it is suggested that the M-40 mRNAs 
represent a new class of zinc-regulating genes, which are specifically associated with the 
prostate gland. 
The initial decreased expression of the M-40 mRNAs in the castrated rat is 
followed by a retum to normal levels. Therefore, when the prostatic tissue has undergone 
atrophy in the absence of androgens, some mRNAs continue to be expressed. The 
continued presence of high concentrations of zinc in the prostate gland even in the 
castrated rats has strongly suggested that zinc is a strong promoter of M-40 mRNA 
expression [Matusik et al., 1986]. 
Probasin is isolated originally from the dorsolateral prostate nuclei and shown to 
be an androgen-regulated nuclear protein [Matuo et al., 1982]. Its concentration increases 
with zinc uptake [Matuo et al., 1984]. Immunocytochemistry shows that probasin is 
abundantly localized in the lumen and acinal regions of the epithelium of the dorsolateral 
prostates, but hardly in the nuclei [Matuo et al., 1985]. Subsequently, Spence et al. [1989] 
reported that the translation product corresponding to the cDNA clone pM-40 is actually 
probasin [Dodd et al., 1983]. They also demonstrated that probasin is localized in both 
the nuclei of epithelial cells and in prostatic secretions. Further evidence showed that the 
secreted and the nuclear protein can be translated from one bifunctional mRNA [Spence 
et al., 1989]. Analysis by amino acid sequencing and immunochemistry reveals that the 
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heparin-binding protein from the rat prostate extracts is identical to the androgen-
dependent protein "probasin" [Matuo et al., 1989]. 
1.2.3 Prostatic Secretory Proteins in Lateral Prostate 
The biochemical properties of lateral prostate are different from that ofdorsal and 
ventral prostate in the rat. The lateral prostate is the major zinc-secreting portion of rat 
prostate. SVSII and probasin are the two proteins highly expressed in the lateral lobe 
[Sweetland et al., 1988; Prins and Carl, 1995; Reiter et al., 1995; Lopes et al., 1996]. 
Investigation by polyacrylamide gel electrophoresis has demonstrated that the lateral type 
2 prostate expresses several low-molecular weight secretory proteins not found in the 
other lobes of the rat prostate [Hayashi et al., 1991]. 
1.3 Human Prostatic Secretion 
The human prostate gland like the canine prostate is a solid gland and is not 
divided into distinct lobes as in the rat and mouse prostates. The contribution of the 
human prostate gland to an average ejaculate (3.5 ml) is between 0.5 to 1.0 ml, i.e. 15 to 
30% of the total volume. The "resting" fluid obtained by prostatic massage amounts to 
0.1-1.0 ml and differs in composition from "stimulated" secretion. The human prostatic 
secretion is a slightly acidic milky fluid rich in phosphatidylethanolamine/cholesterol 
[Schaffner, 1981] and cephalin [Zaneveld and Tauber, 1981]. The protein content of this 
fluid is much lower than that of the seminal plasma. It is notable for its high content of 
monovalent and divalent cations (Na+, K+, Zn?+，Ca�+’ Mg2+), citric acid and many 
enzymes. Most of the seminal spermine is produced by the prostate gland [Zaneveld and 
Tauber, 1981]. 
1.4 Human Prostatic Secretory Proteins 
Prostatic acid phosphatase (PAP), prostate specific antigen (PSA or y-
seminoprotein) and prostatic secretory protein of 94 amino acids (PSP94 or p-
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microseminoprotein, formerly P-inhibin) are the three predominant proteins secreted by 
normal human prostate gland. Immunohistochemical localization of these proteins shows 
that they are localized to the epithelium of normal prostatic acini and ducts. PAP-
immunoreactive cell is also immunoreactive to both PSA- and PSP94-monospecific 
antisera [Dube et al., 1987a; Lilja and Abrahamsson, 1988]. Research interests on these 
secretory proteins resides on their diagnostic use as markers for prostate cancers [Chan et 
al., 1987; Schifman et al., 1987; Lilja and Abrahamsson, 1988]. 
1.4.1 Prostatic Acid Phosphatase (PAP) 
Human prostatic acid phosphatase (PAP) is a glycoprotein, which occurs in vivo 
as a dimer. Each monomer has a molecular weight of approximately 54 kDa. PAP is 
synthesized under androgen regulation by the epithelial cells of the prostate and is 
secreted into the seminal fluid. Enzymatic activity of PAP has been measured in serum 
for several decades to monitor the progression of prostatic malignancies. Although PAP 
has been demonstrated to display phosphotyrosyl-protein phosphatase activity, the 
physiological function of this enzyme remains unknown [Lin et al., 1990]. Non-specific 
acid phosphatase activity was the first serum marker for metastatic carcinoma of the 
prostate. Over years, cross reactivity of the assay with acid phosphatase of non-specific 
sources has been decreased by use of specific substrate (thymolphthalein 
monophosphatase), specific inhibitor (L-tartrate), and ultimately the development of 
poly- and monoclonal antibody technology and assays directed against unique antigens of 
PAP molecules [George et aL, 1990]. 
Several investigators have demonstrated an inverse correlation between the age of 
patient and prostatic fluid PAP levels, as determined by a specific substrate colorimetric 
method [Kirk, 1948; Kavanagh et al., 1982]. The difference between different age groups 
is found to be statistically significant. This suggests a diminished production of this 
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androgen-dependent glycoprotein as aging progresses. Naik and coworkers showed that 
spermatozoa and epididymal fluid demonstrate no direct stimulatory factor for the 
production of PAP. They also showed that there are no differences in seminal acid 
phosphatase levels between fertile men and those who had undergone vasectomy 1-8 
years earlier [Naik et al., 1980]. 
Quantitative differences in PAP activity in prostatic fluid have been observed 
between patients with different disease states, which are independent of age. Kent and 
coworker [1970] found that prostatic fluid PAP concentrations are markedly decreased in 
patients with locally unresectable or metastatic prostate cancer in comparison with 
patients with benign prostatic hyperplasia (BPH) or no prostatic abnormality. They found 
that patients with hypogonadotropic hypogonadism have very low expression level of 
prostatic secretion (EPS) acid phosphatase, confirming that the androgen-dependent 
nature of this enzyme. Grayhach and coworkers [1977] also found that the levels ofPAP 
in the EPS of cancer patients are lower than those patients with either prostatitis or BPH. 
Using histochemical techniques, Kirchheim and coworkers [1964] confirmed the 
PAP staining ofprostatic secretory cells and lumina of acini by specific inhibition with L-
tartrate. BPH and normal prostatic tissues demonstrate a diffused staining in the secretory 
epithelium, whereas carcinomatous cells remain positively stained for acid phosphatase 
even after long periods of androgen deprivation. Dedifferentiation of tumor or a "field 
change" phenomenon involving non-neoplastic prostate cells as well as carcinomatous 
ones resulting in diminished acid phosphatase production have been proposed to explain 
the decreased acid phosphatase levels as observed in the EPS of prostate carcinoma. 
A fragment of a cDNA clone for human prostatic acid phosphatase (PAP) was 
used to study the expression of corresponding mRNA in human tissues [Solin et al., 
1990]. The specificity of its expression in BPH and prostatic carcinoma tissues is 
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indicated in RNA blot analyses. The PAP cDNA probe does not recognize any specific 
mRNAs in RNAs extracted from human liver cancer, lung cancer, pancreatic cancer, 
placenta, breast cancer cells (MCF-7), mononuclear blood cells or acute promyelocytic 
leukemia cells (HL-60), by Northern blot analysis. mRNA for PAP is detected in the 
androgen-dependent human prostatic cancer cell line LNCaP, but not in the androgen-
insensitive human prostatic cancer cell line PC-3. These findings indicate that a highly 
specific expression of the PAP gene in the prostatic tissue. The mean abundance for the 
PAP mRNA expression is 0.26 for prostatic carcinoma samples and 0.46 for BPH 
samples according to slot-blot analysis. The differences observed between the different 
categories of prostatic tissues in PAP mRNA abundance call for additional studies on 
regulation of its expression. 
The expression of PAP in three human prostatic carcinoma cell lines including 
LNCaP, DU145 and PC-3 was studied to explore its potential role as a marker in the 
progression of prostate cancer [Garcia-Arenas et al., 1995]. Although Southern blot 
analysis suggested the presence of PAP gene in all three prostate carcinoma cell lines, the 
Northern blot analysis and the reverse transcriptase-polymerase chain reaction (RT-PCR) 
assay showed that PAP mRNA can be detected only in LNCaP cells. The major 
difference between LNCaP cells and PC-3 as well as DU145 cells is the androgen-
sensitivity of LNCaP cells. The results also demonstrated that the transfection of human 
androgen receptor cDNA into PC-3 cell did not have any detectable effects on the 
expression ofPAP. Furthermore, while the level ofPAP mRNA diminished upon passage 
in LNCaP cells, the androgen receptor mRNA level remained approximately the same. 
Together, the data suggested that the differential expression of PAP in different prostate 
carcinoma cells including high passages of LNCaP cells may occur at the transcriptional 
level and may have little linkage to the expression of androgen receptor. 
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In order to study the protein structure-function relationships of the PAP and the 
mechanism of its androgen regulation, Sharief and coworkers [1989; 1992] have 
undertaken protein sequencing, cDNA cloning and the characterization ofthe exon-intron 
organization of the human PAP gene. Recently, the PAP gene is mapped to chromosome 
3q21-23 [Li and Sharief, 1993]. The DNA fragments from the promoter region ofhuman 
PAP is also isolated and characterized [Banas et al., 1994; Zelivianski et al., 1998], 
1.4.2 Prostate Specific Antigen (PSA) 
1.4.2.1 Molecular Biology ofPSA 
Prostate specific antigen (PSA) was first described in seminal plasma [Hara et al., 
1971] and was later isolated from the normal human prostatic tissue by Wang and 
colleagues in 1979 [Wang et al., 1979]. The PSA molecule is a single-chain glycoprotein. 
The data of amino acid sequence was originally reported to consist of 240 amino acids. 
However, later studies by amino acid sequencing and cDNA cloning showed that the 
peptide length consists o f237 amino acids [McCormack et al., 1995]. In earlier works, 
PSA was characterized to have a molecular weight ranging from approximately 26,000 
(without carbohydrate) to 34,000 Da, depending on the analysis methods. Using ion-
spray mass spectroscopy, Belanger and colleagues have determined that the glycosylated 
PSA has a molecular weight of 28,430 Da, including a carbohydrate moiety attached at 
the aspartate residue at position 45. The A^-linked oligosaccharide is the only one 
detected, although other 0-linked oligosaccharides have been suggested in the past 
[Belanger et al., 1995]. 
The gene for PSA is located on the long arm of chromosome 19 and is 
approximately 6 kilobases in size, consisting of 4 introns and 5 exons [Riegman et al., 
1992]. The PSA gene is under androgen regulation as evidenced by the presence of 
androgen-responsive element in the promoter region [Riegman et al., 1991]. PSA is 
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thought to be translated as a 261-amino-acid prepropeptide. Although the 261-amino-acid 
prepropeptides have not been isolated, the 244 propeptide zymogen form of PSA formed 
after cleavage of the leader peptide during translation is identified. The mature active 
enzyme of 237 amino acids is believed to be formed by the subsequent cleavage with as-
yet-unidentified proteases [Malm et al., 1995; McCormack et al., 1995]. Structurally, the 
molecule consists offive disulfide bonds due to the presence of 10 cysteine residues, with 
the enzymatic active site composed of three amino acids, histidine 41, aspartate 96, and 
serine 189 [McCormack et al., 1995]. 
1.4.2.2 Synthesis ofPSA 
PSA is synthesized in the ductal epithelium and prostatic acini. The secretory 
protein is localized to the secretory granules and vesicles, rough endoplasmic reticulum, 
and lysosomal dense bodies [Ito et al., 1989; Armbruster et al., 1993]. PSA is secreted 
into the lumina of the prostatic ducts via exocytosis. It can reach the blood circulation by 
diffusion or leakage from luminal cells through the epithelial basement membrane and 
prostatic stroma, where it can pass through the capillary basement membrane into the 
blood [Oestering, 1991]. PSA is found in the normal, hyperplastic, primary and 
metastatic prostate tissues. 
1.4.2.3 Kallikrein Gene Family 
PSA functions as a serine protease and exhibits proteolytic activity similar to 
chymotrypsin, cleaving peptide bonds with carboxy terminus of certain leucine and 
tryrosine residues [Wang et al., 1994]. Based on its function, amino acid structure, and 
gene location in 19ql3.2 to 19ql3.4, PSA is characterized as a member of the human 
kallikrein family [Riegman et al., 1992]. The gene for PSA is designated hKLK3. 
Pancreatic or renal kallikrein (hkl) is the product of hKLKl gene. The 238-amino-acid 
protein is produced in salivary glands, pancreas and kidneys. Although hkl is not 
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produced in the prostate, it shares a 62% homology with PSA [McCormack et al., 1995; 
Schedlich et al., 1987; Watt et al., 1986]. On the other hand, the glandular kallikrein, or 
hKG-1 (hKG) translated from the hKLK2 gene shares many more similarities with PSA. 
The hKLK2 gene product has not been isolated. However, the mature protein is predicted 
to consist of 237 amino acids and to show 80% DNA and 78% amino acid sequence 
homology with PSA [Schaller et al., 1987; Schedlich et aL, 1987; Watt et al., 1986; 
Chapdelaine et al., 1988; Morris, 1989]. In addition, the calculated molecular weights for 
hK2 differ by 93d. The mRNA for hK2 is expressed in the prostate gland at 10% to 50% 
that ofPSA mRNA [Chapdelaine et al., 1988; Belanger et al., 1995]. A predicted trypsin-
like function is assigned for hK2. This enzymatic activity distinguishes it from PSA, 
which has a restricted chymotrypsin-like activity. 
1.4.2.4 Physiological Function ofPSA 
Gel-forming proteins including primary seminogelin I and II, and fibronectin, 
produced by the seminal vesicles, are present in the seminal fluid. These proteins are 
responsible for the formation of seminal coagulum formed after ejaculation and the gel 
functions to entrap the spermatozoa. The PSA secreted by the prostate gland becomes a 
component of the seminal fluid after ejaculation. PSA functions to liquefy the coagulum 
and break down the seminal clot by proteolysis of proteins into smaller fragments and 
thus releasing the spermatozoa [Lilja, 1985; Lilja et al., 1987; McGee et al., 1988]. 
A recent observation suggests that PSA may also modulate cell growth and thus 
prostate cancer by affecting the growth factors in the prostate [Cohen et al., 1992]. PSA 
can induce proteolysis of the binding-protein 3, a main carrier of insulin-like growth 
factor (IGF), resulting in decreased binding for IGF-1 and thus can promote cell growth. 
Although most secretory PSA remains within the prostatic ducts under normal 
conditions, a proportion of PSA is absorbed into the blood stream where it is bound 
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mainly to two serum proteins: anti-chymotrypsin (ACT) and a-macroglobulin (aMG), 
leaving only a small proportion of free and uncomplexed form of PSA [Kirby et al., 
1996]. The PSA levels in prostatic fluid are approximately one-million-fold higher than 
serum levels in normal males. However, the structural barriers in the prostate including 
secretory epithelium, a basal cell layer and epithelial basement membrane, separate the 
intraductal PSA from the capillary and lymphatic drainage of the prostate. In case of 
metastatic lesions of prostate cancer, disruption of these structural barriers may allow 
increased PSA leakage into the interstitial tissue space and subsequently the systemic 
circulation resulting in elevated serum levels of PSA. 
At present, efforts are being made to measure free, bound and total PSA in serum 
in order to improve the use of PSA in discriminating between benign and malignant 
forms of prostate disease [Stenman et al., 1991; Christensson et al., 1993]. It has been 
discovered that malignant prostate cells, but not benign tissue, may synthesize ACT and 
thus release ACT-bound PSA into the blood stream [Bjork et al., 1994]. On the other 
hand, only approximately 25% of the patients with BPH will have an elevated serum PSA 
concentration. However, the contribution to PSA serum level by BPH tissues varies from 
patient to patient. Because of this phenomenon, PSA is unreliable as a screening tool for 
the early diagnosis of prostate cancer. However, if combined with digital rectal 
examination and/or transrectal ultrasound, PSA may become a vital part of any early 
detection program [Oesterling, 1991:. 
1.4.2.5 PSA as an Immunohistochemical Marker 
Since PSA is organ-specific, it has been used extensively as an 
immunohistochemical marker for prostatic tissue. Numerous studies have shown that 
PSA is a highly specific and sensitive marker for all types of prostatic tissues including 
benign, malignant and clinically treated samples. One of the diagnostic roles of using 
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PSA as an immunohistochemical marker is to confirm whether a metastatic 
adenocarcinoma is of prostatic origin. PSA is also useful in differentiating primary 
adenocarcinoma of the prostate from primary adenocarcinoma of the bladder and poorly 
differentiated transitional cell carcinoma of either bladder or prostatic periurethral duct 
origin that has infiltrated the prostate [Oesterling, 1991]. 
As an immunohistochemical marker, PSA appears to be more specific than 
prostatic acid phosphatase (PAP). Positive immunostaining for PAP is also found in 
pancreatic islet cells, gastric parietal cells and epithelial cells of seminal vesicles, as in 
insulinoma, breast carcinoma and renal cell carcinoma. In addition, 27% of the carcinoids 
from the gastrointestinal tract are stained positively for PAP. In practice, both PSA and 
PAP are used to immunostain the tissue in order to confirm an adenocarcinoma of 
prostatic origin [Oesterling, 1991]. 
1.4.2.6 PSA is not a Prostate-Specific Molecule 
For many years, PSA was believed to be synthesized specifically by the prostatic 
epithelial cells. However, recent studies have shown that PSA is also present in other 
organs (including sweat, periurethral and anal glands, endometrium and breast), in non-
prostate tumors (breast, salivary gland, colon, ovarian, liver, kidney, adrenal, and parotid) 
and in certain fluids (e.g. milk and amniotic fluid) [Graves, 1995; Yu and Diamandis, 
1995a; and 1995b; Levesque et al., 1995; Parish, 1998]. In these fluids, most of the PSA 
is present in free form with less than 25% complexed with ACT [Yu and Diamandis, 
1995 a and b; Schroder, 1993]. This is in contrast to the blood in which most PSA bind to 
ACT. 
The presence ofPSA in organs other than the prostate may have some implication 
for the use of PSA as a marker for prostate cancer, since positive staining for PSA in 
metastatic cancers is widely used in establishing the prostate as primary site. If PSA is 
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also synthesized by non-prostatic cancers, the diagnostic value of PSA for prostate cancer 
cannot be faithfully relied upon. Moreover, all PSA in sera is presently believed to be 
derived solely from prostatic tissue. If other normal tissues and non-prostatic tumors also 
synthesize PSA, the possibility exists that serum PSA may not exclusively originate from 
prostatic sources. Despite this drawback, PSA is still currently a valuable marker for 
prostatic cancer [Graves, 1995]. 
The observation of PSA present in normal breast milk and amniotic fluid suggests 
that it may be involved in growth control by regulating growth factors and growth factor 
binding protein. This opens up the possibility of using PSA as a new biomarker for breast 
cancer prognosis [Monne et al., 1994]. It has also been claimed that PSA shows promise 
in its routine use as a favorable prognostic indicator in female breast cancer [Diamandis 
and Yu, 1995]. 
1.4.3 Prostatic Secretory Protein of 94 Amino Acids (PSP94) 
Human seminal plasma contains many proteins secreted by the prostate but the 
biological roles of most of these proteins still remain unknown [Lizana and Eneroth, 
1983]. A 14-kDa protein with inhibin-like activity has been isolated from the human 
seminal plasma [Sheth et al., 1985]. This small protein was first designated as p-inhibin 
as it showed an inhibin-like activity and is found in greater amounts in the prostate than 
in the testis [Beksac et al., 1984; Vaze et al., 1979]. The amino acid sequence of this 
inhibin-like protein isolated from seminal plasma shows that it consists of 94 amino 
acids, of which 10 are cysteine residues [Johansson et al., 1984; Seidah et al., 1984]. 
Moreover, the amino acid sequence of p-microseminoprotein appears to be identical to 
the amino-terminal sequence of the inhibin-like protein [Akiyama et al., 1985]. Using the 
data of amino acid sequence of this protein, oligonucleotide probes have been 
synthesized and used as probes for the mRNA expression of this protein in human 
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tissues. The protein has been shown to be expressed widely in the prostate gland and thus 
named as the "prostatic secretory protein of 94 amino acids" or PSP94 [Mbikay et al., 
1987]. 
1.4.3.1 Nucleotide Sequence ofthe PSP94 cDNA 
The cDNA clone of human PSP94 has been isolated from a cDNA library 
constructed from human prostatic Poly(A) RNA [Mbikay et al., 1987]. A 63-bp synthetic 
oligonucleotide probe representing the amino acids 67-87 of human seminal plasma 
PSP94 protein is used to screen a cDNA library. Positive clones were selected and the 
cDNA insert in the plasmids were sequenced. The isolated cDNA was shown to consist 
of 483 nucleotides with a poly A tail of 17 bases [Mbikay et al., 1987]. The open reading 
frame has a length of342 nucleotides with ATG as the initiation codon at position 12 and 
TAA as the stop codon at position 353. At the 5’ end it is flanked by an 11-base stretch, 
whereas at the 3，end, it is flanked by a 130-base noncoding region. The typical 
polyadenylation signal AATAAA common to most eukaryotic mRNA is not found within 
30 nucleotides upstream of the poly A tail, but it is present at position 444-448. The 
mRNA of PSP94 is determined to have a size of 615 bases as estimated by Northern 
blotting. 
1.4.3.2 Amino Acid Sequence ofPSP94 
The amino acid sequence ofPSP94 has been deduced from the cDNA sequence of 
the isolated cDNA clone. The protein is shown to have 114 amino acids, with the first 20 
amino acids at the A^-terminal end (-20 to -1) representing the putative signal sequence 
[Mbikay et al., 1987]. The signal sequence is rich in hydrophobic amino acids and also 
contains the A^-glycosylation site (Asp-Ala-Ser) at the positions 19-21. The derived amino 
acid sequence ofPSP94 is highly homologous, but not identical, to that of the 94-amino-
acid-long p_inhibin [Johansson et al., 1984; Seidah et al., 1984] and the 93-amino-acid 
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long p-microseminoprotein (p-MSP) [Akiyama et al., 1985], differing from the former in 
two positions and from the latter in four positions. However, it has been confirmed 
recently that these proteins under different names are the same protein and belong to the 
immunoglobulin binding factor family in the seminal plasma [Kamada et al., 1998]. 
1.4.3.3 Biological Properties ofPSP94 
Another protein with a size of 16 kDa has been purified from the human seminal 
plasma using ammonium sulfate precipiatation, DEAE-Sepharose CL-613 ion-exchange 
chromatography and gel-filtration with Sephadex G-lOO by Dube and coworkers [Dube 
et al., 1987a]. Their results confirmed with previous reports showing that the 16-kDa 
protein is a major constituent of prostatic fluid and also of the ejaculate [Carter and 
Resnick, 1982; Balema et al., 1982; Rui et al., 1984; Tsai et al., 1984]. Their assay has 
proven unambiguous and provides direct evidence for the prostatic origin of this protein 
since it is concentrated in this tissue, is not decreased in the seminal plasma after 
vasectomy and is virtually absent in the testis, epididymis, vas deferens and liver. This 
16-kDa protein was shown later to be identical to PSP94, because the sequence of the 
first 40 amino acids is identical to that of PSP94, which was previously designated as P-
inhibin. The amino acid sequence of this protein has been reported [Seidah et al., 1984; 
Johansson et al., 1984]. The protein is probably also identical to another protein named p-
microseminoprotein isolated from the seminal plasma and sequenced by Akiyama and 
colleagues [Akiyama et al., 1985], although they obtained different results from the P_ 
inhibin sequence at position 39 and 40. Their study showed for the first time that PSP94 
corresponds to a major protein in the prostatic secretions as analyzed by two-dimensional 
gel electrophoresis. Immunoreactive PSP94 represents about 2% of the total seminal 
plasma proteins, showing that PSP94 is a major protein in the prostatic secretion and thus 
stimulates further studies on this protein in the interests ofprostate cancer. 
29 
The histological distribution of human PSP94 protein and its mRNA has been 
examined by immunohistochemistry and in situ hybridization [Brar et al., 1988]. PSP94 
mRNA is detected in the epithelial cells but not in the stromal cells of the prostate. The 
results of in situ hybridization with a cDNA probe showed that the hybridization signals 
are confined to the cytoplasm of the epithelial cells of the prostate. However, 
heterogeneous staining is described over the epithelial cells, which probably reflects 
different levels of PSP94 mRNA among epithelial cells. The heterogeneity in the 
expression of this protein is also apparent at the protein level as evidenced by 
immunostaining. The cause of this variation is not known, but may result from 
differences in biosynthesis and secretory activity under the influence of local or systemic 
factors such as dihydrotestosterone [Brar et al., 1988]. Moreover, ultrastructural 
localization ofPSP94 has demonstrated that the protein is localized primarily in secretory 
granules, it is suggesting that PSP94 is a secretory protein [Ito et al., 1989]. 
The chromosome locus of the PSP94 is localized to the region q l l .2 of 
chromosome 10 by PCR amplification o fDNAs of rodent-human somatic cell hybrids 
and also by the fluorescence in situ hybridization (FISH) technique [Ochiai et al., 1995]. 
Sasaki et al. [1996] also have assigned the human PSP94 gene to 10ql l . l2 with FISH 
using a phage clone that has an PSP94 gene insert. The authors also argued that there are 
at least a dozen chromosomal regions which harbor putative prostate-cancer suppressor 
genes which have been identified [Cannon-Albright and Eales, 1995]. Among them, two 
regions on chromosome 10 (lOp and 10q24~>qter) represent the site of loss of 
heterozygosity (LOH) in prostate cancer cells [Carter et a l , 1990; Bergerheim et al.， 
1991; Arp et al., 1993]. Since the PSP94 gene does not map to either ofthese regions, it 
is argued that the gene can be ruled out as a candidate for a tumor suppressor gene 
localized to these regions [Sasaki et al., 1996]. 
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1.4.3.4 Physiological Roles ofPSP94 
Sheth and colleagues [Sheth et al., 1985] have reviewed the inhibin-like activity 
of PSP94 as originally suggested by other investigators. This protein is reported to have 
an inhibin activity as shown by its inhibitory effect on the secretion of follicle stimulating 
hormone (FSH) by the pituitary cells and thus called p-inhibin [Seidah et al., 1984; 
Johansson et al., 1984]. In males, inhibin is secreted by Sertoli cells and acts on the 
pituitary gland as a gonadotrophin to inhibit the secretion ofFSH. The absence ofPSP94 
in human testis and its abundance in the prostate clearly indicate that it is a prostatic 
secretory protein unrelated to the testicular inhibin. Later, PSP94 was shown that it is not 
an inhibin [Gordon et al., 1987]. In their bioassay, PSP94 fails to suppress the secretion 
from rat pituitary cells in culture at any of the dose tested. It is concluded that there is no 
statistically significant evidence to indicate PSP94 performs any inhibin biological 
activity. PSP94 has also been shown to be one of the sperm-coated antigens which is 
correlated to be the cause of some cases of infertility in the human male [Ito et al., 1989]. 
Recently, evidence has suggested that a porcine sperm motility inhibitor is identical to 
PSP94 and it functions as a weak competitive inhibitor of Na+K+-ATPase [Chao et al., 
1996]. So far, the exact biological function ofPSP94 still remains unknown. 
1.4.3.5 PSP94 and Its mRNA in Other Non-Prostatic Tissue 
Earlier reports by immunohistochemistry have indicated that inhibin-like proteins 
of 94 amino acids similar to human PSP94 are also present in testis, seminal vesicle, 
stomach, placenta, ovary, respiratory tissues (trachea, bronchi and lung), duodenum, 
breast, bile ducts of liver, epithelium of thin portion of loop of Henle and distal tubule in 
kidney [Sheth et al., 1982; Vaze et al., 1979; Weiber et al., 1990; Ohkubo et al., 1995], in 
addition to the prostate gland [Akiyama et al., 1985; Beksac et al., 1984, Vaze et al., 
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1979]. However, Northern blot analysis of the PSP94 mRNA shows that it is expressed 
abundantly in the human prostate but absent in the testis and placenta. It is also not 
detectable in the testis of rat. The authors explain the negative results as being due to the 
low levels of PSP94 mRNA in these tissues or the fact that the non-prostatic PSP94 may 
be structurally unlike prostatic PSP94 [Mbikay et al,, 1987]. Moreover, Northern blot 
analysis also reveals that the mRNA of PSP94 is also detected in bronchi, trachea and 
stomach [Ulvsback et al., 1989]. Currently, the prostate gland is believed to be the main 
sources of PSP94. However, its expression in other non-prostatic tissue is still under 
investigation. 
1.4.3.6 PSP94 as a Tumor Marker ofProstate Cancer 
The research interests on PSP94 stems from its potential use as a diagnostic 
marker for the human prostate cancer. There is much evidence to support this idea. The 
levels of immunoreactive PSP94 have been estimated in the sera and urine samples of 
patients with benign prostatic hyperplasia (BPH) and prostatic carcinoma (PCa) as 
compared to age-matched controls. PSP94 levels are shown to be remarkably elevated in 
the sera of the patients with BPH and PCa as compared to controls but the elevation in 
PCa patients is not of the same magnitude as that observed in BPH cases [Teni et al., 
1988]. Therefore, elevated serum PSP94 levels reflect either benign or malignant 
conditions of the prostate as compared to normal but fail to differentiate between the two. 
Interestingly, the urinary level ofPSP94 is different from that in the serum. Significantly 
high urine PSP94 levels are observed in BPH patients but extremely low levels ofurinary 
PSP94 in PCa as compared to normal. Furthermore, striking differences in urinary PSP94 
levels are seen between BPH and PCa patients. The results ofthis investigation indicate a 
possible use of urinary PSP94 as a biological marker of prostate cancer [Teni et al., 
1988]. 
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Immunohistochemical studies of the three predominant secretory proteins (PAP, 
PSA and PSP94) in neoplastic prostate glands have shown that the distributions of PSA 
and PSP94 in carcinomas of Gleason grades II and III are almost identical, suggesting 
that PSP94 is not a less sensitive tumor marker than PAP or PSA for monitoring the 
course and treatment of prostatic carcinoma [Abrahamsson et al., 1988]. 
Immunocytochemical studies of PSP94 in human prostate tissues have demonstrated a 
degree of decreased staining intensities as follows: hyperplasia, normal, incidental and 
moderately differentiated carcinomas, poorly differentiated carcinomas, whereas 
metaplasia and granulomatous prostatitis show negative reactions for PSP94. These 
findings indicate a potential use of PSP94 as a marker of prostatic tissue [Doctor et al., 
1986]. Other workers have demonstrated positive immunostaining of PSP94, using a 
specific antiserum generated against PSP94 on rectal biopies with invasion of prostate 
cancer [Sheth et al., 1987]. However, the negative staining reaction is observed on the 
metastatic lesions from the patients with non-prostatic carcinomas. The results have 
demonstrated a potential application of PSP94 in confirming or excluding the prostatic 
origin of invasive tumor in metastatic lesions. 
Therefore, it has been proposed that PSP94 could be used as a third marker for 
prostate cancer besides PAP and PSA. Immunohistochemistry ofPSP94 may be useful to 
evaluate the degree of dedifferentiation of tumors since loss of immunoreactivity for PAP 
and PSA is generally associated with higher Gleason primary pattern. It remains to be 
shown whether PSP94 yields identical or different results from those found with PAP and 
PSA. In previous experiments with PAP and PSA, the cells that are positive for one 
marker may not necessarily be so for other [Epstein and Eggleston, 1984; Mathieu and 
Caillaud, 1985]. Therefore, if all three markers react with different cells, their combined 
use should permit one to sub-classify precisely the undifferentiated carcinoma. A second 
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important application of this new marker could be the identification of the prostatic origin 
of some metastases. However, this will require further testing on the tissue specificity of 
PSP94 both by immunostaining on normal tissue and cancers of various organs [Dube et 
al., 1987b]. 
Since prostate cancer is a heterogeneous tumor, PAP, PSA and PSP94 may not be 
expressed simultaneously by all tumor cells and the use of multiple markers will reduce 
the incidence of false negative reports [Garde et al., 1993a]. However, some recent 
studies have demonstrated a controversy on the use of PSP94 as a tumor marker of 
prostate cancer. When using enzyme-linked immunosorbent assay (ELISA) to measure 
PSP94 concentrations in sera of three different groups (healthy men, men with BPH, and 
men suffering from prostate cancer), the results showed that PSP94 does not possess the 
potential to function as a serum marker for prostate cancer [von der Kammer et al., 1993]. 
The PSP94 expression is also reported to be down regulated in the prostate cancer [Liu et 
al., 1993; Chan et aL, in press]. Further studies on PSP94 are needed in order to confirm 
whether this protein can be used to be a tumor marker of prostate cancer. 
1.4.3.7 Homologous Proteins ofPSP94 
Until recently, further studies ofPSP94 in experimental animals are impracticable 
since its homologous protein has not been identified in any commonly used experimental 
animals such as rat and mouse. However, its homologous protein and cDNA have now 
been cloned in rat prostate [Femlund et al., 1996] and its cDNA has also been cloned in 
mouse prostate by Xuan et al. [1999]. Although there are difference in the cDNA 
sequence and amino acid sequence ofPSP94 between species, the presence of 10 cysteine 
residues present in this protein are consistent among human, monkey, baboon, pig and rat 
species. PSP94 is a protein unusually rich in cysteine residues (about one-tenth of the 
residues) and at least in the pig [Femlund et al., 1994] they are all in disulfide linkages, 
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suggesting a tightly knotted three-dimensional structure of the native protein, similar to 
the echistatin [Gray, 1993]. This highly conserved structural feature is probably essential 
for the function of the PSP94 and may constitute the basis for the similarities in 
physiochemical properties among the human, pig and rat PSP94 proteins in spite of 
dissimilarity in amino acid sequence [Femlund et al., 1996]. 
Because of the identification of this protein in rodents, further study is now 
possible in the experimental rat and mouse, which are more suitable and convenient to 
manipulate under experimental conditions than human, primates and pig. 
1.5 Aim of Study 
The present study is to investigate the expression pattem of PSP94 in the normal 
Noble rat prostate gland by non-radioactive in-situ hybridization, Northern blotting, RT-
PCR, Westem blotting and immunohistochemistry. In order to study the androgen 
regulation of PSP94 in Noble rat prostate gland, the expression pattem of PSP94 in the 
normal, castrated, and androgen-replaced rat prostates was studied by in-situ 
hybridization and semi-quantitative RT-PCR. Since, probasin and SVSII are the major 
secretory proteins in the lateral lobes of rat prostate, and their hormonal regulations have 
been well known, their expression patterns in the normal, castrated, and androgen-
replaced rat prostates were also studied in parallel for comparison. 
Besides androgen, I am also interested to investigate whether there are other 
steroid hormones or factors (such as zinc) which may regulate or affect the expression of 
PSP94 in rat prostate. Therefore, the expression patterns ofPSP94, probasin and SVSII in 
lateral prostates from normal and castrated rats following com oil, DHT, DEX, MPA and 
ZnSO4 treatments were studied by semi-quantitative RT-PCR. 
Since human PSP94 is a potential marker for prostate cancer, in the present study, 
the expression patterns of PSP94, probasin and SVSII in T+E2 induced prostatic 
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intraepithelial neoplasia (PIN) in the lateral prostate of Noble rats were investigated by 
in-situ hybridization. In addition, their gene expressions in two rat prostatic tumors (an 
androgen-dependent Dunning tumor line, R3327H and an androgen-independent tumor, 
AIT, a tumor line was derived originally from an estrone-treated Noble rat) were also 
studied by in-situ hybridization and RT-PCR. 
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Chapter 2. Materia! and Methods 
2.1 Origin and Supply of Noble Rat 
Noble rats of 12-13-week old were used in the present study. This inbred strain 
was originally developed by Dr. R,L. Noble of the Cancer Research Centre in Vancouver 
[Noble, 1977a]. He selected and developed this black-hooded rat colony from the original 
stock derived from Dr. J.B. Collip's laboratory at McGill University in 1940s. In 1970s, 
the Medical Research Council of Canada designated this strain as Noble Q^b) rat after 
evaluation on its genetics and degree of inbreeding contributed by Dr. Noble. The 
ancestor of Noble rat is still ambiguous and is believed that it was the out-cross between 
the Long-Evans and Wistar rats. The offspring were then randomly bred and only the 
blacked-hooded rats were selected for later experiments and used as breeders. 
The original breeders of Noble rats were obtained from the Charles River 
Breeding Laboratories, Japan in 1996. They were then bred by the Laboratory Animal 
Service Centre, The Chinese University of Hong Kong. 
2.2 Chemicals 
Most of the hormones, chemicals and restriction enzymes used in this study were 
obtained from Sigma Chemical Company (St. Louis, USA) and Fluka (Buchs, 
Switzerland), Amersham Pharmacia Biotech. (NJ, USA), Boehringer Mannheim GmbH 
(Mannheim, Germany), GibroBRL (USA), Stratagene (CA, USA). 
2.3 Bilateral Ochidectomy of Animals 
Male Noble rats of about 300gm body weight were anaesthetised by 
intraperitoneal injection of 7% chloral hydrate (300mg/kg body weight) and castrated 
through the scrotal route. The castrated rats were kept in cages supplied with chows and 
water ad libitum for 3 to 60 days before sacrifice. Castrated animals were anaesthetised 
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by intraperitoneal injection of chloral hydrate and sacrificed at 3, 5, 14，30’ 60 days after 
surgery. Intact age-matched rats were used as controls. 
2.4 Androgen Replacement 
For androgen replacement, rats which have been castrated for 60 days were 
implanted subcutaneously at the subscapular region with two 2-cm long Silastic® tubings 
filled with crystalline testosterone. For the controls, the age-matched rats that have been 
castrated for 60-day and without implantation of tubings were used. The animals were 
sacrificed after treatments with hormone for 3 weeks. 
2.5 Hormonal and Drug Treatments on Castrated Animals 
Adult (12-week old) Noble rats were anaesthetised and castrated as above. All 
experimental groups consisted of six age-matched males. Intact adult Noble rats were 
used as the control group. On day 30 post-castration, the castrated rats were received 
daily subcutaneous (S.C.) injections for 7 days of (a) dihydrotestosterone (DHT) at a 
dosage o f3 mg/kg/day; (b) dexamethasone (DEX, a synthetic glucocorticoid), at a dosage 
of 3 mg/kg/day; (c) medroxyprogesterone acetate (MPA, a synthetic progestin), 
intraperitoneally (i.p.) at a dosage 1.5 mg/kg/day; (d) zinc sulfate (ZnSO4) 
intraperitoneally at a dosage of 5 mg/kg/day. Both DHT and DEX were dissolved and 
suspended in com oil. MPA was dissolved first in 90% ethanol and administered in 1% 
gelatin (w/v) in 0.9% saline solution. ZnSO4 was dissolved in 0.9% saline solution. 
Control animals were received vehicles (com oil or saline) only. The animals were 
sacrificed at 7 days after drug treatment and the male accessory sex glands were dissected 
for subsequent analysis. 
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2.6 Induction of Prostatic Intraepithelial Neoplasia in Noble Rat Prostate Gland 
by Long-Term Treatment with Steroids 
2.6.1 Preparation of Steroid Hormone-Filled Silastic® Tubings 
Silastic® laboratory tubings (with inner diameter of l .67mm and outer diameter of 
3.18mm; Dow Coming, 508-008, Michigan, USA) cut with suitable lengths were filled 
with sex steroids. Tubings of 2-cm long were filled with testosterone (T), whereas the 1-
cm tubings were filled with 17p-estradiol (E2) or diethylstilbestrol (DES). The two ends 
of the drug-filled tubings were then sealed with a Silastic® medical adhesive (silicone 
type A; Dow Coming). When the adhesive became hardened, the tubings were soaked 
ovemight in 70% ethanol in order to remove the residual powders of hormones adhered 
on the surface of the tubings and to ensure the tubing were completely sealed. The 
tubings were further immersed in 0.05M phosphate buffered saline (PBS) for another 2 
days before implantation. After blotting dry with Kimwipes, the tubings were stored at 
4°C for later use. 
2.6.2 Surgical Implantation of Silastic® Tubing 
Mature male Nobel rats (12-13 week old) were anaesthetised by intraperitoneal 
injection of 7% chloral hydrate (0.5ml/100g body weight). The implantation sites was 
made over the skin between the scapulae. After hair-shaving with an electric clipper and 
cleaning with 70% ethanol, the skin was cut and a subcutaneous pocket was made by 
blunt dissecting beneath the skin in a caudal direction with blunt forceps in order to 
accommodate the tubings. Testosterone-implants (T) were inserted and placed caudal to 
the left scapula while the estrogen-implants (DES or E2) were placed on the right side. 
After implantation, the skin was sutured and sprayed with a permeable wound dressing 
(Smith & Nephew Medical Limited, England). The animals were then housed in cages 
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and fed on normal chows and drinking water. Post-surgery observation was made twice a 
week. 
2.6.3 Protocols of Hormonal Treatments 
The animals were divided into three groups: 1) combined T+E2, 2) combined 
T+DES and 3) control. For rats under hormonal treatments, two 2-cm tubings filled with 
testosterone and one 1-cm tubings filled with either E2 or DES were implanted 
subcutaneously. For the controls, the age-matched Noble rats without implantation of 
tubings were used. The animals were sacrificed after 4 and 9 months treatments with 
hormones. For 9 months treatments, the tubings were replaced with new ones in every 3 
months. 
2.7 Androgen-Dependent Rat Dunning Prostatic Adenocarcinoma 
Dunning rat prostatic adenocarcinoma is an animal model of prostatic cancer 
originally developed by Dr. Dunning [Dunning, 1963]. It is a transplantable prostatic 
tumor, which was developed spontaneously from the dorsal prostate in an aged 
Copenhagen rat. A number of sublines were then developed [Isaacs et al., 1979]. The R-
3327-H subline used in the present study is an androgen-dependent tumor, which was 
developed from the R-3327 line. This tumor was classified by its pathology as a well-
differentiated prostatic adenocarcinoma. This tumor is maintained subcutaneously in 
nude mice and its growth is stimulated by exogenous androgen. For tumor 
transplantation, fragments of freshly dissected tumors of 0.2 cm^ in size were implanted 
subcutaneously in the subscapular and thigh regions of the male nude mice. In addition, 
one 1-cm Silasic® tubing (with inner diameter 1.96mm and outer diameter 3.18mm, Dow 
Coming, Michigan, USA) filled with testosterone was implanted into the dorsum region 
of the host animals. The tumor was then maintained and grown in the nude mice for three 
months before harvest. The R3327-H dunning prostatic tumor used in our experiment 
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was a generous gift provided by Professor Y.C. Wong of the Department of Anatomy, 
The University ofHong Kong. 
2.8 Androgen-Independent Prostatic Carcinoma Line (AIT) of Noble Rat 
The androgen-independent prostatic carcinoma line of Noble (Nb) rat was 
originally derived from an androgen-stimulated subline Nb-2Pr-A by Dr. Noble [Noble, 
1980b]. This subline originated from the Nb-2Pr-E line that arose from the dorsal-lateral 
prostate of an estrone-treated Nb rat which has been under treatment for 16 weeks psloble 
and Hoover, 1975; Noble, 1977b and 1980a]. Following transplantation ofNb-2Pr-E into 
the testosterone treated syngeneic male Noble rats, the tumor evolved into the androgen-
stimulated Nb-2Pr-A subline. This tumor subline grows rapidly in androgenized or intact 
male rat but slowly in castrated males. This tumor subline was maintained and 
transplanted into the dorsum of male Noble rats, which had been castrated for 2 weeks. 
The tumors were then harvested when they achieved a volume of 2.0 cm^ [Ho et al., 
1988]. The cDNA converted from total RNA and paraffin blocks of the androgen-
independent prostatic carcinoma line (AIT) of Noble rat used in our experiments were 
kindly provided by Dr. Shuk-Mei Ho of the Department of Biology, Tufts University, 
USA. 
2.9 Plasmids 
In the present study, pBluescript KS, which contained the full length ofrat PSP94 
cDNA fragment, were kindly provided by Dr. Jim W. Xuan, University of Westem 
Ontario. pLvB10 plasmid which contained parts of genes encoding rat 18s and 28s 
ribosomal RNAs were kindly provided by Dr. Benjamin Rich, Brigham and Women's 
Hospital, Harvard Institutes of Medicine. cM-40.3 plasmid which carried parts of 
sequence encoding probasin were kindly provided by Dr. Robert J. Matusik, Vanderbilt 
University School of Medicine [Dodd et al., 1983]. 
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Since both pLvB10 and cM-40.3 do not carry any multiple cloning sites flanked 
by T3 and T7 RNA promoters, therefore, the fragments of 18s ribosomal RNA and 
probasin from those two plasmids were released by digestion with the suitable restriction 
enzymes indicated on the enclosed maps as mentioned in Appendixes. The released 
fragments o f l 8 s ribosomal RNA and probasin were then subcloned into pBluescript® SK 
plasmid. Moreover, parts of cDNA fragment of rat SVSII were generated by RT-PCR. 
The cDNA fragment of rat SVSII were also subcloned into pBluescript® SK plasmid. The 
fmal subcloned plasmid with rat SVSII was named as pSK-SVSII. 
2.10 Restriction Enzyme Digestions of pLvB10 and cM-40.3 
The cDNA fragment of rat 18s ribosomal RNA inserted in pLvB10 was released 
by digestion with restriction enzymes Pstl and Xhol. The reaction mixture was prepared 
as follows: 3^ig of the pLvB10 plasmid, 5 i^l of 10x restriction enzyme buffer H and 1^1 
of each Pstl (lOU/^l) and Xhol (15U/^il) were mixed in 28^il milli-Q water. The reaction 
mixture was incubated at 37°C for 1 hour. The cDNA fragment of probasin inserted in 
cM-40.3 was released by digestion with restriction enzyme Pstl. The reaction mixture 
was prepared as follows: l^ig of the cM-40.3 plasmid, 5^1 of 10x restriction enzyme 
buffer H and l^il of Pstl (lOU/^il) were mixed in 43^il milli-Q water. The reaction 
mixture was incubated at 37°C for 1 hour. The digested DNA fragments were separated 
and analyzed by electrophoresis in 1% agarose gel and the DNA fragments were 
extracted and purified from the gel for subcloning. The procedure of purification ofDNA 
fragment was described in Section 2.12. 
2.11 Amplification of Rat SVSII cDNA Fragment by RT-PCR and Subcloning 
The fragment of rat SVSII was generated by RT-PCR using the primers with the 
linker sequences of EcoRl and Clal (underlined). The 5' primer (5,-CGG AAT TCA 
GTG GAC AGC TGA AAT CTG-3') and 3，primer (5，-CCA TCG ATT AGG ATT 
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GGG AGC GTT CTT G-3') were used to amplify a cDNA fragment ofra t SVSII with 
780bp in length. The procedure of RT-PCR was described in Section 2.20. 5^1 of the 
PCR product was analyzed by electrophoresis in 1.5% agarose gel and the remaining 
PCR product was purified by Ultrafree-MC fragment filter units (Millipore Corporation, 
Bedford). The sticky ends of the PCR product of rat SVSII were generated by digestion 
with restriction enzymes EcoRl and Clal. The reaction mixtures were prepared as 
follows: 5pg of the purified PCR product of rat SVSII, 5^il of 10x restriction enzyme 
buffer H and l^il of each Ecol (lOU/^il) and Clal (lOU/^il) were mixed in 23^il milli-Q 
water. The reaction mixture was incubated at 37°C for 1 hour. The digested DNA 
fragments were separated and analyzed by electrophoresis in 1% agarose gel. The DNA 
fragments were extracted and purified from the gel for subcloning. 
2.12 Purification of DNA Fragment from Agarose Gel 
The released cDNA fragment of rat 18s ribosomal RNA, probasin and the sticky 
PCR product of rat SVSII were extracted and purified from the agarose gel after 
electrophoresis. The DNA purification was performed using a Sephaglas BandPrep Kit 
(Amersham Pharmacia Biotech) and the procedure was described as follows. Slices of 
agarose containing the expected DNA bands were cut from the gel and transferred to a 
1.5 ml microcentrifuge tube. 250^il of Gel Solubilizer was added to the tube and 
incubated at 60°C for 5-10 min until the agarose slice was dissolved. After dissolution of 
the gel, 5^il of the Sephaglas BP suspension was added to the dissolved gel slices and 
incubated for 5 min further at room temperature. The mixture was agitated gently at 
minute intervals. The Sephaglas pellet was spun down at slow speed for 30 seconds in a 
microcentrifuge. The supernatant was removed. The pellet was kept and washed with 
80^il of Wash Buffer for 3 times. The pellet was then air-dried for 10 min and dissolved 
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in 10|al of elution buffer. The eluted DNA was obtained by centrifugation at 14,000 xg 
for 1 min and the supernatant was collected and transferred to a clean microcentrifuge 
tube. The eluted DNA was stored at -20°C until subcloning. 
2.13 Subcloning of DNA into Vector 
The cDNA fragments of rat 18s ribosomal RNA, probasin and SVSII were 
subcloned into the pBluescript SK (pSK) vector. The vector was first linearized and the 
linearization was performed as follows: 3^il of pSK (4^ig/^l), 5^1 of 10x restriction 
enzyme buffer H and 2^il of restriction enzymes (i. l^il of each Pstl/ lOU/^il and XhoV 
15U/^il for ratl8s rRNA; ii. 2^il ofPstl/ lOU/^il for probasin; iii. l^il of each ofEcoRl/ 
lOU/^il and ClaV lOU/^il for SVSII) were mixed in 40^il milli-Q water. The reaction 
mixture was incubated at 37°C for 1 hour. 
When the linearization was complete, the linearized vector was processed for 
dephosphorylation and performed as follows: 2^1 of calf intestinal alkaline phosphatase 
(CIAP), 5^il of 10x dephosphorylation buffer were added to the linearized vector mixture. 
The mixture was incubated at 37°C for another 30 min. The dephosphorylated and 
linearized vectors were purified by the phenol-chloroform extraction. The extracted 
vectors were precipitated by lOO i^l of ice-cooled absolute alcohol and 5^1 of 3M sodium 
acetate at -20°C ovemight. The linearized vectors were obtained by centrifugation at 
12,000xg for 10 min at 4°C and redissolved in lO^il milli-Q water. 
The ligation reactions were performed and the reaction mixtures were prepared as 
follows: 5|il of extracted DNA (0.5^ig), 1^1 oflinearized vector, l^il o fDNA ligase (lOU, 
GibcoBRL) and 2^il of 5x ligation buffer. The mixture was diluted with milli-Q water to 
a final volume of 10|ul and incubated ovemight at 16°C in a thermal cycler (GeneAmp 
PCR system 9600’ Perkin Elmer, USA). 
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After ligation, the plasmids with the inserted DNA were transferred to DU5a 
E.coli competent cells which were prepared using calcium chloride [Sambrook et al., 
1989]. The transformations were performed as follows: 4^il ofligation mixture containing 
the plasmid and 200^1 of E.coli competent cells were mixed gently in a sterile 
microcentrifuge tube. The tube was incubated in a 42°C water bath for exactly 2 min. The 
tube was then transferred rapidly to an ice bath and chilled on ice for 2 min. After 
transformation, 1ml LB solution was added to the competent cells and incubated at 37°C 
for 1 hour to allow the bacteria to recover and express the antibiotic resistance marker 
encoded by the plasmid. 
The transformed E.coli competent cells were allowed to grow in a LB agar plate 
for selection. The LB agar contained lOO i^l of ampicillin (50^ig/ml), 40^il of 5-bromo-4-
chloro-3-indolyl-P"D-galactoside (x-gal; 20mg/ml) and 4^il of isopropylthio-p-D-
galactoside (IPTG; 200mg/ml). The suspended competent cells (200^il) were plated onto 
the LB plate and spread well on the surface of the agar plate. The agar plate was 
incubated in an inverted position at 37°C for 12-16 hours. The plate was then stored at 
4°C for another 4 hours for the colour development by p-galactoside activity. After 
colour development, a white single bacterial colony representing the recombinant was 
transferred with a toothstick to a loosely capped 15-ml tube, which contained 5ml o fLB 
medium with ampicillin (50^ig/ml). The culture medium was then incubated at 37°C 
ovemight with vigorous shaking. 
The recombinant plasmid DNA was extracted by using a commercial kit (High 
Pure Plasmid Isolation Kit; Boehringer Mannheim) and described as follows. 1.5ml ofthe 
culture medium containing the recombinant colony was poured into a microcentrifuge 
tube. The bacteria were pelleted by centrifugation at 12,000xg for 20 sec at room 
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temperature and the supernatant was removed with a Pasteur pipette. The pelleted 
bacterial cells were resuspended in 250^1 of suspension buffer and mixed well. The 
bacterial cells were lyzed by alkaline solution. 250^il of lysis buffer was added to the 
resuspended bacterial cells, mixed gently and incubated at room temperature for 5 min. 
The solution would become viscous and clear. 350^il of chilled binding buffer was added 
to the lysis solution, mixed gently by inverting the tube 3 to 6 times and incubated on ice 
for 5 min. The solution would become cloudy and flocky. The solution was then 
centrifuged at maximum speed (approx. 13,000 xg) for 10 min. The High Pure filter tube 
and the collection tube were combined together to make a filtration device. The 
supernatant was transferred to the upper reservoir and centrifuged for 30 to 60s at 13,000 
xg. The flowthrough solution after centrifugation was discarded. A volume of 700^il 
wash buffer II was added to the upper reservoir and centrifuged for 30 to 60s at 13,000 xg 
again. The flowthrough was discarded and the tubes were centrifuged for an additional 30 
to 60s to remove the residual wash buffer. The collection tube was discarded. The filter 
tube containing the plasmid DNA was inserted to a new and clean 1.5 ml microcentrifuge 
tube. A volume of 100^1 elution buffer was added into the filter tube. The plasmid DNA 
was eluted by centrifugation at 13,000 xg for 30s. The extracted plasmid DNA was 
quantified with an UV spectrophotometer (Hitachi U-3000) by measuring the absorbance 
at 260nm. 
Finally, the plasmid, which contains the inserted cDNA fragment of rat 18s 
ribosomal RNA, was analysed by digestion with restriction enzymes Pstl and Xhol. The 
reaction mixture was prepared as follows: 5^1 of the plasmid (about 15^g DNA), 5^1 of 
10x restriction enzyme buffer H and l^il of each Pstl (lOU/^il) and Xhol (15U/^1) were 
mixed with 38^il milli-Q. The reaction mixture was incubated at 37°C for 1 hour. The 
size of digested DNA fragments were confirmed by electrophoresis in 1% agarose gel. 
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For the plasmids carrying the cDNA fragments of probasin and SVSII was 
analyzed by the same procedure of digestion with restriction enzymes. For the cloned 
probasin cDNA, the plasmid was digested with 10U of BamHl and EcoRV, whereas for 
the rat SVSII, the plasmid was digested with 10U of EcoRl and CM. 
2.14 Tissues Preparation for In-situ hybridization 
The rats (n=10) were anaesthetised by intraperitoneal injection of chloral hydrate. 
The anaesthetised animals was perfused briefly with normal saline to flush out the blood 
via the left ventricle, followed by 4% paraformaldehyde in O.lM phosphate buffer, pH 
7.4. The urogenital tract was exposed by a lower abdominal incision and remove en bloc 
(including seminal vesicles, coagulating gland, prostate gland complex, ductus deferens 
and urethra). The seminal vesicle and coagulating gland were excised at their points of 
entrance into the urethra. The urinary bladder was removed with the prostatic urethra left 
in place. The prostate gland complex was further fixed in same fixative ovemight at 4°C. 
After fixation, the tissue was immersed in PBS with 0.5M sucrose ovemight at room 
temperature. The fixed tissue was then dehydrated through graded ethanol, cleared with 
xylene and embedded in paraffin. Horizontal sections of urethra with the surrounding 
prostate gland were cut. 
2.15 Synthesis of Digoxigenin (DIG)-Labeled RNA Probe 
For rat PSP94, DIG-labeled PSP94 RNA probes were generated by in vitro 
transcription with DIG-labeled UTP described as follow. Full length rat PSP94 cDNA 
fragment generated by RT-PCR (490 bp) was subcloned into pBluescript KS- vector 
(Stratagene) [Femlund et al., 1996; GenBank accession no. U65486]. Approximately 2^ig 
of plasmid DNA was linearized with 10U EcoRl and transcribed with T7 RNA 
polymerase to synthesize the antisense probe. For the synthesis of sense probe, the 
plasmid DNA was linearized with 10U BamUl and transcribed with T3 RNA polymerase. 
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Labeled transcripts were synthesized in a 40^1 reaction mixture containing the linearized 
plasmid, transcription buffer (40mM Tris-HCl, 6mM MgCb, lOmM DTT, 2mM 
spermidine, pH 8.0)，DIG RNA Labeling Mix ( lmM of each of ATP, CTP, GTP; 
0.65mM UTP; 0.35mM DIG-labeled UTP, pH 7.5)，80U RNase-inhibitor, and 20U of the 
appropriate RNA polymerase. Following incubation at 3 7 � C for 2hr, 20U DNase-I, 
RNase-free was added to the reaction mixture, in order to digest the plasmid DNA 
template and incubated at 37°C for additional 30 min. The reaction was halted by adding 
2^il of 0.2M EDTA, pH 8.0. The labeled transcription products were precipitated with 4fil 
of 3M sodium acetate and lOO i^l ice-cool absolute ethanol at -20°C for 2hr. The probes 
were pelleted by centrifogation at 14,000 rpm, washed with cold 70% ethanol, dried 
under vacuum and resuspended in 20^il of DEPC-treated water. The probes were 
analyzed in 1.5% agarose gel electrophoresis before use. All enzyme and DIG RNA 
Labeling Mix were obtained from Boehringer Mannheim GmbH (Mannheim, Germany). 
For the in-situ hybridization of rat probasin and SVSII, the pSK plasmids with the 
inserted cDNA fragment of probasin or SVSII were used to synthesis the DIG-labeled 
RNA probes. 
2.16 In-situ Hybridization 
The non-radioactive in-situ hybridization was performed according to the 
procedure described by Komminoth et al. [1992] with some minor modifications. 
Paraffm sections of 4^im in thickness were cut (transverse sections of urethra with three 
different prostatic lobes) and adhered on the glass slides coated with 3-
aminopropyltriethoxysilane. The hydrated sections were pretreated with proteinase K 
(lO^ig/ml in O.lM Tris-buffer and 50mM EDTA, pH 8.0) at 37°C for 20 min followed by 
post-fixation in 4% paraformaldehyde in DEPC-treated PBS for 10 min. After two 
washes in PBS, the sections were acetylated in 0.25% acetic anhydride (v/v) in O.lM 
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triethanolamine, pH 8.0 for 10 min. The sections were prehybridized in buffer containing 
4 X SSC (1 X SSC is 150mM NaCl and 15mM sodium citrate, pH 7.0), 2 x Denhardt's 
solution (1 X Denhardt's solution is 0.02% Ficoll® 400，0.02% polyvinylpyrollidone, 
0.02% BSA), 10% dextran sulfate, 50% deionized formamide at 37°C for at least lhr. 
Sections were then hybridized with DIG-labeled RNA probe (8ng/^il) in the buffer 
containing 4 x SSC, 2 x Denhardt's solution, 10% dextran sulfate, 50% deionized 
formamide and 0.2 mg/ml salmon sperm DNA ovemight at 56°C (for rat PSP94, probasin 
and SVSII) in a humid chamber. After hybridization, sections were rinsed in 4 x SSC for 
10 min at room temperature followed by digestion with RNase A (20 ^ig/ml in 500mM 
NaCl, lOmM Tris-HCl, lmM EDTA, pH 8.0) for 30 min at 37°C. After RNase treatment, 
sections were washed in series of SSC (one rinse in each of 2 x SSC, 1 x SSC, 0.5 x SSC, 
0.1 X SSC) at room temperature followed by one final rinse in 0.1 x SSC for 30 min at 
60°C. After post-hybridization washes, sections were left ovemight in 2 x SSC 
containing 0.05% Triton X-100 and 2% normal goat serum (GibcoBRL). The sections 
were then washed in washing buffer (lOOmM Tris, 150mM NaCl, pH7.5) and then 
blocked in same washing buffer containing 1% normal goat serum and 0.3% Triton X-
100 (dilution buffer) for 30 min. The hybridized signals were then visualized by alkaline 
phosphatase immunohistochemistry. Sections were incubated with a sheep anti-DIG 
antibody conjugated to alkaline phosphatase (diluted 1:200 in dilution buffer; Boehringer 
Mannheim) ovemight at room temperature. After incubation with antibody, sections were 
rinsed in washing buffer followed by a wash in 100mM Tris, 100mM NaCl and 50mM 
M g C l 2 , pH 9.5 (substrate buffer). For the detection ofhybridization signals, sections were 
incubated in a chromogen solution containing 45^il nitroblue tetrazolium (NBT, 75 
mg/ml in dimethylformamide), 35^il 5-bromo-4-chloro-3-indolylphosphate (BCIP, 50 
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mg/ml in dimethylformamide) and 0.24 mg/ml levamisole (lmM) in 10 ml substrate 
buffer at 37°C for 2-3 hr in darkness. The color reaction was stopped by incubating in 
stop buffer (lOmM Tris, lmM EDTA, pH 8.0) and then rinsed in tap water. Sections 
were counter-stained with 1% methyl green before being mounted in aqueous mounting 
solution (Clearmount™, Zymed Labs. Inc.). Photography was made by a Zeiss Axioskop 
microscope. 
2.17 Total RNA Extraction 
Total RNA from frozen tissues was extracted by using a Trizol reagent 
(GibcoBRL). The reagent contains phenol and guanidine isothiocyanate mixture and is 
used in a single-step method for RNA isolation developed originally by Chomizynski and 
Sacchi [1987]. The tissue was homogenized with pestle in a small mortar under liquid 
nitrogen. About 50-100 mg homogenized tissue was incubated with 1ml Trizol reagent. 
The ground tissues were further homogenized by shearing using 23G x 1.5" needle and 
2.5ml syringe. The homogenate was transferred to a microcentrifuge tube and incubated 
at room temperature for 5 min. Chloroform (200^1) was added to the homogenate and the 
mixture was shaken vigorously for 15 seconds. After incubation for 3 min at room 
temperature, the aqueous phase and organic phase was separated by centrifugation at 
12,000 xg for 15 min at 4°C. The supernatant, i.e. the aqueous phase, was transferred to 
another microcentrifuge tube and 0.5 ml of isopropyl alcohol was added. The mixture 
was incubated at room temperature for 10 min in order to precipitate RNA. The RNA 
pellet was obtained by centrifugation at 12,000 xg for 10 min at 4°C. The supernatant 
was removed carefully. The pellet containing the extracted RNA was washed gently with 
ice-cold 70% ethanol, air dried and re-dissolved in 20^1 DEPC-treated water. The 
resuspended RNA was quantified by measuring its absorbance at 260nm with a UV 
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spectrophotometer (U-3000, Hitachi). The RNA sample was stored at -70°C until 
subsequent analysis. 
2.18 Northern Blotting Analysis 
Approximately 20)ng of RNA samples were separated in duplicates by 
electrophoresis in 1.2 % agarose in lx MOPS and 2 % formaldehyde. The RNA samples 
were mixed with an RNA loading buffer in volume ratio of 1:3. The RNA samples were 
denatured at 65°C for 10 min in RNA loading buffer, and placed on ice immediately 
afterward. The loading buffer contained freshly deionised formamide (250^il), 37% 
formaldehyde (83^il), 10x MOPS (50^il). 1% xylene cyanol and 1% bromophenol blue 
(5^il) was added in each sample. After heat denaturation, the samples were loaded into 
the dry wells of gel. RNase-free electrophoresis buffer ( lx MOPS) was added to the 
buffer tank up to the edge of the gel. The RNA samples were allowed to run into the gel 
at 100 constant voltage. After the RNA samples had moved into the gel, lx MOPS buffer 
was added to the buffer tank so as cover the gel completely with the buffer. The RNA 
samples were continued to be electrolyzed. The electrophoresis was stopped when the 
bromophenol blue has migrated to approximately 8cm from the wells. Sizes of RNAs 
were estimated by referring to the RNA molecular weight markers (0.3-7.4kb, Boehringer 
Mannheimer). The lane of gel containing the markers was cut. The remaining gels 
containing the separated RNA samples were stained with 5 ^ig/ml ethidium bromide in lx 
MOPS buffer for 5 min in dark with gentle shaking. The stained gel was destained for 2 
hr in 500ml DEPC-treated water with 3 changes in dark with gentle shaking. The 
destained gel was aligned with a transparent ruler and photographed under UV 
illumination. The integrity o fRNA was examined in duplicate gels stained with ethidium 
bromide under UV for the 18S and 28S rRNAs. If the 18s and 28s rRNAs have 
demonstrated a ratio of 2:1 to 1:1, the RNA samples would then be for further Northern 
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blotting analysis. Duplicate unstained gels were washed extensively in DEPC-treated 
water and soaked in RNase-free 20x SSC (1 x SSC is 150mM NaCl and 15mM sodium 
citrate, pH 7.0) for 30 min to remove the formaldehyde before transferring onto 
positively-charged nylon membrane (Boehringer Mannheim) by upward capillary force 
method [Khandjian, 1987]. After ovemight transfer, the position and orientation of the 
wells were marked on the membrane by soft pencil. The transfer stack was dissembled. 
Both sides of the membrane UV-crosslinked were exposured to 254nm wavelength 
ultraviolet light for UV-crosslinking (ultraviolet crosslinker CL-1000, UVP, USA) while 
it was still wet. The crosslinked membrane was rinsed in DEPC-treated milli-Q water, 
and then pre-hybridized in a prehybridization solution (DIG Easy Hyb, Boehringer 
Mannheim) for 1 hr at 56°C. Before hybridization, the hybridization solution (DIG Easy 
Hyb) was pre-warmed to 56°C. The riboprobes were denatured at 95°C for 5 min and 
quickly chilled on ice. The membrane was then hybridized with a DIG-labeled riboprobe 
for rat PSP94 of about 490bp (l^g/ml in pre-warmed DIG Easy Hyb) for 16 hr at 56°C 
with gentle agitation. After hybridization, the blots were washed twice in 2x SSC with 
0.1% SDS at 25�C for 15 min, twice in lx SSC and 0.1% SDS at 25°C for 15 min, twice 
in O.lx SSC and 0.1% SDS at 65°C for 30 min. After post-hybridization washes, the 
membranes were rinsed briefly in washing buffer (lOOmM maleic acid, 150mM NaCl, 
0.3% [v/v] Tween-20®, pH 7.5) for 5 min. The hybridized signals were visualized by 
immuno-alkaline phosphatase procedure. The membranes were incubated in a blocking 
solution (lOOmM maleic acid, 150mM NaCl and 1% blocking reagent [Boehringer 
Mannheim], pH 7.5) for 1 hr followed with a sheep anti-DIG antibody conjugated to 
alkaline phosphatase diluted 1:10,000 in blocking solution for 1 hr at 25°C. After 
incubation with antibody, the membranes were washed twice in washing buffer for 30 
min and then in a detection substrate buffer (lOOmM Tris-HCl, 100mM NaCl, pH 9.5) for 
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5 min. The hybridized signal was detected by a chemilumininescence method using CDP-
Star™ (diluted 1:100 in substrate buffer, Boehringer Mannheim) as substrate. The 
membranes were exposed to X-ray film (Lumi-Film Chemiluminescence Detection Film, 
Boehringer Mannheim). In order to assess the amount and integrity of total RNAs loaded 
in each gel, the blotted membranes used for PSP94 hybridization were stripped in 50 mM 
Tris-HCl with 50% formamide and 1% SDS, pH 8.0, at 75°C for 30 min to remove the 
hybridized RNA probe and rehybridized with a DIG-labeled riboprobe for rat 18s 
ribosomal RNA. The riboprobe for rat 18s rRNA was generated by in vitro transcription 
using a pSK vector containing the cDNA fragment of rat 18s ribosomal RNA. 
2.19 Primers and Cycling Conditions 
The primer sequences for rat PSP94 [Xuan et al., 1999], probasin [Haughney et 
al., 1998] and p_actin [Amoureux et al., 1995] were designed according to the published 
sequences. The primer sequences for rat SVSII were designed using a web-shared 
software (Primer 3; Whitehead Institute; MIT Center for Genome Research). 
The respective 5’ and 3’ primers for rat PSP94 spanned nucleotides 32-52 (5'-
AGT CCT GCT TTG CCA CCA TG-3,) and 502-522 (5'-TTT CAA GAC ATC CTG 
GCT CTG-3') of the rat beta-microseminoprotein (PSP94) cDNA sequence as reported 
by Femlund et al. [1996; GenBank accession no. U65486]. The conditions o f P C R to 
amplify rat PSP94 cDNA were: 94�C for 1 min, 63�C for 1 min, 7 2 � C for 2 min (for 1-5 
cycles), 94°C for 1 min, 57°C for 1 min, 72°C for 2 min (for 6-20 cycles). 
The respective 5，and 3，primers for probasin spanned nucleotides 1-30 (5'-CTT 
GTC AGT GAG GTC CAG ATA CCT ACA GAG-3') and 747-776 (5,-GCA AGT GAA 
ATA GAT TTA TTT AAA CAT TCA-3') of the published probasin cDNA sequence 
[Spence et aL, 1989; GenBank accession no. M27156]. The conditions ofPCR to amplify 
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probasin cDNA were: 9 4 � C for 30 sec, 6 5 � C for 30 sec, 72°C for 30 sec (for 1-5 cycles), 
94°C for 30 sec, 60°C for 30 sec, 7 2 � C for 30 sec (for 6-20 cycles). 
The respective 5, and 3, primers for rat SVSII spanned nucleotides 2661-2681 
(5'-AGT GGA CAG CTG AAA TCT GGA-3,) and 3405-3424 (5'-TAG GAT TGG 
GAG CGT TCT TG-3') of the rat SVSII cDNA sequence as reported by Harris et al. 
[1990; GenBank accession no. J05443 & M54795]. The conditions of PCR were: 94°C 
for 1 min, 60°C for 1 min, 72°C for 2 min (for 1-20 cycles). 
The rat P-actin cDNA was amplified using a sense primer (5'-ATG GAT GAC 
GAT ATC GCT GCG-3') and an antisense primer (5'-CTC CAT ATC GTC CCA GTT 
GGT-3') which generated a 249bp fragment of rat P-actin [Amoureux et al., 1995]. 
2.20 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
Total RNA samples were first digested by DNase-I before reverse transcription to 
avoid any contamination with genomic DNA. For each reaction, approximately 1.5^ig of 
total RNA, l^il DNase-I, RNase-free (lOU/^l, Boehringer Mannheim) and l^il 10x PCR 
buffer (200 mM Tris-HCl, pH 8.4，500 mM KC1) were added to DEPC-treated water to a 
final volume of lO^il. The reaction mixture was incubated at 3 7 � C for 30 min. EDTA 
(l^il, 25mM) was added to the reaction mixture and incubated at 65°C for 15 min in order 
to inactivate the activity of DNase-I. The reaction mixture was then chilled on ice. The 
mixture can be directly used for reverse transcription. 
The reverse transcription of total RNA to complementary DNA (cDNA) was 
performed by using a commercial kit (SUPERSCRIPT™ Preamplification System for 
First strand cDNA Synthesis, GibcoBRL, USA). The mixture after DNase-I digestion 
was then mixed with 1^1 Oligo(dT)12-i8 (0.5^ig/^l). The mixture was incubated at 70°C 
for 10 min and quick chilled on ice afterwards. Other reaction components including 2^il 
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of 10x PCR buffer, 2^il of25mM M g C l 2 , 1^1 of lOmM dNTP mix (lOmM of each dATP, 
dCTP, dGTP, dTTP) and 2^il O.lM DTT were added to the mixture and incubated at 
42°C for 5 min. After incubation, the reverse transcriptase (SUPERSCRIPT II RT, 200U) 
was added to the mixture and incubated at 42°C for 50 min in order to synthesize the first 
strand cDNA. The reverse-transcription was stopped at 7 0 � C for 15 min. After the 
reverse transcription, 2^il of E. coli RNase-H (2U/^il) was added to the cDNA 
components and incubated at 37°C for 15 min in order to digest the remaining total RNA. 
The reversely transcribed cDNA was stored at -20°C until subsequent PCR reaction. 
After reverse transcription, the target cDNA was amplified by PCR using the 
antisense primer and sense primer specific for target genes. A PCR reaction mixture was 
mixed over ice bath as follows: 2^il of reverse transcription reaction product or cDNA, 
l^il each o f the antisense and sense primers (20 ^iM), 5 …of 10x PCR buffer, 3 i^l of 25 
mM M g C l 2 , 1 i^l of 10 mM dNTP mix, 0.5 i^l of Taq DNA polymerase (5 U/fil， 
GibcoBRL) and 36.5^il of autoclaved milli-Q water. The mixture was amplified in a 
thermal cycler (GeneAmp 9600，Perkin Elmer). The conditions of PCR amplification 
were stated in previous paragraphs. The reaction was terminated at 4°C. Control reactions 
lacking the cDNA template were performed by omitting the reverse transcriptase or total 
RNA in order to examine the possible contamination by genomic DNA. The amount of 
and integrity of total RNA applied in each RT-PCR reaction were assessed by RT-PCR 
amplification of rat p-actin mRNA in each samples using a sense primer and an antisense 
primer specific for rat p-actin [Amoureux et al., 1995]. The reaction would generate a 
249 bp fragment. The rat P-actin was amplified under the same conditions of either rat 
PSP94, probasin or SVSII amplification, with the exception that the reactions were 
extended to 27 cycles. The PCR products (lO^il) were analyzed by electrophoresis in 
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1.5% agarose gel in lx TBE buffer ( lx TBE contains 0.089 M Tris base, 0.089 M borate 
and 0.002 M EDTA), stained with ethidium bromide and photographed under UV 
illumination. 
2.21 Southern Blotting Analysis 
2.21.1 Southern Blotting 
The PCR products of rat PSP94 amplified in prostatic tissues were further 
analyzed by Southem blotting using a full-length rat PSP94 cDNA as DNA probe. The 
procedure was described as follows. About lO^il of the PCR product was separated by 
1.5% agarose gel electrophoresis without ethidium bromide. After electrophoresis, the 
agarose gel was submerged in a denaturation buffer (0.5N NaOH, 1.5M NaCl) with 
gentle shaking for 15 min at room temperature with 2 changes and then transferred to a 
neutralization buffer (0.5M Tris, 1.5M NaCl, pH 7.5) for 15 min at room temperature 
with 2 changes. After neutralization, the PCR products from the gel were transblotted 
onto positively charged nylon membranes with 20x SSC buffer by an upward capillary 
force method. After capillary transfer, the blots were crosslinked by exposure to 254nm 
wavelength ultraviolet light (ultraviolet crosslinker CL-1000, UVP, USA). 
2.21.2 Preparation ofDIG-dUTP Labeled Rat PSP94 cDNA Probe 
Rat PSP94 cDNA probe (490 bp) was generated by PCR as follows. Rat PSP94 
cDNA was synthesized by PCR using the antisense and sense primers for rat PSP94 and 
the pKS-vector with the full-length rat PSP94 cDNA insert as template. The PCR DNA 
product was separated in a 1.5% agarose gel electrophoresis and the cDNA with the 
expected size (490bp) was extracted from the gel using a commercial kit (Sephaglas 
BandPrep Kit, Pharmacia Biotech). The amount ofDNA was quantified by measuring its 
absorbance at 260 nm. 
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The rat PSP94 cDNA amplified by PCR was then labeled with DIG-dUTP by 
random primed labeling method [Feinberg and Vogetstein., 1983]. The labeling 
procedure was described as follows. About l,5^ig purified rat PSP94 cDNA fragment was 
first diluted in milli-Q water to a total volume of 15^il, and then denatured at 100°C in 
boiling water for 5 min. After heat- denaturation, the template DNA was quickly chilled 
on ice. 2^il of 10x Hexanucleotide mix (containing 0.5 M Tris-HCl, 0.1 M M g C l 2 , 1 mM 
dithioerythritol, DTE, 2 mg/ml bovine serum albumin, hexanucleotides, [62.5 A260 
units/ml], pH 7.2)，2 i^l of 10x DIG DNA Labeling Mix (1 mM dATP, 1 mM dCTP, 1 
mM dGTP, 0.65 mM dTTP, 0.35 mM DIG-dUTP, alkali-labile, pH 7.5), 2^il ofKlenow 
enzyme, (2 U/^1, labeling grade, mixed to a final concentration of lOOU/ml), were mixed 
with the template DNA on ice. The reaction mixture was incubated at 37°C for 6 hr. The 
reaction was stopped by adding 2^il of 0.2M EDTA (pH 8.0) to the mixture. The labeled 
DNA was precipitated by adding 2.5^il o f 4 M LiCl and 75^il prechilled (-20�C) ethanol 
and left at -20°C for 16 hr. The labeled DNA was pelleted by centrifUgation at 12,000 
rpm for 20 min. The pellet obtained was washed in 200 i^l cool 70% ethanol and dried 
briefly under vacuum. Finally, the DNA pellet was dissolved in 20 i^l autoclaved milli-Q 
water. 
2.21.3 Hybridization 
The membranes with the transblotted cDNA were prehybridized in 
prehybridization solution (DIG Easy Hyb, Boehringer Mannheim) for 1 hr at 56°C. 
Before hybridization, the hybridization solution (DIG Easy Hyb) was pre-warmed to 
56�C. The DNA probe was denatured at 95°C for 5 min and chilled on ice quickly before 
use. The membrane was then hybridized with the DIG-labeled DNA probe for rat PSP94 
of about 490bp in size (25ng/ml in DIG Easy Hyb) for 16 hr at 56°C with gentle 
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agitation. After hybridization, the blots were washed twice in 2 x SSC with 0.1 % SDS at 
2 5 � C for 15 min, twice in 1 x SSC and 0.1 % SDS at 25°C for 15 min, twice in 0.1 x SSC 
and 0.1% SDS at 68°C for 30 min. After post-hybridization washes, the membranes were 
rinsed briefly in washing buffer(100 mM maleic acid, 150 mM NaCl, 0.3% [v/v] Tween-
® 
20，pH 7.5) for 5 min. The hybridized signals were visualized by alkaline phosphatase 
immunochemistry as for Northem blotting. In brief, the membranes were incubated in a 
blocking solution (100 mM maleic acid, 150 mM NaCl and 1% blocking reagent from 
Boehringer Mannheim, pH 7.5) for 1 hr followed by a sheep anti-DIG antibody 
conjugated to alkaline phosphatase diluted in 1:10,000 in blocking solution for 1 hr at 
25°C. The membranes were washed twice in washing buffer for 30 min and then in the 
detection substrate buffer (lOOmM Tris-HCl, 100mM NaCl, pH 9.5) for 5 min. The 
hybridized signal was detected by chemilumininescence using CDP-Star™ (diluted 1:100 
in substrate buffer, Boehringer Mannheim) and expose to Lumi-Film Chemiluminescence 
Detection Film (Boehringer Mannheim). 
2.22 Restriction Mapping 
The sequence of PCR product of rat SVSII (764bp) was analyzed by restriction 
mapping. There is a total of 122 enzymes cut in the sequence. The restriction enzyme 
Nco\ was selected to digest the PCR product ofra t SVSII. The reason is that Nco\ cut one 
site in the PCR product of rat SVSII and generated two cut products. The enzyme 
digestion mixture was prepared as follows. 15^1 of the PCR product, 5^il of 10x 
restriction enzyme buffer K, 5^il of 0.1% BSA and 2|al ofA^coI were mixed with 23^il 
milli-Q water. The reaction mixture was incubated at 3 7 � C for 1 hour. The digested DNA 
fragments were analysed by electrophoresis in 1.5% agarose gel. As a result, two reaction 
products with sizes of 614 bp and 150 bp appeared in the gel in addition to the intact PCR 
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2.23 Semi-Quantitative RT-PCR 
Total RNA (1.5^ig) was reverse transcribed using the SUPERSCRIPT™ 
Preamplification System for First strand cDNA Synthesis as described previously 
(GibcoBRL). After transcription, 2^1 of the resulting cDNA samples was used in PCR 
amplification for rat PSP94, probasin, SVSII and p-actin, respectively. The PCR 
conditions and primer sequences for rat PSP94, probasin and SVSII were as described in 
previous sections. The optimal PCR conditions were evaluated so that the amplifications 
of the products were linear with respect to the amount of input cDNA. The linear range of 
the PCR reaction was determined by performing RT-PCR as described above and 
stopping the amplification of replicate samples at regular time intervals. Separate 
reactions were also performed in parallel using primers for rat p_actin cDNA for 
comparative measurements. PCR cycle numbers for rat PSP94, probasin and rat SVSII 
were 20，whereas for rat p-actin, it was 27. After PCR reactions, the products were 
resolved on a 1.5% agarose gel with ethidium bromide (EtBr). The image was captured 
under UV transillumination with black and white photographs. The intensities of the 
bands were quantified by measuring their relative densitometry using a software for gel 
electrophoresis (ImageQuant analyses, Molecular Dynamics). Signal intensities of the rat 
PSP94, probasin and rat SVSII products were normalized to those of ra t P-actin products 
as ratios in order to produce arbitrary units of relative abundance. 
2.24 Statistical Analysis 
Statistical analyses were performed using Sigmastat. For studies of androgen 
regulation, statistical differences between intact control values and various treatment 
group values were determined using one-way ANOVA followed by Tukey post-hoc test. 
For studies of regulation by other steroids and zinc, statistical differences between com 
oil-treated control values and various treatment group values were determined using one-
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way ANOVA followed by Tukey post-hoc test. Differences were considered significant if 
P< 0.05. 
2.25 Protein Extraction, SDS-PAGE and Western Blotting Analysis 
The frozen dissected individual prostatic lobes obtained from intact adult rats 
were homogenized (Polytron PT 2000, Brinkmann) in 10x volumes (per gm wet weight 
tissue) ofcold lysis buffer (20 mM PIPES, 0.25 M sucrose, 1 mM EDTA, 1 mM EGTA, 
10 mM monothioglycerol, 0.5 mM PMSF, 2 ^ig/ml aprotinin and 5 i^M leupeptin). The 
homogenates were centrifuged at 800 xg at 4 � C for 15 min. The pellets were re-
suspended in 5x volumes of lysis buffer, re-homogenized and re-centrifuged at 800 xg. 
The low-speed supernatant was pooled together and centrifuged at 10,000 xg for 15 min 
at 4°C. The supernatant was recovered and further centrifuged at 100,000 xg for 40 min 
at 4°C. The protein concentrations of the supematants after 100,000 xg (cytosolic 
fractions) were determined by the bicinchoninic acid protein assay with bovine serum 
albumin as standard (BCA Protein Assay, Pierce, USA) before aliquoting and keeping at 
-70°C until electrophoretic analysis. 
For the collection of secretory fluids, the freshly dissected prostatic gland were 
gently cut by a surgical blade and the tissues were slightly squeezed with the blade over a 
sheet of aluminum foil. The fluids were then collected by a pipette. The chopped tissues 
were further centrifuged at 14,000 xg for 10 min at 4°C. the suspematants were removed 
and pooled with the previously collected fluids. These fluids were designated as the 
secretory fluids from different gland or prostate lobes and the protein concentrations were 
determined by the BCA protein assay with bovine serum albumin as standard before 
aliquoting and keeping at -20°C until electrophoretic analysis. 
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For frozen tissues collected from the castrated, androgen-replaced and drug-
treated rats, proteins were extracted by Trizol reagent according to the procedure 
described by the manufacturer (GibcoBRL). First, the tissues were homogenized under 
liquid nitrogen with pestle in a small mortar. About 50-100 mg homogenized tissue was 
incubated in 1ml Trizol reagent and further homogenized by shearing action using a 23G 
X 1.5" needle and a 2.5ml syringe. The homogenate was transferred to a microcentrifuge 
tube and incubated at room temperature for 5 min. Chloroform (200^il) was then added to 
the homogenate and the mixture was shaken vigorously for 15 seconds. After 3 min 
incubation at room temperature, the aqueous phase and organic phase was separated by 
centrifugation at 12,000 xg for 15 min at 4 � C . The aqueous phase was removed. A 
volume of0.3 ml 100% ethanol was added into the organic phase and the samples mixed 
by inversion. The mixtures were incubated at room temperature for 3 min and centrifuged 
at 2,000 xg for 5 min at 4°C. Proteins were precipitated from the phenol-ethanol 
supernatant with isopropyl alcohol. The supernatant was transferred to another 
microcentrifuge tube and a volume of 1.5ml isopropanol was added. The mixture was 
incubated again at room temperature for 10 min in order to precipitate proteins. The 
protein pellet was obtained by centrifugation at 12,000 xg for 10 min at 4°C. The 
supernatant was discarded. The protein pellet was washed 3 times in a solution containing 
0.3 M guanidine hydrochloride in 95% ethanol. A volume o f 2 ml washing solution was 
added to the protein pellet. During each wash cycle, the protein pellet was incubated in 
the washing solution for 20 min at room temperature and centrifuged at 7,500 xg for 5 
min at 4 � C . After the final wash, the protein pellet was vortexed in 2 ml of 100% ethanol 
and remained in ethanol for 20 min at 4°C. The protein pellet was centrifuged at 7,500 xg 
for 5 min at 4 � C . The ethanol was discarded and the protein pellet obtained was then 
dried under vacuum and dissolved in 1% SDS by repeated pipetting. In order to ensure 
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complete dissolution of the extracted proteins, the samples were incubated at 50°C 
ovemight. The sample was centrifuged at 10,000 xg for 1 min to sediment any insoluble 
material. The supernatant was collected and the protein concentrations were determined 
by the BCA protein assay with bovine serum albumin as standard before aliquoting and 
keeping at -20°C until electrophoretic analysis. 
For the gel electrophoresis, the protein samples were first mixed with 0.2 volume 
of 2x sample buffer (0.125 M Tris-HCl, pH 6.8，5 % SDS [w/v], 20 % glycerol [w/v], 
0.002 % bromophenol blue, 10 % 2-mercaptaethanol) and heated up to 100°C for 5 min. 
The denatured protein samples were separated by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) in 15 % gel using a mini-gel apparatus (Bio-Rad, USA). 
Proteins were loaded at 15 ^ig per lane. The gels were run at 100V constant voltage per 
slab for 2 hr. Protein molecular weight markers were obtained from Amersham Life 
Science (ECL protein markers, England) or Bio-Rad Laboratories. For the analysis of 
total proteins, gels were stained by Coomassie Blue staining. The gels were submerged in 
0.2 % Coomassie blue staining solution (0.2 % Coomassie blue in destaining solution) for 
about 10 min. The stained gels were washed in destaining solution (methanol: glacial 
acetic acid: distilled water, 3:1:6 v/v). 
For Westem blotting, gels were fixed in the transfer buffer containing 25 mM 
Tris，192 mM glycine and 10 % methanol, pH 8.3 for 30-45 min. Proteins were 
electrophoretically transferred onto the PVDF membranes (0.2^m, Schleicher & Schuell) 
in the transfer buffer at 100V at 4°C for 1 hr. The blotted membranes were blocked with 
1 % Tween-20 in PBS for 1 hr and then washed in washing buffer (PBS with 0.05 % 
Tween-20) for 30 min. The membranes were then incubated with a rabbit antiserum 
against the recombinant GST-rat PSP94 diluted 1:2,500 in PBS with 2 % non-fat milk 
powder at 2 5 � C for ovemight. This antibody has been characterized by Dr. Jim W. Xuan 
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of the University of Westem Ontario [Kwong et al., 1999]. For control blots, membranes 
were incubated in 1 % normal goat serum. After washing with washing buffer, the 
membranes were incubated with a biotinylated goat-anti rabbit IgG secondary antibody 
(diluted, 1:500) for 1 hr at 25°C. After washing with washing buffer, the membranes 
were further incubated with streptavidin conjugated to alkaline phosphatase (diluted, 
l : 5 0 0 ) f o r l h r at 25�C. 
The antibody binding sites were detected by a colorimetric method. The 
membranes were incubated in a substrate buffer (100 mM Tris, 100 mM NaCl and 50 
mM M g C l 2 , pH 9.5) for 10 min. Then, the color reaction was developed by incubation in 
a chromogen solution containing 45 |il nitroblue tetrazolium fNBT, 75 mg/ml in 
dimethylformamide), 35 i^l 5-bromo-4-chloro-3-indolyl-phosphate (BCIP, 50 mg/ml in 
dimethylformamide) and 0.24 mg/ml levamisole (1 mM) in 10 ml substrate buffer at 
25°C for several minutes. The color reaction was stopped by incubating in stop buffer (10 
mM Tris, 1 mM EDTA, pH 8.0) and then rinsed with distilled water. The color-
developed membranes were dried between blotting paper. 
2.26 Immunohistochemistry 
Paraffin sections of transverse sections of urethra with three different prostatic 
lobes were cut, dewaxed in xylene and hydrated. The hydrated sections were treated with 
0.5 % hydrogen peroxide in absolute methanol for 15 min in order to remove the 
endogenous peroxidase activity. The sections were then rinsed in phosphate buffered 
saline (PBS, pH 7.4) for 20 min. Antigen retrieval was preformed by heating the sections 
in 0.1 M Tris-HCl, pH 9.2，containing 5% urea in a microwave oven two times for 5 min 
each and remained in the solution for 15 min before washing in PBS [Shi et al., 1996]. 
The sections were blocked in 1 % bovine serum albumin (BSA) in 0.05 % PBS for 15 
min and then incubated with a rabbit antiserum against the recombinant GST (glutathione 
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S-transferase)-rat PSP94 [Kwong et al., 1999] (diluted in 1:100 in blocking solution) 
overnight at 4°C in a moist chamber. For control sections, the primary antibody was 
replaced by 1 % BSA in 0.05 M PBS. After incubation with primary antibody, the 
sections were washed with PBS, 3 changes of 15 min each. The sections were then 
incubated with a biotinylated goat anti-rabbit IgG (Jackson ImmunoResearch Labs) for 1 
hr at room temperature in a moist chamber. The sections were rinsed with PBS for 15 
min. The antibody binding sites were demonstrated by avidin-biotin peroxidase complex 
method (ABC) [Hsu et al., 1981] for 1 hr in room temperature. The ABC complex was 
prepared by mixing 10 i^g avidin (EY Laboratories, San Mateo, USA) and 2.5 i^g biotin-
conjugated horseradish peroxidase (Jackson ImmunoResearch Labs) in 0.05 M PBS. The 
ABC mixture was allowed to stand for 30 min in room temperature before applying to the 
sections. After incubation with ABC, the sections were rinsed in PBS with 3 changes, 
each for 15 min. The peroxidase activity was visualized by a glucose oxidase-
diaminobenzidine (DAB)-nickel intensifying procedure [Chan and Choi, 1995]. In brief, 
the sections were pre-incubated with ammonium nickel sulfate-DAB solution (0.4g 
ammonium nickel sulfate, 20 mg P-D-glucose, 4.0 mg ammonium chloride and 5.0 mg 
DAB in 10 ml O.lM acetate buffer, pH 6.0) for 5-10 min and then glucose oxidase 
solution (0.5 mg per 2.0 ml distilled water; Sigma, Type VII) was added. The reaction 
sites were demonstrated in a dark blue or black color. The reaction was stopped by 
incubating sections in 0.1 M sodium acetate, pH 6.0, followed by washing in running tap 
water. The sections were briefly counter-stained with Mayer's hematoxylin, dehydrated 
and mounted with Permount®. Photography was made by a Zeiss Axioskop microscope. 
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Chapter 3: Results 
3.1 Subcloning of DNAs into Vector 
3.1.1 Subcloning of 18s Ribosomal RNA cDNA Fragment 
The cDNA fragment of rat 18s ribosomal RNA inserted into pLvB10 was released 
by digestion with restriction enzymes Pstl and Xhol. The digested DNA fragments were 
separated and analyzed by electrophoresis in 1% agarose gel (Fig. la). The cDNA 
fragment of 18s ribosomal RNA with a molecular size about 1.6 kb was released after 
restriction enzyme digestion (Fig. la, Lane 2，arrow). 
The DNA fragments with the expected size were extracted and purified from the 
agarose gel. The extracted DNA products were then electrophoresed and analyzed in 1% 
agarose gel. The DNA sample showed a correct size of about 1.6 kb (arrow) which 
confirmed with the size of the released cDNA fragment of 18s ribosomal RNA after 
purification and agarose gel electrophoresis (Fig. lb, Lane 1). The Pstl and Xhol digested 
pBluescript SK (pSK) vector was also separated and analyzed by 1% agarose gel 
electrophoresis (Lane 2, arrowhead). 
The extracted DNA was first ligated with linearized pBluescript SK vector. The 
pSK plasmids were then transformed into DU5a E.coli competent cells. The E.coli 
competent cells were grown in agar plate, which contained the x-gal and IPTG for lac-
selection. Two kinds of colonies were seen on the plates: the white-coloured colonies 
were recombinants and the blue-coloured colonies were untransformed non-
recombinants. The white-coloured colonies were then picked up and further grown in the 
LB medium for subsequent small-scale extraction of plasmids. The extracted plasmids 
were analyzed by digestion with restriction enzymes Pstl and Xhol. The digested 
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products showed fragments of two sizes. One DNA fragment showed a size of 2.96 kb 
(Fig. lc, arrowhead) represented the pSK vector, whereas the other fragment showed a 
size of about 1.6 kb which corresponded to the cDNA fragment of 18s ribosomal RNA 
(Fig. lc, arrow). 
3.1.2 Subcloning of Probasin cDNA Fragment 
The cDNA fragment of probasin from cM40.3 was released by digestion with 
restriction enzyme Pstl. The digested DNA fragments were separated and analyzed by 
electrophoresis in 1% agarose gel. The cDNA fragment of probasin with a molecular size 
about 550 bp was released after restriction enzyme digestion (Fig.2a, arrow). 
The DNA fragments with the expected size were extracted and purified from the 
agarose gel. The extracted DNA products were then electrophoresed and analyzed in 1% 
agarose gel. The DNA sample showed a correct size of about 550 bp (arrow) which 
confirmed with the size of the released cDNA fragment of probasin after purification and 
agarose gel electrophoresis (Fig. 2b). 
After subcloning into pSK vector and transformation of E.coli, the extracted 
plasmids were analyzed by digestion with restriction enzyme Pstl. The digested products 
showed fragments of two sizes. One DNA fragment showed a size of 2.96 kb (Fig. 2c， 
arrowhead) which represented the pSK vector, while the other fragment showed a size of 
about 550 bp (Fig. 2c, arrow) which corresponded to the cDNA fragment ofprobasin. 
3.1.3 Subcloning of SVSII cDNA Fragment 
The cDNA fragment of rat SVSII was generated by RT-PCR using the primers, 
with the linker sequences {EcoRi. and Clal). The 5，primer (5 ‘-CGG AAT TCA GTG 
GAC AGC TGA AAT CTG-3') and 3’ primer (5，-CCA TCG ATT AGG ATT GGG 
AGC GTT CTT G-3') were used to amplify the cDNA fragment ofrat SVSII of780bp in 
length (Fig. 3a，arrow). Expression pattern of the PCR products using these pair of 
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primers is similar to the result of figure 15b. PCR products of SVSII mRNA transcripts of 
expected size 780 bp was strongly detected in the lateral prostate (LP) and seminal 
vesicles (SV) (Fig. 3a). A moderate band was detected in the dorsal prostate (DP) and 
coagulating gland (CG). However, there was no expression in the ventral prostate (VP). 
The sticky ends of the PCR product of rat SVSII were generated by digestion with 
restriction enzyme EcoRl and Clal. The digested DNA products were then 
electrophoresed and analyzed in 1% agarose gel. The DNA fragment showed a correct 
size of about 780 bp, which confirmed with the size of the digested DNA fragment of 
SVSII with sticky ends (Fig. 3b，lane 1, arrow). The EcoRl and Clal digested pBluescript 
SK vector was also separated and analyzed by 1% agarose gel electrophoresis (Fig. 3b， 
lane 2，arrowhead). 
The extracted plasmids were analyzed by digestion with restriction enzymes 
EcoRl and Clal. The digested products showed fragments of two sizes. One DNA 
fragment showed a size of 2.96 kb (Fig. 3c, arrowhead) which is same as the length of 
pSK vector, while the other fragment showed a size of about 780 bp (Fig. 3c, arrow) 
which corresponded to the cDNA fragment ofSVSII and it was named as pSK-SVSII. 
3.1.4 Restriction Enzyme Mapping for PCR Product of SVSII 
PCR analysis was performed on cDNA samples prepared from seminal vesicles 
and the pSK containing rat SVSII cDNA fragment (pSK-SVSII), using primer pairs 
specific to the SVSII gene (Fig. 4a). The PCR products with a molecular size 764 bp 
were demonstrated in both samples (Fig.4a, arrow). The authenticity o f the PCR product 
of SVSII was further confirmed by restriction digestion by Ncol. The digested products 
showed fragments of two sizes. One DNA fragment showed a size o f 6 1 4 bp, while the 
smaller fragment showed a size of 150 bp (Fig. 4b). The DNA fragment with 764 bp 
represents the undigested PCR product of SVSII (Fig. 4b). 
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3.2 Detection of mRNA and Protein Expression of PSP94 in Normal Rat 
Prostates 
3.2.1 In situ Hybridization 
Strong positive hybridization signals for PSP94 were detected in the lateral lobe 
(LP) of the rat prostate gland (Figs. 5a, 5b). Positive signals were localized to the 
cytoplasm of the secretory epithelial cells but negative in the stromal fibromuscular 
tissues (Fig. 5b). In the dorsal lobe (DP), weak signals were seen over some individual 
epithelial cells (Fig. 5c). However, there were no signals in the ventral lobe (VP, Fig 5d), 
coagulating gland, seminal vesicles, vas deferens and urethra (as seen in low-power view 
in Fig. 5a). In-situ hybridization was also performed in other non-prostate tissues (lung, 
trachea, stomach, and intestines) in order to examine its tissue specificity. No 
hybridization signals were detected in these non-prostatic tissues (not shown). When 
sections were hybridized with the DIG-labeled sense riboprobe, no signals were seen in 
the lateral lobe (Fig. 5e). 
3.2.2 Northern Blotting 
After Northem blotting, high expression level of PSP94 mRNA with a molecular 
size of about 575 bp was detected in the lateral lobe. Moderate expression was detected in 
the dorsal lobe and a weak expression was also revealed in the coagulating gland. 
However, no hybridization signal was shown in the ventral lobe and seminal vesicle (Fig. 
6). The amount and quality of total RNAs used for Northem blotting was evaluated by 
hybridization of the stripped membranes with a riboprobe for rat 18s rRNA. Northem 
blotting was also performed in other non-prostate tissues (including lung, trachea, 
stomach, and intestines) in order to examine its tissue specificity and no signals were 
detected in these tissues (not shown). 
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3.2.3 RT-PCR Amplification 
RT-PCR was used to amplify the mRNA transcripts of PSP94 in the male 
accessory sex glands and other non-prostatic tissues in order to determine whether it is a 
prostate-specific protein. PCR product of expected size 490 bp was primarily detected in 
the lateral and dorsal lobes (Fig 7a). A weak band was also detected in the coagulating 
gland. However, PSP94 mRNA transcripts were not detected in the ventral lobe and 
seminal vesicle. The specificity of the RT-PCR of PSP94 in the male sex glands was 
evaluated by Southern blot hybridization of the PCR products with a full-length rat 
PSP94 DNA probe. The results showed that the PCR products in the lateral and dorsal 
lobes, and coagulating gland hybridized with the DNA probe but not in the ventral 
prostate and seminal vesicles (Fig. 7b). Its expression pattem in non-prostatic tissues was 
also examined by RT-PCR. However, it was not detected in the tissues of urinary tract 
(urinary bladder, kidney), male reproductive organs (testis, epididymis), female 
reproductive organs (ovary, uterus, mammary gland), digestive tract and associated 
glands (pylorus of stomach, duodenum, colon, liver, salivary gland), respiratory tract 
(trachea, bronchus, lung), skeletal muscle, striated muscle (diaphragm), cardiac muscle 
and brain (Fig. 8). 
3.2.4 Immunohistochemistry 
The apical cytoplasm of the secretory epithelial cells and the secretions in the 
acinar lumen of the lateral lobe were moderately reacted with the antibody against the 
recombinant GST-rat PSP94. After microwave heating in O.lM Tris-HCl with 5% urea, 
the immunoreaction was slightly enhanced (Figs. 9a, 9b). The fibromuscular stroma was 
unreacted. The acini of the ventral lobe were not stained (Fig. 9b). No positive staining 
was observed when the primary antiserum was replaced by blocking solution (Fig. 9c). 
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3.2.5 Western Blotting 
The proteins from the cytosolic extracts of the ventral, dorsal and lateral lobes, 
coagulating gland and seminal vesicle were electrophorezed on a 15% SDS-PAGE and 
further analyzed by Westem blotting with a polyclonal antibody against the recombinant 
GST-rat PSP94 (Fig. lOb). The antibody recognized a strong band or a smear of about 
14.5 kDa in the lateral lobe and also a weak band of identical position in the dorsal lobe 
(Fig. lOb). The strong band appeared as a doublet migrating between 14 and 16 kDa in 
both lateral and dorsal prostates. There was no binding reaction in the ventral lobe, 
coagulating gland and seminal vesicle. No binding was detected in the blots when the 
antiserum was replaced by normal goat serum (not shown). The cytosolic protein patterns 
of individual sex gland were shown by Coomassie blue staining (Fig. lOa). 
Glandular secretions from the ventral, dorsal and lateral lobes, coagulating gland 
and seminal vesicle were also electrophorezed on a 15% SDS-PAGE and further 
analyzed Westem blotting using the same antibody. The protein pattem of the secretions 
from each gland was shown by Coomassie blue staining (Fig. 1 la). A major band at the 
position of 14.5 kDa was shown in the secretion o fLP (Fig. 1 la, lane LP, arrow). On the 
Westem blots, the antibody recognized a strong band of about 14.5 kDa in the secretion 
of lateral prostate and a weak band of identical molecular size in the secretion of dorsal 
prostate. Whereas, it was negative in the secretion of ventral prostate, coagulating gland 
and seminal vesicles (Fig. 1 lb). 
The total proteins extracted by using TRIZOL reagent was also evaluated by 
electrophoresis on a 15% SDS-PAGE and further analyzed Westem blotting using the 
same antibody (Fig. 12b). The total protein pattern by the TRIZOL extraction was 
analyzed by Coomassie Blue staining (Fig. 12a). Identical results on the total protein 
pattem and Westem blots were observed as compared to the results obtained by the 
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traditional method of protein extraction (c.f. Fig. 10 and Fig. 11) .The antibody 
recognized a strong band of about 14.5 kDa in the lateral prostate and a weak band of 
identical molecular size in the dorsal prostate. Whereas, it was negative in the TRIZOL 
extracts of ventral prostate, coagulating gland and seminal vesicles (Fig. 12b). 
3.3 Detection of mRNA Expression of Probasin and SVSII in Normal Rat 
Prostates 
3.3.1 In-situ Hybridization 
The mRNA expression of probasin in normal rat prostate was detected by in-situ 
hybridization. Strong positive hybridization signals for probasin were detected in the 
lateral lobes (LP) of the rat prostate gland (Figs. 13a, 13b, 13 c). Positive signals were 
localized to the cytoplasm of the secretory epithelial cells but negative in the stromal 
fibromusclar tissues (Figs. 13b，13c). There was no signal in the dorsal lobe (DP, 
Fig.l3d), ventral lobe (VP, Fig. 13e), coagulating gland, seminal vesicles, vas deferens 
and urethra (Fig. 13a). When sections were hybridized with the DIG-labeled sense 
riboprobe, no signals were seen in LP (Fig. 13f). 
For SVSII, strong positive hybridization signals were also detected in the lateral 
lobes (LP) of the rat prostate gland (Fig. 14a) and seminal vesicle (SV, Fig 14d). In the 
lateral prostate and seminal vesicle, positive signals were localized to the cytoplasm of 
the secretory epithelial cells but negative in the stromal tissues (Fig. 14a). However, there 
was no signal in the dorsal prostate (Fig. 14 b) and ventral prostate (Fig.l4c), coagulating 
gland, vas deferens and urethra (not shown). The negative result by using sense riboprobe 
was shown in Fig. 14e. 
3.3.2 RT-PCR Amplification 
The mRNA expression of probasin and SVSII in normal rat prostate glands was 
also detected and analyzed by RT-PCR. For probasin, PCR product ofexpected size 776 
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bp was primarily detected in lateral lobe (Fig. 15a). A moderate band was also detected in 
the dorsal lobe and coagulating gland. However, probasin mRNA transcripts were 
detected weakly in the ventral lobe and seminal vesicles. 
PCR product of SVSII mRNA transcripts of expected size 764 bp was strongly 
detected in the lateral lobe and seminal vesicles (Fig. 15b), A moderate band was 
detected in the dorsal lobe. However, its expression was weak in coagulating gland, and 
negative in the ventral lobe. 
3.4 Androgen Regulation of PSP94, Probasin and SVSII mRNA Expression 
3.4.1 In-situ hybridization 
Adult Noble rats were castrated. The prostate glands were removed on 7, 14, 30 
and 60 days after castration. For androgen replacement, the 60-day castrated rats were 
replaced with androgen for 3 weeks by implantation with testosterone-filled Silastic 
tubings. Intact males were used as the untreated controls. 
Strong hybridization signals for PSP94 were detected in the lateral lobe of the 
intact rat prostate gland (Fig. 16a). After castration for 7 and 14 day, the hybridization 
signals became weak over the secretory epithelium of lateral prostate (Fig. 16b，16c). 
After 30-day post-castration, the secretory acini of the lateral prostate became atrophied 
and the hybridization signals for PSP94 decreased significantly (Fig.l6d). The 
hybridization signals became totally lost in the secretory epithelium of lateral prostate 
after 60 days of castration (Fig. 16e). After replacement with androgen for 3 weeks, the 
hybridization signals restored again in the lateral prostate in the rats, which had been 
castrated for 60 days (Fig. 16f). 
The hybridization signals for probasin were detected strongly in the secretory 
epithelium of lateral lobe of intact rat prostate and no signal was detected in the stromal 
tissues (Fig. 17a). The signals became decreased in the secretory epithelium of lateral 
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prostate after 7 and 14 days of castration (Fig 17b, 17c). After castration for 30 days, the 
secretory acini reduced in size and the hybridization signals became weakened (Fig. 17d). 
The hybridization signals became totally lost after 60 days of castration in the lateral lobe 
(Fig. 17e). The hybridization signal reappeared in the lateral prostate after androgen 
replacement for 3 weeks (Fig. 17f). 
For SVSII, strong hybridization signals were detected in the secretory epithelium 
of the intact rat lateral prostate (Fig. 18a). The intensity of signals dropped rapidly after 
7-days of castration (Fig 18b). Very weak hybridization signals (arrows) were still 
detected in the secretory epithelium after 14-days post-castration (Fig. 18c). However, no 
signals detected in the lateral prostates after 30 and 60 days of castration (Figs. 18d, 18e). 
Similar to PSP94 and probasin, the hybridization signals for SVSII were restored in the 
secretory epithelium of lateral prostate when the castrated animals were replaced with 
dihydrotestosterone (Fig. 18f). 
3.4.2 Relative Expression Levels of PSP94, Probasin and SVSII mRNA in Normal, 
Castrated and Androgen Replaced Rat Lateral Prostates as Measured by a 
Semiquantitative RT-PCR Method 
3.4.2.1 Determination ofExponential Range ofPCR 
For the purpose of comparison, we determined the range of linearity of the PCR 
amplification for different secretory proteins and p_actin with reference to the number of 
PCR amplification cycles. The linear ranges ofPCR were determined by performing RT-
PCR starting with the same amount of total RNA samples and terminating the 
amplification of replicate samples at regular intervals (Figs. 19, 20, 21). In the PCR 
program for PSP94 amplification, we chose 20 cycles for the PSP94 (Fig.l9a) and 27 
cycles for the y^actin (Fig. 19b), since these conditions were within the linear range of 
amplification for both the PSP94 and >^actin primer set. For the PCR program to amplify 
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probasin mRNA, we chose 20 cycles for the probasin (Fig. 20a) and 27 cycles for the P-
actin (Fig. 20b); whereas for SVSII, we chose 20 cycles for the SVSII (Fig. 21a) and 27 
cycles for the ^^actin (Fig. 21b). 
3.4.2.2 Semi-Quantitative RT-PCR 
In order to assess the effects of androgen on the expression of PSP94, probasin 
and SVSII, their mRNA transcripts were examined after androgen removal by castration 
and replacement with dihydrotestosterone. RT-PCR analysis was performed on RNA 
samples prepared from lateral prostates which had been removed from normal rats, rats 
castrated for 3, 5，14，30 and 60 days, and castrated rats followed by androgen 
replacement, using primer pairs specific to the rat PSP94, probasin or SVSII genes. 
Similar reactions were carried out using primers specific to the rat y^actin gene for 
internal control. The PCR products were separated by 1.5% agarose gel electrophoresis 
(Figs. 22a，23a, 24a). After scanning photographs of the ethidium bromide-stained gels, 
band intensities for PSP94, probasin or SVSII products were normalized with reference 
to their y^actin counterparts. The mean values of three separate experiments were plotted 
as percentages of day 0 control (normal intact LP; Figs. 22b, 23b and 24b). 
This method of measurement was only semi-quantitative. However, we have 
observed that there was a significant change in the PSP94 mRNA expression in lateral 
prostate following castration (Fig. 22b). By days 30 post-castration, there was an 
approximate 70% decrease in PSP94 mRNA level in the lateral prostate. The decline in 
PSP94 mRNA expression continued up to 60 days following castration. There was an 
almost 90% decrease ofPSP94 mRNA expression at 60 days post-castration as compared 
to the intact normal lateral prostate. The expression level o fPSP94 in the lateral prostate 
returned to normal level after androgen replacement. 
7 4 
The semi-quantitative RT-PCR analysis demonstrated that there was no 
significant decrease in the probasin mRNA following 60 days of castration in the lateral 
prostate (Fig. 23b). The expression level of probasin remained at approximately 80% of 
the normal level after 3 and 5 days castration. Interestingly, its expression level 
rebounded to approximately 90% at 14 days post-castration. Afterwards, there was a 
continuous decline in probasin mRNA expression at 60 days post-castration and its 
expression level dropped to 60% at 60-days post-castration. The probasin transcripts 
returned to normal level after androgen administration for 3 weeks. 
On the other hand, there was a significant decrease in SVSII expression level 
following castration in the lateral prostate (Fig. 24b). By days 14 post-castration, there 
was an almost 90% decrease in the SVSII mRNA expression in the lateral prostate. There 
was only a residual 2 % of SVSII mRNA expression in the lateral prostate, which has 
been castrated for 60 days. After androgen replacement, SVSII transcripts rebound to the 
normal levels as observed in the intact lateral prostate. 
3.4.3 Western Blot Analysis 
In order to study the effect of androgen on the protein expression ofPSP94 in rat 
prostates, total proteins were extracted from the lateral prostates of normal rats, rats 
which had been castrated for 3，5, 14, 30 and 60 days, and castrated rats followed by 
androgen replacement by using TRIZOL reagent. The protein samples were 
electrophoresed on a 15% SDS-PAGE and further analyzed by Westem blotting with a 
polyclonal antibody against the recombinant GST-rat PSP94 (Fig. 25). The antibody 
recognized a strong band of about 14.5 kDa in the normal lateral lobe (LP) ofrat prostate. 
The intensities of the bands of identical molecular size became decreased in the castrated 
lateral prostates for 3 and 5 days. There was only a weak signal in the lateral prostate, 
which has been castrated for 14 days. No binding signal was detected in the 30- and 60-
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day castrated lateral prostates. After androgen replacement, the binding intensity of 
PSP94 was as strong as in the normal intact lateral prostate. 
3.5 Effect of Steroid Hormones and Zinc on the PSP94, Probasin and SVSII 
Expressions in Castrated Rat Prostates 
3.5.1 Semi-Quantitative RT-PCR 
In order to study whether there are other steroid hormones or factors affecting the 
expression ofPSP94, probasin and SVSII in the castrated rat prostates, the animals which 
had been castrated for 30 days were received daily injection of either dihydrotestosterone 
(DHT), a synthetic glucocorticoid (dexamethasone, DEX), a synthetic progestin 
(medroxyprogesterone acetate, MPA), or zinc sulfate (ZnSO4) for 7 days. Controls 
animals received vehicle (com oil or saline) alone. The PSP94, probasin and SVSII 
mRNA transcripts were examined by RT-PCR after drug treatments. RT-PCR analysis 
was performed on RNA samples prepared from normal, com oil, DHT, DEX, MPA or 
ZnSO4 treated rat lateral prostates, using primer pairs specific to the rat PSP94, probasin 
or SVSII gene. For internal control, similar reactions were carried out on same RNA 
samples using primers specific to the rat /？-actin gene. The PCR products were separated 
by 1.5% agarose gel electrophoresis (Figs. 26a, 27a, 28a). After scanning photographs of 
the ethidium bromide-stained gels, band intensities for PSP94, probasin or SVSII 
products were normalized to their y^actin counterparts, and the mean values of three 
experiments were plotted as percentages ofnormal LP control (Figs. 26b, 27b, 28b). 
The semi-quantitative RT-PCR analysis demonstrated that there were significant 
increases in PSP94 mRNA expression in the lateral prostate after treating the castrated 
rats with DHT, DEX and MPA as compared its expression to that in the com oil treated 
rats (Fig. 26b). After treating the castrated rats with DHT, the expression level ofPSP94 
mRNA has increased up to 90% of the normal level. After treating the castrated rats with 
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DEX and MPA, the expression level of PSP94 has also increased up to approximately 
20% and 35% respectively. On the other hand, there was no increase in PSP94 expression 
level in the ZnSO4 treated lateral prostate. 
There were also significant increases in the probasin mRNA expression after 
similar treatments of the castrated rats (Fig. 27b). When the castrated rats were treated 
with DHT, probasin transcripts rebound to the normal level (100%) as observed in the 
intact rats. DEX and MPA treatments also increased the probasin mRNA expression in 
the castrated lateral prostates up to approximate 75% of the normal level. ZnSO4 
treatment increased slightly the mRNA expression of probasin to about 45% of the 
normal level. 
On the other hand, the expression of SVSII mRNA in the castrated lateral 
prostates was only affected significantly by DHT (Fig. 28b). After treatment with DHT, 
the SVSII mRNA expression in the castrated lateral prostates has stimulated to 
approximate 80% of the normal level. MPA treatment increased slightly the mRNA 
expression of SVSII to about 20% of the normal level. However, there was no effect or 
significant change in the expression of SVSII mRNA in the castrated lateral prostates 
after DEX and ZnSO4 treatment. 
3.5.2 Western Blot Analysis 
The effects of steroid hormones and zinc on the protein expression of PSP94 in 
the castrated prostates were also examined by Westem blotting with a polyclonal 
antibody against the recombinant GST-rat PSP94 (Fig. 29). A strong band with molecular 
size ofabout 14.5 kDa was observed in the total protein extracts from the normal lateral 
prostate (LP). No binding signal was detected in the com oil-treated control. After 
treating the castrated rats with DHT, the immunoblotting signal for PSP94 was detected 
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in the protein extracts of the castrated lateral prostates. However, no band was detected in 
the protein extracts from the DEX, MPA and ZnSO4 treated lateral prostates. 
3.6 Detection of PSP94, Probasin and SVSII mRNA Expression in Dysplastic 
and Neoplastic Rat Prostates 
3.6.1 Detection of PSP94, Probasin and SVSII mRNA Expression in T+E2-Induced 
Prostatic Intraepithelial Neoplasia (PIN) of the Lateral Prostate of Noble 
Rats by In-situ hybridization 
The expression patterns ofPSP94, probasin and SVSII mRNA in the lesions of rat 
prostatic intraepithelial neoplasia were also studied by in-situ hybridization. Prostatic 
intraepithelial neoplasia (PESf) is divided into low grade and high grades [Bostwick and 
Brawer, 1989; Bostwick et al., 1993]. The results showed that the hybridization signals of 
PSP94, probasin and SVSII became lost or reduced in the epithelial cells in both low 
grade and high grade PIN in the rat lateral prostate (Figs. 30，31，32). In the high grade 
PIN of lateral prostate, the hybridization signals of PSP94, probasin and SVSII became 
lost in different histopathological patterns of PIN lesions such as lesions appeared in 
cribriform pattem (Figs. 30a，31a，32a), tufting pattern (Figs. 30b，31b，32b)， 
micropapillary pattem (Figs. 30c，31c, 32c) and flat pattem (Figs. 30f, 31f, 32c). 
However, the hybridization signals of PSP94, probasin and SVSII were still weakly 
expressed throughout the secretory epithelium in low grade PD^ oflateral prostate (Figs. 
30d, 31d, 32d). However, hybridization signals were still detected in the dysplastic 
epithelial cells located at the basal compartment of secretory epithelium in high grade 
PIN (Figs. 30e, 30f, 31e, 31f, 32e, 32f). 
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3.6.2 Detection of PSP94, Probasin and SVSII mRNA Expression in Dunning 
Tumor and AIT Prostatic Tumor 
3.6.2.1 In-situ hybridization 
No hybridization signal of PSP94, probasin and SVSII was detected in both 
Dunning tumor R3327-H (Figs. 33a, 33c，33e) and AIT tumor (Figs. 33b，33d，33f). 
3.6.2.2 RT-PCR Amplification 
The mRNA expressions of PSP94, probasin and SVSII was detected in Dunning 
tumor R3327-H and AIT tumor by RT-PCR (Fig. 34). During the course of RT-PCR 
amplification ofPSP94 cDNA, using two primers located near the two ends of the PSP94 
cDNA sequence [Femlund et al., 1996], original PCR product of expected size 490 bp 
was primarily detected in normal lateral lobe of rat prostate. However, two forms of 
PSP94 cDNA were found in Dunning R3327-H. The larger RT-PCR product corresponds 
the expected original band with 490 bp and the smaller one is a new form with 300 bp in 
size. In AIT tumor, only smaller form (300 bp) was detected (Fig. 34a). 
For probasin, PCR product of expected size 776 bp was primarily detected in 
normal lateral prostate. A weak band with identical size was also detected in Dunning 
R3327-H. No band was detected in AIT tumor (Fig. 34b). 
PCR product of SVSII mRNA transcripts of expected size 764 bp was strongly 
detected in the normal lateral prostate. A weak band with identical size was detected in 
both Dunning R3327-H and AIT tumors (Fig. 34c). 
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Figures la to lc. Subcloning of cDNA fragment of 18s ribosomal RNA into vector, (a) 
The cDNA fragment of 18s ribosomal RNA is released by digestion with restriction 
enzymes, Pstl and Xhol. The band of 1.6 kb represents the released cDNA fragment of 
18s ribosomal RNA (Lane 2，arrow). The undigested pLvB10 is also electrophoresed in 
the agarose gel and shown in Lane 1. (b) The released cDNA fragment of 18s ribosomal 
RNA (1.6 kb) is shown in lane 1 (arrow) and the linearized pSK (2.96 bp) is shown in 
lane 2 (arrowhead), (c) After subcloning, the pSK plasmid with the inserted cDNA 
fragment of 18s ribosomal RNA is digested with Pstl and Xhol. Two bands are seen in 
the agarose gel: the larger band with a size of 2.96 kb (arrowhead) corresponds to the 
whole length o f the pSK vector, whereas the smaller bands with a size of 1.6 kb (arrow) 
corresponds to the inserted cDNA fragment of 18s ribosomal RNA. 
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Figures 2a to 2c. Subcloning of cDNA fragment of probasin into vector, (a) The cDNA 
fragment ofprobasin is released by digestion with restriction enzyme Pstl. The band with 
about a size 550 bp corresponds to the released probasin cDNA fragment (Lane 1，arrow), 
(b) The released cDNA fragment of probasin (550 bp) is purified and electrophoresed 
again in the agarose gel (Lane 1，arrow), (c) After subcloning, the plasmid with the 
cDNA fragment ofprobasin is digested with Pstl Two bands are seen in the agarose gel: 
the larger band with a size of2.96 kb (arrowhead) corresponds to the whole length of the 
pSK vector, whereas the smaller bands with a size of 550 bp (arrow) corresponds to the 
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Figures 3a to 3b. Subcloning of PCR product of SVSII into vector, (a) RT-PCR 
amplification (20 cycles) of SVSII transcript using total RNA (1.5^ig) extracted from 
samples of male accessory sex glands and primers with linker sequences. A strong band 
of780 bp is seen in LP and SV. A moderate band is also seen in DP and CG. There is no 
amplification signal in VP. (b) The PCR product of SVSII with a size of780 bp (Lane 1, 
arrow) after digestion with EcoRl and Cla\ and the linearized pSK with a size of 2.96 kb 
(arrowhead) are electrophoresed in the agarose gel. (c) After subcloning, the plasmid with 
the PCR product of SVSII is digested with EcoRl and Clal. Two bands are seen in the 
agarose gel: the larger band with a size of2.96 kb (arrowhead) corresponds to the whole 
length of the pSK vector, whereas the smaller bands with a size of 780 bp (arrow) 
corresponds to the inserted PCR product of SVSII. 
CG= coagulating gland; DP= dorsal prostate; LP= lateral prostate; SV= seminal vesicle; 
VP= ventral prostate. 
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Figures 4a and 4b. Restriction enzyme mapping ofPCR product of SVSII. (a) The result 
ofthe PCR to amplify the SVSII from the cDNA sample of seminal vesicles (Lane 1) and 
pSK-SVSII, the plasmid containing the cDNA fragment of SVSII (Lane 2) using primers 
specific for SVSII. The size ofthe PCR product ofSVSII is 764 bp. (b) The PCR product 
of SVSII is then digested with restriction enzyme Nco\. Three bands are seen in the 
agarose gel: the largest band with a size of 764 bp corresponds to the undigested PCR 
product ofSVSII, whereas the other two smaller bands of 614 bp and 150 bp correspond 
to the fragments of digested PCR product of SVSII. 
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Figures 5a to 5e. In-situ hybridization (ISH) ofPSP94 in rat prostates, (a) Lower-power 
survey micrograph showing that the rat lateral prostate (LP) is specifically stained. Weak 
signals are also seen in dorsal prostate (DP) but negative in ventral prostate (VP), 
coagulating gland (CG), seminal vesicles (SV) and vas deferens (VD). X 12.5. (b) ISH in 
rat LP. The secretory epithelium is intensely reacted. X 100. (c) ISH in rat DP. The 
cytoplasm ofsome individual epithelial cells is weakly stained. X 100. (d) ISH in rat VP, 
which is negatively stained. X 100. (e) Control section of rat LP hybridized with the 
sense DIG-labeled PSP94 riboprobe. No signal is seen in the secretory epithelium. X 100. 
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Figure 6. Northern blot analysis ofPSP94 mRNA in male accessory sex glands ofmature 
rat. Upper panel: Total RNAs extracted from samples of dissected sex glands are 
hybridized with a DIG-labeled PSP94 riboprobe. A strong hybridization band of 
approximate 575 bp is seen in both LP and DP. A very weak band of same size is also 
shown in CG. There is no hybridization signal in VP and SV. Lower panel: After 
stripping, the blot is re-hybridized with a 1.6 kb 18s rRNA riboprobe. A strong band of 
equal intensity is shown in every sample. Approximate sizes of RNA molecular weight 
markers (575 and 1821 bp) are shown on the left. 
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Figures 7a and b. (a) Upper panel: RT-PCR amplification (20 cycles) ofPSP94 transcript 
using total RNA (1.5^g) extracted from samples of male accessory sex glands. A strong 
band of 490 bp is seen in DP and LP. A weak band is also seen in CG. There is no 
amplification signal in VP and SV. Controls for RT-PCR lacking cDNA template are 
absence of reverse transcriptase (RT), total RNA and cDNA templates. No amplification 
signal is shown in the controls. Lower panel: RT-PCR amplification (27 cycles) ofrat p-
actin mRNA in samples of sex glands tested for the PSP94. A band (249 bp) of equal 
intensity is seen in all tested samples except in the controls, (b) Southern blot analysis of 
RT-PCR products of PSP94 in male sex glands hybridized with a 490 bp DIG-labeled 
DNA probe for PSP94. Similar to RT-PCR, a strong hybridization band is seen in both 
LP and DP. A moderate band is also seen in CG, whereas there is no hybridization signal 
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Figure 8. Expression pattem of PSP94 mRNA transcripts in non-prostatic tissues as 
determined by RT-PCR. Non-prostatic tissues tested including urinary bladder, testis, 
epididymis, uterus, ovary, mammary gland, lung, bronchus, trachea, salivary gland, 
stomach (pyloric region), duodenum, colon, liver, skeletal muscle, diaphragm (striated 
muscle), cardiac muscle, brain and kidney. Upper panel: No amplification band ofPSP94 
is shown in all tested tissues and in controls (no RT and no RNA). Lower panel: RT-PCR 
of y^actin is performed and an amplification band (249 bp) is shown in all tested tissues 
























































































































































































































































































































Figures 9a and b. (a) Immunohistochemistry of PSP94 in rat prostate. After antigen-
retrieval by microwave heating, positive immunoreaction is seen over the apical surfaces 
of the epithelial cells and the secretions in the acinar lumen in the lateral prostate (LP). X 
100. (b) On the contrary, no reaction is seen in the ventral prostate (VP). X 100. (C) 
Control section o fLP stained with blocking solution with 1% BSA. No positive reaction 
is seen over the secretory epithelium and the luminal secretions. X 100. 
* , 
88 
^"l'iiil"iMliin “_••‘ ’ “ ‘ •‘〜、巧： Z^mKl^Ask�• V' . ‘二‘ t k ^ <、， 




砂 — . f 入 ‘ ^ / ^ ^ 巧 、 、 
b Jr' :J^7W : � 
讓 , 翻 
圓 
Fig. 9 
Figures 10a and b. (a) The protein patterns of the extracted cytosols from the male 
accessory sex glands are illustrated on a 15% SDS-PAGE and visualized by Coomassie 
blue staining. Molecular weight markers (broad and low ranges) are shown in the first 
two lanes on the left, (b) Westem blot analysis ofPSP94 protein in the cytosolic fractions 
of the male accessory sex glands. The PVDF membrane is probed with a polyclonal 
antibody against the recombinant rat PSP94 (1: 2,500 dilution). A strong band (a smear 
and a doublet) at about 14.5 kDa is seen in LP and a weak band of similar size is also 
revealed in DP. No immunoreactive band is shown in VP, CG and SV. 
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Figures 1 la and b. (a) The protein patterns of the secretions collected from different male 
accessory sex glands are illustrated on a 15% SDS-PAGE and visualized by Coomassie 
blue staining. Molecular weight markers (broad and low ranges) are shown in the first 
lane on the left, (b) Westem blot analysis of PSP94 protein in the secretions from 
different male accessory sex glands. The PVDF membrane is probed with a polyclonal 
antibody against the recombinant rat PSP94 (1: 2,500 dilution). A strong band (a smear or 
a doublet) at about 14.5 kDa is seen in the secretion of LP and a weak band of similar 
size is also revealed in the secretion of DP. No immunoreactive band is shown in the 
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Figures 12a and b. (a) The total protein patterns extracted from different male accessory 
sex glands using TRIZOL reagent are illustrated on a 15% SDS-PAGE and visualized by 
Coomassie blue staining. Molecular weight markers (broad and low ranges) are shown in 
the first two lanes on the left, (b) Westem blot analysis of PSP94 on the same protein 
preparations from male accessory sex glands. The PVDF membrane is probed with a 
polyclonal antibody against the recombinant rat PSP94 (1: 2,500 dilution). A strong band 
(a smear and a doublet) at about 14.5 kDa is seen in LP and a weaker band ofsimilar size 
is also revealed in DP. No immunoreactive band is shown in VP, CG and SV. 
» , 
91 
M M VP DP LP CG SV 
kDa s ^ ' ^ ¾ |fer^  •丄-"^ ^ ‘ • '“^  f ^ ^ ‘ 
••"• ^ ^ ^ - j ^ ^ ： 
45 一 ；二樣 B v ^ m^^- r=-"•“ 
• . .. .....•� l K B B H p i t ) ^ .-'fcrrtrx-:r. ~ -- • - . - -
^?¾^^^ *^^^*^^ •' • ^ ® ® ^ 
31 ~" o '1^^姥'^£5^ —L— ^^ 5^fT 
.v；><^ -"^ ^^ : ‘ 
21.5 — ,翁： 一 一 
• 。. ’. • 一�一--， 
14.5 — 鍵 • 一 14.5 kDa 
6.5 一 C*3 
(a) 
M M VP DP LP CG SV 
kDa 、一：二 ''-'''--




i ^ ^ B ^ . 




Figures 13a to 13f. In-situ hybridization (ISH) of probasin mRNA in rat prostates, (a) 
Low-power survey micrograph showing that the rat lateral prostate (LP) is specifically 
stained. No signal is observed in dorsal prostate (DP) and ventral prostate (VP). X 12.5. 
(b) ISH in rat LP. The secretory epithelium is intensely reacted. X 100. (c) ISH in rat LP. 
A high-power micrograph showing that cytoplasm, which is rich in rough endoplasmic 
reticulum [Brandes, 1996] is strongly stained. The epithelial nuclei are unstained and 
appear halo. X 200. (d) ISH in rat DP, which is negatively stained. X 100. (e) ISH in rat 
VP. No hybridization signal is observed. X 100. (f) Control section of rat LP hybridized 
with the sense DIG-labeled probasin riboprobe. No signal is seen in the secretory 





麵 ： ® ( 
% 众 、 , 、 藝 
| | W ^ f ^ _ 
3 i 瓜 — ， v : 嫩 — _ . " ' 
Figures 14a to 14b. In-situ hybridization (ISH) of SVSII mRNA in rat prostates and 
seminal vesicles, (a) ISH in rat LP. The secretory epithelium is intensely reacted. X 100. 
(b) ISH in rat DP, which is negatively stained. X 100. (c) ISH in rat VP. No hybridization 
signal is observed. X 100. (d) ISH in rat SV. The secretory epithelium is stained 
intensely. X 100. (e) Control section of rat SV hybridized with the sense DIG-labeled 
SVSII riboprobe. No signal is seen in the secretory epithelium. X 100. 
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Figures 15 a and b. (a) RT-PCR amplification (20 cycles) of probasin transcript using 
total RNA (1.5^g) extracted from samples of different male accessory sex glands. A 
strong band of776 bp is seen in LP. A moderate band is seen in DP and CG. A very weak 
band is also seen in VP and SV. Controls for RT-PCR lacking cDNA template are 
absence of reverse transcriptase (RT), total RNA and cDNA templates. No amplification 
signal is shown in the controls, (b) RT-PCR amplification (20 cycles) ofSVSII transcript 
using total RNA (1.5|ig) extracted from samples ofdifferent male accessory sex glands. 
A strong band of 764 bp is seen in LP and SV. A moderate band is seen in DP. A very 
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Figures 16a to 16f. In-situ hybridization (ISH) ofPSP94 mRNA in normal, castrated and 
androgen replaced rat prostates, (a) ISH in normal rat LP. The secretory epithelium is 
intensely reacted. No signal is found in the stromal tissue. X 100. (b) ISH in LP castrated 
for 7 days. The hybridization signals ofPSP94 are weakened in the secretory epithelium. 
X 100. (c) ISH in 14 days post-castrated LP. The hybridization signals of PSP94 are 
weakened in the secretory epithelium. X 100. (d) ISH in LP castrated for 30 days. The 
secretory acini decreased in size and the intensity of hybridization signals are further 
reduced. X 100. (e) ISH in 60 days post-castrated LP. The hybridization signals become 
totally lost in the secretory epithelium (arrows). X 100. (f) ISH in castrated LP after 
androgen replacement. The hybridization signals of PSP94 restore again in the secretory 
epithelium. No signals are seen in stromal tissue. X 100. 
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Fig. 16 
Figures 17a to 17b. In-situ hybridization (ISH) of probasin mRNA in normal, castrated 
and androgen replaced rat prostates, (a) ISH in normal rat LP. The secretory epithelium is 
intensely reacted. No signal is found in the stromal tissue. X 100. (b) ISH in 7 days post-
castrated LP. The hybridization signals of PSP94 are weakened in the secretory 
epithelium. X 100. (c) ISH in LP castrated for 14 days. The hybridization signals of 
PSP94 are weakened in the secretory epithelium. X 100. (d) ISH in 30 days post-castrated 
LP. The secretory acini are reduced in size and the intensity of hybridization signals is 
further decreased. X 100. (e) ISH in 60 days post-castrated LP. The hybridization signals 
become totally lost in secretory epithelium (arrows). X 100. (f) ISH in androgen-replaced 
castrated LP. The hybridization signals of PSP94 restore again in the secretory 
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Figures 18a to 18b. In-situ hybridization (ISH) of SVSII mRNA in normal, castrated and 
androgen replaced rat prostates, (a) ISH in normal rat LP. The secretory epithelium is 
intensely reacted. No signal is found in the stromal tissue. X 100. (b) ISH in 7 days post-
castrated LP. The hybridization signals of SVSII become significantly weakened in the 
secretory epithelium. X 100. (c) ISH in 14 days post-castrated LP. The hybridization 
signals of PSP94 become lost in the secretory epithelium. Very weak signals are detected 
in a few individual epithelial cells (arrows). X 100. (d) ISH in 30 days post-castrated LP. 
The secretory acini are decreased in size and no hybridization signal is found in the 
epithelium. X 100. (e) ISH in 60 days post-castrated LP. No hybridization signal is found 
in the secretory epithelium. X 100. (f) ISH in androgen-replaced castrated LP. The 
hybridization signals of SVSII restore again in secretory epithelium and show a stronger 
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Figures 19a and b. Determination of the range oflinearity ofPCR amplification ofPSP94 
with reference to the number ofPCR amplification cycles. The linear range ofthe PCR is 
determined by performing RT-PCR starting with same amount oftotal RNA samples and 
terminating the amplification of replicate samples at regular intervals, (a) RT-PCR 
amplification of PSP94 in LP at 10，15, 20, 25’ 30, 35 and 40 cycles. A program of 20 
cycles is chosen to amplify PSP94. (b) RT-PCR amplification of /？-actin in LP at 20, 25, 
27, 30，35 and 40 cycles. A program of 27 cycles is chosen to amplify y^actin. These 
amplification cycles are chosen as the amplification signals are within the linear range of 
amplification for both the PSP94 and y^actin primer sets. 
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Fig. 19 
Figures 20a and b. Determination of the range of linearity of the probasin amplification 
with reference to the number ofPCR amplification cycles. The linear range ofthe PCR is 
determined by performing RT-PCR starting with same amount of total RNA samples and 
terminating the amplification of replicate samples at regular intervals, (a) RT-PCR 
amplification of probasin in LP after 10, 15, 18, 20, 25, 30, 35 and 40 cycles. An 
amplification of 20 cycles is chosen to amplify probasin. (b) RT-PCR amplification of p~ 
actin in LP at 20, 25, 27，30，35 and 40 cycles. An amplification o f27 cycles is chosen to 
amplify ^actin, since these conditions are within the linear range of amplification for 
both the probasin and y^actin primer sets. 
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Fig. 20 
Figures 21aand b. Determination of the range oflinearity with reference to the number of 
PCR amplification cycles. The linear range of the PCR is determined by performing RT-
PCR starting with same amount of total RNA samples and stopping the amplification of 
replicate samples at regular intervals, (a) RT-PCR amplification ofSVSII in LP at 20，25, 
30, 35 and 40 cycles. An amplification of 20 cycles is chosen to amplify SVSII. (b) RT-
PCR amplification of y^actin in LP at 20，25, 27，30, 35 and 40 cycles. An amplification 
program of 27 cycles is chosen to amplify /？-actin. It is shown that the intensity of 
amplification signal under these conditions is within the linear range of amplification for 
both the SVSII and /？-actin primer sets. 
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Figures 22a and b. Semi-quantitative RT-PCR of PSP94 in normal, castrated and 
androgen-replaced rat lateral prostates (LP), (a) Upper panel: RT-PCR amplification (20 
cycles) ofPSP94 transcripts using total RNA (1.5^ig) extracted from normal, 3, 5, 14，30 
and 60 days post-castrated, and androgen-replaced LPs from a typical experiment. The 
bands with a size of 490 bp represented the PCR products ofPSP94. The amplification 
signal is strong in normal LP. It becomes weakened after castration for different time 
periods and no signal is seen at days 60 post-castration. After androgen replacement, the 
amplification signal of PSP94 is rebound again and shows a stronger signal than the 
normal LP. Controls for RT-PCR lacking normal LP cDNA templates are absence of 
reverse transcriptase (RT), total RNA and cDNA templates. No amplification signal is 
shown in the controls. Lower panel: RT-PCR amplification (27 cycles) of rat ^act in 
mRNA in the same samples tested for the PSP94. A band (249 bp) ofsimilar intensity is 
seen in all tested samples except in the controls, (b) The results of densitometric analysis 
obtained from agarose gel electrophoresis of PCR products are expressed as percentage 
ofintact control (normal LP). Each data point is the mean 士 standard error oftriplication 
measurements. Asterisks indicate significant differences of those expression levels as 




























































































































































































































































































































































































Figures 23a and b. Semi-quantitative RT-PCR of probasin in normal, castrated and 
androgen-replaced rat lateral prostates (LP), (a) Upper panel: RT-PCR amplification (20 
cycles) ofprobasin transcripts using total RNA (1.5|Lig) extracted from normal, 3，5，14, 
30 and 60 days post-castrated, and androgen-replaced LPs from a typical experiment. The 
bands with a size of 776 bp represent the PCR products of probasin. The amplification 
signal is strong in normal LP. It becomes weakened after 60-day castration. After 
androgen replacement, the amplification signal of probasin is intensified again. Controls 
for RT-PCR lacking cDNA templates are absence of reverse transcriptase (RT), total 
RNA and cDNA templates. No amplification signal is shown in the controls. Lower 
panel: RT-PCR amplification (27 cycles) of rat /？-actin mRNA in the same samples tested 
for the probasin. A band (249 bp) of similar intensity is seen in all tested samples except 
in the controls, (b) Densitometric analysis of the PCR products expressed as percentage 
of the intact control (normal LP). Each data point is the mean 士 standard error of 
triplication measurements. Statistical analysis shows that probasin mRNA expression 
levels of the castrated LPs do not vary significantly from intact control after 60-day 





























































































































































































































































































































































































































Figures 24a and b. Semi-quantitative RT-PCR of SVSII in normal, castrated and 
androgen-replaced rat lateral prostates (LP), (a) Upper panel: RT-PCR amplification (20 
cycles) of SVSII transcripts using total RNA (1.5^ig) extracted from normal, 3, 5, 14, 30 
and 60 days post-castrated, and androgen-replaced LPs from a typical experiment. The 
bands with a size of 764 bp represent the PCR products of SVSII. The amplification 
signal is strong in normal LP. It is reduced significantly after 14 days castration and is 
lost totally after 60-day castration. After androgen replacement, the amplification signal 
of SVSII rebounds again. Controls for RT-PCR lacking cDNA templates are absence of 
reverse transcriptase (RT), total RNA and cDNA templates. No amplification signal is 
shown in the controls. Lower panel: RT-PCR amplification (27 cycles) of rat /？-actin 
mRNA in the same samples tested for the SVSII. A band (249 bp) ofsimilar intensity is 
seen in all tested samples except in the controls, (b) Densitometric analysis of the PCR 
product products of SVSII expressed as percentage of intact control (normal LP). Each 
data point is the mean 土 standard error of triplication measurements. Asterisks indicate 






















































































































































































































































































































































































Figure 25. Westem blot analysis of PSP94 protein in normal, 3, 5, 14, 30 and 60 days 
post-castrated, and androgen-replaced rat lateral prostates (LP). The total protein extracts 
from the samples are electrophoresed by 15% SDS-PAGE and analyzed by Western 
blotting. A PVDF membrane is probed with a polyclonal antibody against the 
recombinant rat PSP94 (1: 2500 dilution). A strong band (a smear or a doublet) at about 
14.5 kDa is seen in normal LP. The intensity of immunoreactive signals becomes 
decreased in LP after different time period of castration. The binding signals become 
totally lost after 30- and 60-day castration. After androgen replacement, a strong band of 


















































































































































Figures 26a and b. Semi-quantitative RT-PCR ofPSP94 in lateral prostates from normal, 
castrated rats following with com oil, DHT, DEX, MPA and ZnSO4 treatment, (a) Upper 
panel: RT-PCR amplification (20 cycles) of PSP94 transcript using total RNA (1.5^ig) 
extracted from normal LP, castrated LPs following with com oil, DHT, DEX, MPA and 
ZnSO4 treatments from a typical experiment. The bands with size of 490 bp represent the 
PCR products of PSP94. Controls for RT-PCR lacking cDNA templates are absence of 
reverse transcriptase (RT), total RNA and cDNA templates. No amplification signal is 
shown in the controls. Lower panel: RT-PCR amplification (27 cycles) of rat y^actin 
mRNA in the same samples tested for the PSP94. A band (249 bp) of similar intensity is 
seen in all tested samples except in the controls, (b) Densitometric analysis of PCR 
products of PSP94 expressed as percentages of intact control (normal LP). Each data 
point is the mean 士 standard error of triplication measurements. Asterisks indicate 
significant differences from those levels expressed in the group of castrated animal 
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Figures 27a and b. Semi-quantitative RT-PCR of probasin in lateral prostates from 
normal, castrated rats following with com oil, DHT, DEX, MPA and ZnSO4 treatments, 
(a) Upper panel: RT-PCR amplification (20 cycles) of probasin transcripts using total 
RNA (1.5jug) extracted from normal LP, castrated LPs following with com oil, DHT, 
DEX, MPA and ZnSO4 treatments from a typical experiment. The bands with size of776 
bp represent the PCR products of probasin. Controls for RT-PCR lacking cDNA 
templates are absence of reverse transcriptase (RT), total RNA and cDNA templates. No 
amplification signal is shown in the controls. Lower panel: RT-PCR amplification (27 
cycles) ofrat y^actin mRNA in the same samples tested for the probasin. A band (249 bp) 
of similar intensity is seen in all tested samples except in the controls, (b) Densitometric 
analysis of PCR products of probasin expressed as percentages of intact control (normal 
LP). Each data point is the mean 士 standard error of triplication measurements. Asterisks 
indicate significant differences from those levels expressed in the group of castrated 
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Figures 28a and b. Semi-quantitative RT-PCR of SVSII in lateral prostates from normal, 
castrated rats following with com oil, DHT, DEX, MPA and ZnSO4 treatments, (a) Upper 
panel: RT-PCR amplification (20 cycles) of SVSII transcripts using total RNA (1.5^ig) 
extracted from normal LP, castrated LPs following with com oil, DHT, DEX, MPA and 
ZnSO4 treatments from a typical experiment. The bands with size of 764 bp represent the 
PCR products of SVSII. Controls for RT-PCR lacking cDNA templates are absence of 
reverse transcriptase (RT), total RNA and cDNA templates. No amplification signal is 
shown in the controls. Lower panel: RT-PCR amplification (27 cycles) of rat y^actin 
mRNA in the same samples tested for the SVSII. A band (249 bp) of similar intensity is 
seen in all tested samples except in the controls, (b) Densitometric analysis of PCR 
products of SVSII expressed as percentages of intact control (normal LP). Each data 
point is the mean 士 standard error of triplication measurements. Asterisks indicate 
significant differences from those levels expressed in the group of castrated animal 
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Figure 29. Westem blot analysis of PSP94 protein in normal, castrated following with 
com oil, DHT, DEX, MPA and ZnSO4 treated rat lateral prostates (LP). The total protein 
extracts from the samples are electrophoresed by a 15% SDS-PAGE and analyzed by 
Westem blotting. A PVDF membrane is probed with a polyclonal antibody against the 
recombinant rat PSP94 (1: 2500 dilution). A strong band (a smear or a doublet) at about 
14.5 kDa is seen in normal LP. The immunoreactive signal is also detected in the 
castrated LP following with DHT treatment. No immunoreactive signal is detected in the 







































































Figures 30a to 30f. In-situ hybridization of PSP94 in T+E2 induced prostatic 
intraepithelial neoplasia (PIN) in the lateral prostate of Noble rats. Prostatic 
intraepithelial neoplasia can be divided into two histological grades (low grade and high 
grade). Four architectural patterns of high-grade PIN including, tufting, micropapillary, 
cribriform, and flat can be distinguished, (a) This glandular lesion shows an early 
cribriform pattem with a well-formed epithelial arch (arrow). The hybridization signals of 
PSP94 become lost in the acini. Few hybridization signals are detected in some epithelial 
cells located at the basal compartment of the secretory epithelium. X 100. (b) Acini 
showing a tufting pattem ofhigh grade ?JN in LP begin to lose their PSP94 expression. 
X 100. (c) The epithelial cells in acini with a micropapillary pattem almost lose their 
PSP94 expression. X 100. (d) Lesions of low grade PIN in LP. The epithelial cells show 
weak hybridization signals. X 100. (e) Acini show a tufting pattem of high grade PIN. 
The secretory epithelium begins to lose its PSP94 expression signal. Moderate signals are 
observed in epithelial cells located at the basal compartment ofepithelium in the acini. X 
200. (f) Acinus with a flat pattem of high grade PIN in LP. Only a few epithelial cells 
located at the basal compartment of secretory epithelium show positive hybridization 
signals. X 200. 
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Figures 31a to 31b. In-situ hybridization of probasin in T+E2 induced prostatic 
intraepithelial neoplasia (PIN) in the lateral prostate of Noble rats, (a) Acini show the 
tufting and early cribriform patterns of high grade PIN. Epithelial cells in the high-grade 
PIN show weak or no hybridization signals, whereas the normal epithelial cells in the 
adjacent areas show strong positive signals. X 100. (b) Acini with the tufting pattem of 
high grade PIN lose their expression of probasin mRNA. X 100. (c) Acini with the 
micropapillary pattem ofhigh grade ?JN lose their probasin expression. X 100. (d) Acini 
with low grade ?IN. Very weak hybridization signals are detected over the secretory 
epithelium of the low grade PIN (arrow), whereas its expression loses at the high grade 
PIN lesion (arrowhead). X 100. (e) Acini with tufting pattem of high grade PIN. Empty 
cavities, which may be occurred previously by some apoptotic cells, are found within the 
epithelium. These apoptotic cells may either remain in the empty spaces or are shed into 
the lumen. The hybridization signals are mainly localized to the epithelial cells located at 
the basal compartment of secretory epithelium (arrows). X 200. (f) Acini with a flat 
pattem of high grade P m . The apical secretory epithelial cells lose their hybridization 
signals. These positively stained epithelial cells are mostly located at the basal 
compartment of secretory epithelium. X 200. 
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Figures 32a to 32b. In-situ hybridization of SVSII in T+E2 induced prostatic 
intraepithelial neoplasia (PESf) in the lateral prostate of Noble rats, (a) Acini show the 
tufting and the cribriform pattern, with a well-formed epithelial arch, ofhigh grade PIN. 
Most ofthe secretory epithelium shows weak or negative hybridization signals, whereas a 
few acinar cells show strong positive signal. X 100. (b) Acini with the tufting pattem of 
high grade PIN lose their expression of SVSII mRNA, whereas a few acinar cells in the 
adjacent normal region show strong positive signals. X 100. (c) Acini with the flat pattem 
of high grade PIN lose their probasin expression. X 100. (d) Low grade PIN. Weak 
hybridization signals are detected over the secretory epithelium of the low grade PIN. X 
100. (e) Acini with tufting pattem ofhigh grade PIN. Vacuoles within the epithelium may 
represent the apoptotic bodies, which are either remained in the empty space or are shed 
into the lumen. The hybridization signals are mostly localized to those epithelial cells 
located at the basal compartment of secretory epithelium (arrows). X 200. (f) Acini with 
the tufting pattem of high grade PESf. The hybridization signals become lost in those 
apical secretory epithelial cells. The epithelial cells located at the basal compartment of 
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Figures 33a to 33f. (a) In-situ hybridization (ISH) of PSP94 in Dunning tumor. No 
hybridization signal is observed. X 100. (b) ISH ofPSP94 in AIT. No hybridization 
signal is observed. X 100. (c) ISH of probasin in Dunning tumor. No hybridization signal 
is observed. X 100. (d) ISH of probasin in AIT. No hybridization signal is observed. X 
100. (e) ISH of SVSII in Dunning tumor. No hybridization signal is observed. X 100. (f) 
ISH ofSVSII in AIT. No hybridization signal is observed. X 100. 
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Figures 34 a to 34c. (a) RT-PCR amplification (35 cycles) of PSP94 transcript using total 
RNA (1.5 i^g) extracted from normal LP, Dunning R3327-H tumor and androgen-
independent tumor (AIT). Upper panel: A strong band of 490 bp (arrow) is seen in normal 
LP. Two forms of RT-PCR product of PSP94 are found in Dunning tumor. The larger one 
with 490 bp (arrow) corresponds the expected PCR product of PSP94 and the smaller one is 
300 bp (arrowhead). Only smaller band (300 bp) is detected in AIT tumor. Controls for RT-
PCR lacking cDNA template are absence of reverse transcriptase (RT), total RNA and cDNA 
templates. No amplification signal is shown in the controls. Lower panel: RT-PCR of /？-actin 
is performed and an amplification band (249 bp) is shown in all tested tissues except in the 
controls, (b) RT-PCT amplification (35 cycles) of probasin transcript using total RNA (1.5 
Hg) extracted from normal LP, Dunning R3327-H tumor and androgen-independent tumor 
(AIT). Upper panel: A strong band of 776 bp is seen in normal LP. A weak band with 
identical size is observed in Dunning tumor. No band is detected in AIT tumor. Controls for 
RT-PCR lacking cDNA template are absence of reverse transcriptase (RT), total RNA and 
cDNA templates. No amplification signal is shown in the controls. Lower panel: RT-PCR of 
y^actin is performed and an amplification band (249 bp) is shown in all tested tissues except 
in the controls, (c) RT-PCT amplification (35 cycles) of SVSII transcript using total RNA 
(1.5 ^g) extracted from normal LP, Dunning R3327-H tumor and androgen-independent 
tumor (AIT). Upper panel: A strong band of764 bp is seen in normal LP. A weak band with 
identical size is detected in both Dunning tumor and AIT tumor. Controls for RT-PCR 
lacking cDNA template are absence of reverse transcriptase (RT), total RNA and cDNA 
templates. No amplification signal is shown in the controls. Lower panel: RT-PCR of y^actin 
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Chapter 4: Discussion 
4.1 Specific Expression of PSP94 in the Lateral Lobe of Rat Prostate 
The rat prostate gland comprises of several discrete lobes: the ventral, dorsal, 
lateral, and anterior (also called as coagulating gland), and they are different in their 
histology. Different lobes secrete and elaborate different carbohydrates and proteins 
[Shivaji et al., 1989; Chan and Ho, 1999]. For example, the rat ventral prostate secretes 
high amount of citrate, spermine, spermine-binding protein [Liang et al., 1978] and a 
major secretory protein called "prostatic binding protein" or "prostatein" [Heyns, 1977; 
Heyns and DeMoor, 1977; Heyns et al., 1978a; Heyns et al., 1978b; Lea et al., 1979]. 
Two major androgen-dependent secretory glycoproteins, dorsal prostates I and II (DP I， 
II) are secreted by the rat dorsal prostate [Wilson and French, 1980; Bartlett et al., 1984]. 
Another two secretory proteins have been identified and characterized in the rat lateral 
prostate, including seminal vesicle secretion 11/ SVSII and probasin [Dodd et al., 1983; 
Matusik et al., 1986; Harris et al., 1990]. Among these, probasin is the most characterized 
prostatic secretory protein and cloning of its gene has been recently developed into 
several transgenic mouse models for prostate cancer [Greenberg et al., 1995; Kasper et 
al., 1998; Yan et al., 1998]. In contrast to PSP94, there is no similar protein homologous 
to rat probasin has been identified so far in human or primates and thus might limit its 
clinical application in the prostate disease. 
The prostatic secretory protein of 94 amino acids (PSP94) is one of the major 
proteins secreted by the human prostate, in addition to prostatic acid phosphatase (PAP) 
and prostate specific antigen (PSA) [Lilja and Abrahamsson, 1988; Hara and Kimura, 
1989]. Its homologous protein has been purified from rat prostate [Femlund et al., 1996]. 
From amino acid sequencing, Femlund and colleagues have been able to clone the 
protein. Their results show that the overall amino acid identities of rat PSP94/p-
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microseminoprotein are only 45, 50, and 40% in homology as compared to its 
homologous proteins from the human, the ape, and the pig, respectively. However, all 
these four molecular species contain 10 cysteines. PSP94 is a protein unusually rich in 
cysteine residues (about one-tenth of the residues) and at least in the pig [Femlund et al., 
1994] they are all in disulphide linkage, suggesting a tightly knotted three-dimensional 
structure of the native protein. The authors suggest that this strictly conserved structural 
feature is essential for the function of PSP94 and may constitute the basis for the 
similarities in physicochemical properties of the human, pig, and rat proteins in spite of 
their dissimilarity in amino acid sequence [Femlund et al., 1996]. 
In the present study, I have demonstrated that rat PSP94 is a prostate-specific 
protein. It is highly expressed in the lateral prostate, moderately in the dorsal prostate, 
weakly in the coagulating gland but negative in the ventral prostate and seminal vesicle. 
Its lobe-specific gene expression is demonstrated by the results of in-situ hybridization 
(Fig. 5) and Northern blotting (Fig. 6), and protein expression is further confirmed by 
Westem blotting (Figs.lO, 11 and 12) and immunohistochemistry (Fig. 9). Its molecular 
mass as estimated by the Westem blotting is about 14.5 kDa and is comparable to that 
determined by Femlund et al. [22 kDa; 1996], and also to the molecular mass ofhuman 
[10.7 kDa as calculated from the sequence; Seidah et al., 1984] and porcine [10 kDa as 
determined by mass spectrometry; Femlund et al., 1994] PSP94s. Its expression in the 
dorsal lobe is moderate as shown by Northern blotting but weak in Westem blotting and 
immunohistochemistry, indicating that it is also secreted in smaller amounts by the dorsal 
lobe. Similar lobe specific expression ofPSP94 is also observed in the lateral lobe of the 
mouse prostate gland but not in dorsal and ventral lobes [Xuan et al., 1999; Fig. 6]. Thus, 
it is concluded that PSP94 is a major secretory protein of the lateral lobe in both rat and 
mouse prostates. PSP94 transcripts are also detected in the dorsal prostate and 
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coagulating gland by a more sensitive method, RT-PCR (Fig. 7). Dorsal prostate and 
coagulating gland are very similar in their morphology, as shown by the presence of 
dilated cisternae of rough endoplasmic reticulum in their secretory epithelial cells [Dahl 
et al., 1973]. Both glands secrete some of their products in an apocrine manner, as 
evidenced by the presence of apical cytoplasmic blebs and their detachment into lumen 
[Dahl et al., 1973; Aumtlller and Adler, 1979; Chan and Ho, 1999; Groos et al., 1999]. 
Biochemically, both glands are rich in fructose and glucose [Mann, 1964; Fouquet, 
1971]. Two major androgen-dependent proteins, dorsal proteins I and II，are secreted by 
both dorsal prostate and coagulating gland [Wilson and French, 1980]. Comparing the 
results ofNorthem blots and RT-PCR, dorsal prostate might secrete more PSP94 than the 
coagulating gland as PSP94 could not be detected in the coagulating gland by Westem 
blots. Fernlund and colleagues [1996] have demonstrated a high expression level of p-
microseminoprotein in the dorsolateral prostate and also a weak expression in the ventral 
prostate and seminal vesicle by Northern blotting. However, in the present study, I could 
not detect its transcripts or protein in the ventral prostate and seminal vesicle by in-situ 
hybridization (Fig. 5), Northern (Fig. 6) and Westem blotting (Figs. 10, 11 and 12), and 
RT-PCR (Fig. 7). 
Recently, a distinct zonal expression pattem of PSP94 has been observed in the 
human pubertal and adult prostate gland by in-situ hybridization and 
immunohistochemistry [Chan et al., in press]. The granular acini in different zonal 
divisions of the human prostate are different in their expression levels of mRNA and its 
protein. It is shown that it is intense in the peripheral zone, weak and variable in the 
transition zone, but negative in the central zone in fetal and pubertal prostates. In 
addition, the secretory acini in the central zone in adult prostate show variable signals 
instead of negative expression as observed in the pubertal prostate. Therefore, the zonal 
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distribution of PSP94 in human fetal and pubertal prostate gland is similar to its lobe-
specific expression in rat prostate. However, the significance of this lobe-specific 
expression is unclear. 
In the present study, it is shown that PSP94 is mainly expressed and synthesized 
in the rat prostate gland as in the human. Its expression in rat tissues is restricted to the 
prostate gland. Its transcripts were not detected by RT-PCR in all non-prostatic tissues 
tested (Fig. 8). It is interesting to note that this highly specific and restricted expression in 
rat tissues is in contrast to its homologue in human. Besides prostate gland as the major 
source, human PSP94 or P-microseminoprotein has been shown by 
immunohistochemistry to be widely expressed and secreted by a number of non-prostatic 
tissues such as goblet cells and submucosal glands in respiratory tract, antrum of 
stomach, Bmnner,s gland, colon mucosa, ciliated epithelia of respiratory tract, Fallopian 
tube and Gartner ducts of uterine cervix, mammary gland, bile ducts and liver cells, 
esophageal gland, bulourethral gland, salivary gland, kidney, pancreas and endometria 
[Weiber et al., 1990; Teni et al., 1992; Ohkubo et al., 1995; Weiber et al., 1997]. 
Moreover, its transcript is also demonstrated by Northern blotting in trachea, bronchus 
and autrum of stomach [Ulvsbach et al.，1989], and by in-situ hybridization in gastric 
mucosa [Weiber et al., 1997]. Because of its wide distribution in glandular and mucosal 
tissues, human PSP94 has been suggested to function as a mucosal surface protein 
[Weiber et al., 1990]. However, this proposed function is doubted in the rat as shown by 
its highly specific expression in the prostate gland. 
There are some reports suggesting that PSP94 is identical to a human sperm-
coating antigen [Johansson et al., 1984; Ito et al., 1989, Hirano et al., 1996] and probably 
functions as a sperm motility inhibitor in pig sperm [Chao et al., 1996]. Moreover, it has 
been reported that it may belong to member of immunoglobulin binding factor (IgBF) 
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family [Kamada et al., 1991; Liang et al., 1992; Kamada et al., 1994; Maegawa et al., 
1996; Hirano et a l , 1996; Kamada et al., 1998]. The immunoglobulin binding factor 
(IgBF) interacts with IgG as monomers under reducing condition and suppresses the 
activation o f B cells. Therefore, it has been suggested that it may play a role in preventing 
antibody production against allogeneic sperms in the female reproductive tract [Mori et 
al., 1998]. However, the exact biological function of PSP94 in reproduction is still 
unclear. Rat PSP94 might offer a very good working model to elucidate its reproductive 
functions. 
4.2 Androgen Regulation of PSP94 
4.2.1 Molecular Mechanism of Androgen Action 
In order to understand the androgen regulation ofPSP94 in rat lateral prostate, the 
molecular mechanism of androgen action will be discussed [reviews see Hiipakka and 
Liao, 1998; White and Parker, 1998]. Testosterone is the major androgenic steroid 
circulating in the blood of males and the testis is the principle source of testosterone. The 
adrenal gland also provides small amounts of testosterone, either directly or after 
conversion of its secretory products androstenedione, dehydroepiandrosterone and 
dehydroepiandrosterone sulfate (DHEAS) to testosterone in the peripheral tissues. Blood 
DHEAS levels are more than 100 times greater than those of testosterone and represent a 
significant source of precursor for testosterone synthesis. The contribution of these 
adrenal androgen precursors to normal androgen endocrinology is unclear. 
Both testosterone and 5a-dihydrotestosterone are present in blood at 
concentrations 10-100 times of the level needed to saturate the receptor. However, these 
steroids are tightly bound to serum proteins, such as sex hormone-binding globulin 
(SHBG), which limits their bioavailability. Approximately 1-2 % of these steroids are 
free or loosely bound to proteins like albumin in blood and available for uptake into cells. 
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It is this small fraction that is believed to be biologically active. Certain androgen-
responsive cells (such as prostate cells) have cell membrane receptor for SHBG, and 
binding of a steroid-SHBG complex to the cell initiates events that increase intracellular 
cAMP, as well as the transcription of androgen-dependent genes [Ding et al., 1998]. 
After entering the cell, testosterone is metabolized to a variety of steroids, but in 
many androgen-sensitive tissues testosterone is converted to the more potent androgen, 
5a-dihydrotestosterone (DHT), by the NADPH-dependent enzyme 5a-reductase. The 
5a-reductase plays a key role in the prostatic growth and this enzyme is mainly located 
on the nuclear membrane. DHT is three to five times more potent than testosterone itself 
in binding to the androgen receptors. 
The androgen receptor is necessary for androgen action because a frame-shift 
mutation that disrupts androgen receptor function results in testicular-feminized mice. 
Androgen receptor is a ligand-dependent transcription factor that regulates, either directly 
or indirectly, the expression of androgen-responsive genes [Wang et al., 1997]. The 
androgen receptor is a member of the superfamily of nuclear receptor, which includes 
among others the receptors for estrogen, progestins, glucocorticoids, mineralocorticoids, 
vitamin D, thyroid hormones and retinoic acid. 
Androgen receptors, like other nuclear receptors, regulate specific gene 
transcription by binding to hormone responsive elements (HREs) in the vicinity of the 
regulated gene. These elements are usually present in the 5'-flanking region of the gene, 
but also effective when present in the introns and 3'-flanking sequences. Several genes 
regulated by androgen have been shown to contain androgen responsive elements 
(AREs). These AREs are similar to the consensus HRE for progestin, glucocorticoid and 
mineralocorticoid receptors, which has the sequence 5'-GGTACANNNTGTTCT-3 ‘. The 
ability of steroid receptors to activate transcription through very similar responsive 
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elements is inconsistent with the specific effects of these steroid hormones in vivo. 
Specificity might be achieved through several means. In vivo, surrounding DNA, perhaps 
as far as 1 kb (or more) away can have a modulating effect on the specificity of gene 
expression. Minor sequence differences in HREs can alter the receptor preference for an 
HRE, especially in the context of adjoining sequences. Histone and non-histone proteins 
can affect the accessibility of a transcription factor to a gene, and these proteins can vary 
between different genes or the same gene in different cells. Certain steroid receptors are 
expressed in a cell-specific manner and this would limit their effects on selected cells. 
Cell-specific metabolism of individual steroid hormones can limit exposure of a receptor 
to potent ligands. Finally, receptor-specific co-activators might be required for expression 
of certain genes, and the cell-specific expression of these co-activators might limit the 
biological response to cells expressing the specific co-activator. 
Androgen receptors, as well as other nuclear receptors, recruit a variety of co-
activators that modify the surrounding chromatin and interact with general transcription 
factors to stabilize the transcription initiation complex [Shibata et al., 1997]. 
Transactivation by androgen receptors is enhanced by co-activators such as F-SRC-1, 
CBP/p300, TIF2/GRIP1, RAP6/BAG-1, ARA70 and RIP-140, which also enhance the 
transcriptional activity of the other nuclear receptors [Hong et al., 1996; Ikonen et al., 
1997; Froesch et al., 1988; Yeh et al., 1998]. Some of these co-activators interact directly 
with nuclear receptors or indirectly through interactions with other co-activators. 
CBP/p300 and SRC-1 have histone acetylase activity, and it has been postulated that 
acetylation of core histones leads to a more open chromatin structure, allowing the 
recruitment of other transcription factors, RNA polymerase II and associated factors that 
make up the initiation complex. Androgen receptor interacts with the general 
transcription factor TFIIF, and so another possible mechanism of transcriptional 
120 
activation by androgen receptor is direct binding to TFIIF and the subsequent recruitment 
of other components of the transcriptional pre-initiation complex [McEwan and 
Gustafsson, 1997]. Certain nuclear receptors associate with transcriptional co-repressors 
in the absence of ligand or when bound to antagonists. Some of these co-repressors are 
histone deacetylases. Co-activators and co-repressors appear to be rate-limiting factors in 
transcriptional control by nuclear receptors, and regulation of their intracellular levels and 
their association with nuclear receptors determines the transcriptional activity of a ligand 
and its receptor [Lavinsky et al., 1998]. 
4.2.2 Androgen Regulation of PSP94 in Rat Lateral Prostate 
In order to test whether the expression ofPSP94 in the lateral lobes of rat prostate 
is under androgen regulation, the mRNA expression of PSP94 in the lateral prostates 
from normal, castrated, and castrated rats followed by androgen replacement, have been 
examined by in-situ hybridization and semi-quantitative RT-PCR. 
My hypothesis is that the mRNA and protein expressions of PSP94 are under 
androgen regulation. Therefore, I have examined its mRNA expression in lateral 
prostates from normal, castrated, and castrated rats followed by androgen replacement by 
in-situ hybridization (Fig. 16). For comparison, the probasin and SVSII transcripts are 
also examined in the parallel experiments (Fig. 17 and 18). Since both probasin and 
seminal vesicle secretion II (SVSII) are also secreted from the rat lateral prostate [Matuo 
et al., 1985; Matusik et al., 1986; Dodd et al., 1986; Spence et al., 1989; Prins and 
Woodham, 1995], the androgen regulation ofthe mRNA expression of these two proteins 
was also studied in parallel. In the present study, it has been reconfirmed that both 
probasin and SVSII are mainly expressed in the rat lateral prostate. By in-situ 
hybridization, probasin mRNA is highly expressed in the lateral prostate but negative in 
the ventral and dorsal prostates (Fig. 13). On the other hand, SVSII mRNA is highly 
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expressed in the lateral prostate and seminal vesicles but negative in the ventral and 
dorsal prostates (Fig. 14). However, by a more sensitive method, RT-PCR, probasin and 
SVSII transcripts are also detected in the dorsal prostate and coagulating gland (Fig. 15 
and Fig. 3a). 
After castration, the transcripts of PSP94, probasin and SVSII decrease in the 
secretory epithelia of the lateral prostate. The hybridization signals of PSP94 and 
probasin disappeared only after 60-day post-castration. For SVSII, no hybridization 
signal was detected after 30 days of castration. After replacement with androgen for 3 
weeks, the hybridization signals for PSP94, probasin and SVSII restored again in the 
lateral prostate of the rats which had been castrated for 60 days. The results indicate that 
the mRNA expressions of PSP94, probasin and SVSII are under androgen regulation. 
Moreover, the response of SVSII to androgen withdrawal is faster than that ofPSP94 and 
probasin. 
The relative expression levels of PSP94, probasin and SVSII mRNAs in normal, 
castrated and androgen replaced rat lateral prostates are measured by a semi-quantitative 
RT-PCR assay. It is a method commonly used to compare the relative abundance of a 
message in tissue samples. The amount of target PCR product derived from its cDNA is 
normalized to that from a housekeeping gene sequence such as p-actin. From the semi-
quantitative RT-PCR analysis (Fig. 22, 23 and 24), PSP94 transcripts drop significantly 
after 30-day post-castration. For SVSII, its transcripts drop significantly after 5 days of 
castration. However, there is no significant decrease of probasin mRNA expression after 
castration. The expression level of probasin remains at approximately 80% of the normal 
level after 3 and 5 days of castration and rebounds to approximately 90% at post-
castration 14 days. Afterward, there is a continuous decline in probasin mRNA 
expression after 60 days of castration. When the castrated animals were replaced with 
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androgen, the transcripts of PSP94, probasin and SVSII returned to the normal levels as 
observed in the intact lateral prostate. According to the results, the sensitivity to androgen 
withdrawal is observed with an order of SVSII > PSP94 > probasin. 
The probasin gene is shown to be regulated in vivo by androgens [Dodd et al., 
1983]. Dot hybridization experiments have demonstrated that the pM-40 specific mRNAs 
(probasin mRNA) decrease in the dorsal prostate following castration and are restored 
after testosterone administration. However, the low levels of same mRNAs in the ventral 
prostate are not alternated by androgen manipulation. 
Immunohistochemistry of probasin using a monoclonal antibody has been 
examined in the castrated dorsolateral prostates [Matuo et al., 1985]. Matuo and 
colleagues report that strong immunofluorescence is detectable only in lumen of the 
normal prostates. In the dorsolateral prostates of rats castrated for 7 days, 
immunofluorescence in the lumen is hardly observed because of remarkable decrease in 
the content of secretory proteins. The authors suggest that the synthesis of probasin is 
under androgen control. 
The regulation of the probasin (M-40) gene in the prostate has been studied by 
investigating the levels of mRNA expression during development and under hormonal 
manipulation [Matusik et al., 1986]. In the dorsolateral prostate, the probasin mRNAs 
increase between 3 and 6 weeks of age. These changes coincide with the onset of 
androgen production by testis and zinc uptake by the prostate. However, at 4 weeks of 
age, the probasin mRNA is less than 10 % of the level found at maturity. Furthermore, 
the probasin mRNA is expressed at a low level in the immature ventral prostate and 
further decreases towards sexual maturation. This apparent developmental switch in 
which the probasin gene is expressed in the ventral prostate of prepubertal animals and in 
the dorsolateral prostate of postpubertal animals suggests that androgen alone are not 
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responsible for probasin gene expression. This is confirmed by studies of the mRNA 
levels in mature male rats following castration. The probasin mRNAs decrease initially in 
response to androgen removal but then retum to normal levels between 9 and 12 days 
following castration. Since the effect of androgen removal on probasin is only short term, 
the authors suggests that another inducer may be present. Zinc is examined as a likely 
candidate. It is because zinc levels are 25-fold higher in the lateral lobe of the rat prostate 
than any other tissue. In addition, the zinc content ofthe prostate increases between 3 and 
6 weeks of age [Matuo et al., 1984] in parallel with the increase in probasin gene 
expression. In order to examine the effect of zinc, mature male rats were castrated to 
reduce the influence of androgens and to lower the level of the probasin. On day 7 after 
castration, the castrated rats were injected with either androgens or zinc. Tissue was 
removed 48 hours after treatments. The levels of the probasin mRNAs retum to normal 
after either the androgen or zinc treatment. The results indicate that the probasin gene is 
inducible by androgen and also inducible by zinc in the absence of androgens. 
Similar result of post-castration rebound of probasin has also reported by 
Sweetland et al. [1988]. In their experiment, mature rats were castrated and the 
dorsolateral prostate was removed on 6，7，8 or 12 days later. Intact males served as the 
untreated controls. Total RNA isolated from individual rat prostates is analyzed for 
probasin mRNA expression by dot blot hybridization. At 6，7 and 8 days after castration, 
a statistically significant drop in probasin mRNA levels occur as compared to control 
levels. By 12 days after castration, the probasin mRNA level has retumed to pre-
castration levels and is significantly elevated as compared to levels on 6，7 and 8 days 
post-castration levels [Sweetland et al., 1988]. The authors suggested that besides 
androgen, zinc may upregulate the gene expression of probasin, and possibly through 
mechanism mediated in part by adrenal steroid. 
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Recently, Rennie et al. [1993] report that the probasin gene is regulated in vitro by 
androgens. They have determined the location and sequence of androgen responsive 
elements (AREs) in the 5'- flanking DNA of the rat probasin gene. In support of 
collateral receptor-binding sites, preferential induction ofthe probasin gene by androgens 
is shown to involve the participation of two different cis-aciing DNA binding elements 
that bind the androgen receptor. Transfection experiments reveal that neither the first site 
(ARE-1, located at positions -236 to -233), whose sequence resembles a glucocorticoid-
responsive element, nor the second site (ARE-2, located at positions —140 to -117), which 
have a non-glucocorticoid-responsive element-like sequence, can act independently as an 
androgen-responsive element. Moreover, Kasper and colleagues [1994] further 
characterize the functional and structural relationship between the two androgen receptor-
binding sites in the probasin gene. They show that the androgen-specific regulation of 
probasin gene transcription requires an androgen-responsive region (positions -286 and 
+28) containing two androgen receptor-binding sites, where the binding of the androgen 
receptor to both sites occur in a cooperative, mutually dependent manner. 
From the reviews, we know that the gene expression of probasin is regulated by 
androgens. However, the post-castration rebound of probasin mRNA expression is also 
observed in my present result. In view of this I would like to suggest that androgens 
regulate the mRNA expression of probasin but other factors or steroid hormones may 
also regulate the gene expression of probasin. 
On the other hand, the androgen regulation of SVSII (RWB) mRNA has also been 
studied by Matusik et al. [1986] and Sweetland et al. [1988]. The results show that, in 
contrast to probasin, the SVSII mRNA decreases rapidly in response to androgen removal 
and remains low as long as the animals are androgen-deficient. Moreover, the level of the 
SVSII mRNA response to the androgen treatment only and not to the zinc [Matusik et al., 
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1986; Fig. 5]. Furthermore, Dodd and colleagues [1986] have studied the effect of 
androgen on SVSII mRNA ofrat dorsolateral prostate. The result shows that castration of 
mature male rats reduces the SVSII mRNA 7-fold in the dorsolateral prostate in 9 days. 
Androgen administration to one-week castrates brings the SVSII mRNA level to normal 
within 48 hours. They suggest that the SVSII mRNA expression is regulated by 
androgen. Moreover，the SVSII and its family genes (IV-VI) all share conserved elements 
in the 5'- flanking region which are potentially involved with androgen regulation [Harris 
et al., 1990]. 
In the present study, I have observed that there is a significant drop of SVSII 
transcripts after 14 days post-castration. Their mRNA expression returns to normal level 
after androgen replacement. Therefore, I would suggest that the mRNA expression of 
SVSII is solely regulated by androgen as compared to probasin. 
For PSP94, the androgen dependence of its mRNA expression was studied by 
both in-situ hybridization and semi-quantitative RT-PCR. The results show that the gene 
expression of PSP94 is under androgen regulation. In addition, the protein expression of 
PSP94 in the lateral prostate from normal, castrated, and castrated rats followed with 
androgen replacement has been studied by Westem blotting (Fig. 25). The result shows 
that the immunoreactive signals become lost after 30 and 60 days of castration and it 
restores to the normal level after androgen replacement. Therefore, we conclude that both 
mRNA and protein expressions ofPSP94 are under androgen regulation. 
4.3 Effect of Steroid Hormones and Zinc on the PSP94, Probasin and SVSII 
Expressions in Castrated Rat Lateral Prostates 
Since the relative sensitivity of androgen withdrawal has been determined to be in 
the order of SVSII > PSP94 > probasin in the previous study, I would like to further 
study whether there are other steroid hormones or factors affecting the expression of 
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PSP94, probasin and SVSII. In my experiments, animals which had been castrated for 30 
days, were injected daily with dihydrotestosterone (DHT), a synthetic glucocorticoid 
(dexamethasone, DEX), a synthetic progestin (medroxyprogesterone acetate, MPA), or 
zinc sulfate (ZnSO4) for 7 days. Control animals were received vehicles (com oil or 
saline). The lateral prostates were removed after drug treatments. The PSP94, probasin 
and SVSII mRNA transcripts were examined by a semi-quantitative RT-PCR assay. The 
semi-quantitative RT-PCR assays demonstrate that there are significant increases in 
PSP94 mRNA expression in the lateral prostates after treating the castrated rats with 
DHT, DEX and MPA as compared its expression to that in the com oil-treated rats (Fig. 
26). There are also significant increases in the probasin mRNA expression in the 
castrated lateral prostates after DHT, DEX and MPA treatments, and only an approximate 
20% increase after treatment with zinc as compared its expression to that in the com oil-
treated rats (Fig. 27). On the other hand, the expression of SVSII mRNA in the castrated 
lateral prostates is only affected significantly by DHT. The MPA treatment slightly 
increases its mRNA expression to about 20% of the com oil-treated control (Fig. 28). 
The mRNA expression of probasin is upregulated by DHT treatment in the 
castrated rats. This is expected as two androgen responsive elements (ARE-1 and ARE-2) 
are located at the 5' flanking region of probasin gene [Rennie et al., 1993]. Moreover, 
Kasper et al. [1994] found that the androgen-specific regulation of the probasin gene 
probably involves a complex interplay of many agents. It is not mediated through the 
binding of androgen receptors to a single hormone-responsive element. Instead, androgen 
receptors bind in a cooperative, mutually dependent manner to two distinct DNA 
sequence motifs contained within an androgen-responsive region. 
In the present study, the mRNA expression of probasin is upregulated in the 
castrated rats after glucocorticoid (DEX) treatment. Matusik et al. [1991] also reported 
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that the endogenous probasin gene can respond to glucocorticoids in the castrated rat. 
Moreover, the transfection experiments have demonstrated that a ^ 2 6 / 2 8 probasin-CAT 
gene is responsive to both androgens and glucocorticoids [Rennie et al., 1993]. 
However, my present observation on the effect of DEX on probasin expression is 
in contrary to the previous reports. The expression of a transgene, consisting of the 
bacterial chloramphenicol acetyltransferase (CAT) reporter linked to a fragment of 5' 
flanking probasin (-426 to +28) DNA containing the two androgen receptor binding sites, 
is shown to be prostate-specific and inducible by androgens, but not by glucocorticoids 
[Greenberg et al., 1994]. Probasin-CAT activity in the prostate of the transgene declines 
after castration to 3.5% ofthe precastration level, and the CAT activity in castrated males 
approach precastration levels when mice are supplemented with testosterone. Transgene 
expression in castrated males is not induced by dexamethasone. Recently, the androgen 
responsive element (ARE-2) in the promoter region of probasin gene has been studied 
that it is induced only by androgens but not by glucocorticoids [Claessens et al., 1996]. 
Furthermore, another transgenic mice line, which consists of the CAT reporter linked to a 
larger fragment of the probasin promoter (LPB, -11,500 to +28), show that the probasin-
CAT expression is regulated by androgens but not by glucocorticoids [Yan et al., 1997]. 
Hormone ablation by castration in the mature transgenic mice dramatically reduces 
transgene expression, whereas treatment with androgens can retum the LPB-CAT 
expression to precastration levels. In contrast, treatment with glucocorticoids has no 
significant effect on LPB-CAT gene expression. 
The rat dorsolateral prostate has been found to contain more total zinc than any 
other tissue, except the bone [Mawson and Fischer, 1951]. In addition, a number of 
previous studies have shown that zinc ions are concentrated in the lateral lobe and to a 
lesser extent in the dorsal lobe of the prostate [Byar et al., 1969; Gunn et al., 1955; 
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Sorensen et al., 1997]. It is proposed that zinc ions are able to regulate the expression of 
the secretory proteins in rat lateral prostate. Matusik et al. [1986] reported that the mRNA 
expression of probasin is upregulated by zinc treatment in the castrated rats. Moreover, 
zinc treatment of the castrated LPB-CAT trangenic mice can increase three- to four-fold 
of LPB-CAT expression in the ventral and lateral prostates [Yan et al., 1997]. However, 
in my present result, there is only an approximate 20 % increase in probasin mRNA 
expression after zinc treatment, as compared to the level of com oil-treated rats. Zinc 
could influence a wide range of cellular processes in the rat prostate. In the absence of 
androgens, zinc may increase the probasin mRNA expression in an indirect manner, 
probably through other regulatory factors such as some sequence-specific DNA binding 
proteins (SDBP) with zinc finger motif [Berg, 1990; Blok et al., 1995]. 
There is so far no information on the probable progesterone regulation of the 
probasin transcription activity. However, progesterone does regulate the mRNA 
expression of prostatic binding protein (PBP) in the ventral lobe of rat prostate. Pelletier 
et al. [1988] studied the effects of sex steroids on regulation of the levels o f C l peptide of 
rat PBP mRNA. Densitometric quantification of autoradiographic hybridization signals 
reveal that a significant decrease in C1 mRNA levels after 5 hours of castration. Levels of 
C1 mRNA decrease by 50% after 2.5 days post-castration, while undetectable levels are 
reached after 7 days post-castration. Administration of the potent androgen, 5a-
dihydrotestosterone, to the castrated rats cause a progressive increase in C1 mRNA levels 
which become significant 5 hours after first injection, while prolonged DHT treatment for 
3 and 7 days, causes 50 and 100% reversals respectively of the effect of castration on C1 
mRNA levels. Moreover, administration of progesterone (2 mg twice daily) to 
orchiectomized adult rats for 14 days, causes a marked increase in C1 mRNA levels 
[Pelletier et al., 1988]. Similarly, administration of synthetic progestin 
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(medroxyprogesterone acetate, MPA) to 4-day castrated rats for 4 days, at a dosage of 
0.45 mg twice daily, also leads to significant increases in PBP-C1 and PBP-C3 mRNA 
levels [Labrie et al., 1990]. 
In the present study, the synthetic progestin (MPA) significantly increases the 
mRNA expression of probasin in the castrated rats. This may be reasoned by the fact that 
at high concentrations, certain weak androgen agonists such as medroxyprogesterone 
acetate (MPA) activate androgen receptor through a mechanism that does not involve the 
AR NH2-terminal and carboxyl-terminal interaction [Kemppainen et al., 1999]. MPA is 
classified as a weak androgen by direct measurement of in vivo bioactivity [Kemppainen 
et al., 1999]. MPA increases the synthesis of p-glucuronidase in the mouse kidney at 100-
fold higher doses relative to testosterone [Bardin et al., 1984; Mowszowicz et al., 1974]. 
In the androgen-insensitive testicular-feminized (Tfm) mouse mutant, P-glucuronidase 
activity does not increase in response to MPA, indicating that gene activation in response 
to MPA is androgen receptor mediated [Mowszowicz et al., 1974]. A significant higher 
dose (1000 times) than testosterone is required to increase ventral prostate weight in 
castrated rats [Raynaud et al.，1980]. However, high dose (0.9 mg/ day) of MPA is still 
less effective than low-dose of DHT (0.2 mg/ day) in stimulating the synthesis of rat 
prostatic binding protein (PBP) mRNA [Labrie et al., 1990]. The effects of MPA on 
ventral prostate are inhibited by flutamide, indicating that the in vivo activity of MPA is 
androgen receptor mediated. Therefore, in the present experiments, MPA acts as a weak 
androgen to upregulate the expression of probasin mRNA in the castrated lateral 
prostates. 
In conclusion, besides androgens, glucocorticoid, progesterone, and zinc also 
regulate the gene expression of probasin. It may also explain the low sensitivity to 
androgen withdrawal in the probasin mRNA expression. 
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In contrast to probasin, the expression of SVSII mRNA in the castrated lateral 
prostates is only affected significantly by DHT. It indicates that the gene expression of 
SVSII is solely regulated by androgen. Although there is few information on the 
promoter region of SVSII gene, Harris et al. [1990] found that the 5'flanking region 
contains three conserved elements as also found in other seminal vesicle secretion genes 
(SVSIV-VI genes) within the 250 bp of the transcription start site as well as a 
glucocorticoid response element at positions -314 in the SVSII gene. The authors suggest 
that the identification of androgen-response elements devoid of glucocorticoid response 
has proven difficult. Since a glucocorticoid response element sequence (GGTCCA 
atcTGTCCT) is observed in the SVSII gene upstream at position -314, glucocorticoids 
may likely play a role in SVSII gene expression [Harris et al., 1990]. They also suggest 
that most glucocorticoid-response elements will response to androgens in systems where 
the androgen receptor is present. For example, MMTV-CAT constructions transfected 
into DDT1 cells [Harris et al., 1988; Karr et al., 1991]. However, in the present study, it 
was observed that the synthetic glucocorticoid (DEX) does not have any effect on the 
expression of SVSII mRNA. 
The up-regulation of SVSII mRNA expression by MPA may be attributed to the 
fact that MPA acts as a weak androgen [Kemppainen et al., 1999]. Therefore, it is 
concluded that the gene regulation of SVSII is solely and tightly regulated by androgens. 
It also explains the results why SVSII is the most sensitive one to androgen withdrawal as 
compared to PSP94 and probasin. 
On the other hand, the promoter region ofhuman PSP94 gene has been studied by 
Nolet et al. [1991]. A conserved steroid-hormone responsive element is identified in the 
promoter region, and also an estrogen-responsive element in the first intron of the human 
PSP94 gene. The incidence of these genetic elements strongly suggests that expression of 
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human PSP94 gene may be regulated by steroid, particularly sex hormones [Nolet et al., 
1991]. In addition, another glucocorticoid-responsive element (GRE) is also found at the 
first intron (+151) of human PSP94 gene [Ochiai et al., 1995]. It is also suggested that 
human PSP94 may be regulated by glucocorticoid. 
Although, the 5' flanking promoter region of rat PSP94 gene has not been 
characterized, the present study has demonstrated that the PSP94 gene expression in the 
rat lateral prostate is regulated by androgen as well as other steroids. DHT, DEX and 
MPA treatment can upregulate the mRNA expression ofPSP94 in the castrated rat lateral 
prostates. Since androgen, glucocorticoid, and progesterone receptors are located in the 
rat prostate gland [Belis et al., 1984; Chang et al., 1987; Prins et al., 1991; Schultz et al., 
1993; Lau et al., 1998], it is speculated that these steroid hormones (DHT, DEX and 
MPA) may regulate the mRNA expression ofPSP94 in rat prostate through their specific 
receptors. Moreover, the cyclic AMP response element (CRE) has been characterized to 
present in the promoter region of human PSP94 gene [Ueyama et al., 1998]. They also 
show that the expression of human PSP94 gene is regulated by cAMP via the element. In 
addition, the receptor for SHBG (RsHBc) has been located in the prostatic cells, and 
binding of steroid-SHBG complex to the cell will initiate a number of cellular events that 
increase intracellular cAMP as well as the transcription of androgen-dependent genes 
[Ding et al., 1998]. Therefore, it is speculated that the initiation of the transcription of 
PSP94 may be via the Rsmc by a signal transduction pathway involving cAMP. 
However, when we examined the protein expression of PSP94 in the lateral 
prostates removed from the castrated rats following with drug treatments by Westem 
blotting (Fig. 29), only DHT treatment can restore the immunoreactive signal ofPSP94 in 
the castrated rats. The result suggests that the processes of PSP94 translation in rat 
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prostate cells are under androgen control. Glucocorticoid and progesterone are only able 
to initiate the transcription activity of rat PSP94 gene, but not in translation level. 
4.4 Detection of PSP94, Probasin, SVSII mRNA Expression in Dysplastic and 
Neoplastic Rat Prostates 
The development of prostate cancer, like other tumors, is a multi-stepped process 
including initiation, promotion and progression. The progression ofprostate carcinoma is 
divided into several subsequent stages, which can be distinguished by their 
histopathology. The epithelial cells in the lesions are transformed from normal epithelium 
to prostatic intraepithelial neoplasia (PES[), histologic prostate carcinoma and metastatic 
carcinoma. In most patients with prostate cancer, continuous androgen suppression 
(CAS) therapy causes tumor regression with an accompanying decrease in serum prostate 
specific antigen (PSA). However, after a variable period of time averaging 24 months, the 
tumor inevitably recurs with increasing serum PSA levels and progresses to androgen-
independent. At this time, hormone refractory carcinoma appears. 
Prostatic intraepithelial neoplasia (PIN) refers to the putative precanerous (also 
called dysplasia) end of the morphologic continuum of cellular proliferations within 
prostatic ducts, ductules, and acini. [Bostwick and Brawer, 1987]. Two grades of PIN 
(low-grade and high-grade) are identified in human prostate gland. The high-grade PFN is 
considered to be a precursor of invasive carcinoma. According to the multi-steps theory 
of malignant transformation, the normal prostatic epithelium is transformed to 
hyperplasia, then through increasing grades of PIN to become early invasive carcinoma. 
Low-grade PIN corresponds to very mild to mild dysplasia. High-grade PIN corresponds 
to moderate to severe dysplasia and carcinoma in-situ. The precursor state ends when 
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malignant cells invade the stroma. This invasion occurs where the epithelial basal cell 
layer is disrupted and the basement membrane is disintegrated. 
In low-grade PIN, the cells within ducts and acini are heaped up, crowded, and 
irregularly spaced with marked variation in nuclear size (anisonucleosis). Elongated 
hyperchromatic nuclei and small nucleoli are also observed, but these are not usually 
prominent features. The diagnosis of PES[ requires a combination of both cytologic and 
architectural features, and lesions displaying some but not all of these features are 
considered atypical but not dysplastic. High-grade PIN exhibits features similar to low-
grade PIN, although cell crowding and stratification are usually more pronounced, with 
less variability in nuclear size because the majority of nuclei are enlarged. Presence of 
prominent nucleoli, often numerous in the epithelial nuclei, is a prominent diagnostic 
feature [Bostwick, 1992]. Four histological patterns ofhigh-grade PIN can be recognized: 
tufting, micropapillary, cribriform, and flat [Bostwick et al., 1993]. Tufting is 
characterized by stratified mounds and heaps of epithelial cells protruding into the 
lumens, usually no more than five cell layers in thickness. The micropapillary pattem is 
characterized by numerous slender, finger-like structures with bulbous tips projecting 
into the lumens, occasionally accompanied by delicate fibrovascular cores. The 
cribriform pattem is characterized by complex intraluminal proliferation of cells 
punctuated by multiple lumens varying from rigid, neatly punched-out rounded spaces to 
variably sized, ovoid to slit-like spaces. The flat pattem is characterized by one or two 
layers of cells lining glands without evidence of stratification. Increasing grades of PIN 
are associated with progressive disruption of the basal cell layer and basement 
membrane. Early invasive carcinoma occurs at sites of glandular out-pouching and basal 
cell disruption [Bostwick and Brawer, 1987]. 
134 
Animal model of PESf or atypical dysplasia lesion can be induced in Noble rat by 
long term treatment with combined testosterone and 17p_estradiol. Leav et al. [1988] 
reported that atypical prostatic hyperplasia, "dysplasia", and carcinoma can be induced in 
the Noble rat prostate gland. The authors suggest that the induced lesions of dysplasia in 
Noble rat prostate gland mimic the PIN lesions in human prostate gland, and the 
dysplastic lesion may progress to carcinoma after long-term hormonal treatment. 
In the present study, the expression patterns of PSP94, probasin and SVSII 
mRNA in the lesions of prostatic intraepithelial neoplasia (PIN) in rat lateral prostate 
were studied by in-situ hybridization. The results showed that the hybridization signals of 
these secretory proteins became lost or weakened in the epithelial cells in both low-grade 
and high-grade PIN in the rat lateral prostate (Figs. 30, 31 and 32). Their hybridization 
signals were weakly expressed over the secretory epithelium in low-grade PIN. In the 
high-grade PES[, their hybridization signals became lost in different patterns of PIN 
lesions including tufting, micropapillary, cribriform and flat patterns. Interestingly, their 
hybridization signals were still detected mostly in the dysplastic epithelial cells located at 
the basal compartment of the secretory epithelium in high grade PES[, whereas those 
epithelial cells located at the luminal compartment became lost their hybridization 
signals. The loss and weakening of hybridization signals in both low-grade and high-
grade PIN of rat lateral prostate suggests that a downregulation in normal expression of 
these proteins appear in the PESL 
In human prostate glands, the hybridization signals of PSP94 are observed to 
become decreased or lost in different Gleason grades PIN lesions [Chan et al., in press]. 
Besides PSP94, immunohistochemical studies ofPAP and PSA in prostatic intraepithelial 
neoplasia have observed that their intensities are weaker than that observed in benign 
epithelium and cancer [McNeal et aL, 1988; Chan et al., in press]. Immunoreactivities of 
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PAP and PSA are reduced in dysplastic lesions and often absent in severe dysplasia, 
indicating that reduced differentiation is an early change in prostatic carcinogenesis. In 
contrast to prostatic secretory proteins, the expression of human glandular kallikrein 2 
(hK2) and prostatic specific membrane antigen (PSM) incrementally increase from 
benign epithelium to high grade-PIN and cancer [Darson et al., 1997; Bostwick et al., 
1998]. 
The mRNA expressions of these prostatic secretory proteins in the Dunning 
R3327-H and AIT tumors were also examined by in-situ hybridization (Fig. 33). No 
hybridization signals of PSP94, probasin and SVSII were detected in both Dunning 
R3327-H and AIT tumors. On the other hand, by the more sensitive RT-PCR method, 
two forms of RT-PCR products were found in the Dunning R3327-H tumor. The larger 
product corresponds to the original expected PCR product of PSP94 (490 bp), whereas 
the smaller band (300 bp) probably represents the new form of PSP94 PCR product. 
Interestingly, only the smaller form of PSP94 PCR product was detected in AIT tumor. 
By RT-PCR, two forms of PSP94 cDNA are also detected in the human prostate cancer 
specimens [Xuan et al., 1995]. The authors analyzed the PCR products by Southern 
blotting probing with exon-specific oligonucleotides. The short form of PSP94 mRNA, 
designated as PSP57 is resulted by the deletion of exon III due to alternative splicing of 
PSP94. The two mRNA forms are further confirmed by cloning and sequencing of the 
RT-PCR products. In present study, the smaller PCR products of PSP94 detected in 
Dunning R3327-H and AIT tumors (300 bp) is speculated as an alternative spliced form 
of the full length PSP94 mRNA. However, it needs further study by DNA sequencing in 
order to confirm this DNA sequence of the smaller form ofPCR products ofPSP94. 
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A weak expression of probasin transcript is detected in Dunning R3327-H but it is 
negative in the AIT tumor. However, weak expressions of SVSII transcript are detected 
in both Dunning R3327-H and AIT tumors. 
The present study suggests a decreasing level of PSP94 mRNA expression in the 
progression of prostate cancer. A decreasing immunoreactivity of inhibin-like material 
and P-microseminoprotein (homologous protein of PSP94) in the prostate cancers has 
been described by some authors [Doctor et al., 1986; Tremblay et al., 1987; Abrahamsson 
et al., 1988; Hyakutake et al.，1993; Tsurusaki et al., 1998]. Moreover, by subtractive 
cDNA cloning, the expression of PSP94 appears to be down-regulated in the cancerous 
cells [Liu et al., 1993]. However, in a separate but controversial study ofPSP94 by Dube 
and colleagues [1987b], a stronger immunoreactivity ofPSP94 was demonstrated in the 
poorly differentiated carcinomas than in the well-differentiated carcinomas. 
In another study, the immunostaining of PSP94 is more intense that than of PSA 
and PAP in androgen independent human prostate cancer lines (PC-3, DU-145 and TSU-
Prl) using PIP antibody (anti-PIP). The antibody also cross-reacts with the Dunning rat 
prostate cancer cell lines and tumors [Garde et al., 1993a]. 
Recently, several research groups have explored the use of PSP94 as a novel and 
apparently non-toxic form of therapy for hormone independent prostate cancer [Garde et 
al., 1993b; Mundle et al., 1993; Lokeshwar et al., 1993; Garde et al., 1999]. Garde et al. 
[1993b] suggest that PIP (a protein homologous to PSP94) may inhibit the growth of 
prostate cancer by inhibiting FSH. PIP may represent a novel hormonal treatment for 
prostate cancer. Mundle et al. [1993] suggests that human seminal plasma inhibin (HSPI) 
(a protein homologous to PSP94) can suppress the basal and stimulated DNA synthesis 
and also induce apoptotic cell death in rat prostate. Moreover, PSP94 have been found to 
suppress the growth of androgen-independent prostate cell line (PC-3) and xenografts by 
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inducing apoptosis [Garde et al., 1999]. The authors suggest that PSP94 may represent a 
novel, apoptosis-based, antitumor agent applicable to the treatment of hormone-refractory 
human prostate cancers. Furthermore, Lokeshwar et al. [1993] demonstrate that prostatic 
inhibin (PI) (a protein homologous to PSP94) not only inhibit in vitro growth of tumor 
cells but also suppress tumor growth in vivo. These inhibitory activities are similar in 
both androgen-dependent and androgen-independent Dunning tumor cell lines. 
The expression of PSP94 and PSP94 binding proteins in LNCaP cell line have 
been evaluated recently [Yang et al., 1998a and b]. The authors found that PSP94 is 
expressed and secreted in the LNCaP cells. They also reported that LNCaP cells express 
some surface membrane proteins capable of binding PSP94 in a specific and saturable 
manner. Exposure of LNCaP cells to exogenous PSP94 results in the up-regulation of 
PSP94 binding sites. The authors suggest that the expression of PSP94 and its putative 
membrane receptors may be partially regulated the growth of LNCaP cell line by an 
autocrine pathway. 
The expressions of probasin and SVSII mRNA in Dunning R3327H and AIT 
tumor are studied for the first time in present study. The expressions of probasin and 
SVSII mRNA are down-regulated in the Dunning R3327H tumor. This is explained by 
the dedifferentiation in this well-differentiated tumor. No probasin mRNA expression is 
observed in the AIT tumor, probably due to the reduced differentiation and the loss of 
androgen-dependence in the AIT tumor. Interestingly, a weak expression of SVSII 
mRNA is still detected in the AIT tumor. In fact, the progression of prostate cancer 
involves the shifting of cell regulation from androgen-dependent growth to an androgen-
independent state, sometimes with the loss or mutation of the androgen receptors in 
prostate cancer cells. Both autocrine and paracrine pathways are up-regulated in 
androgen-independent tumors and may replace androgens as primary growth stimulatory 
138 
factors in cancer progression [Russell et al., 1998; Lalani et al., 1997; Davies and Eaton, 
1991; Lee, 1997]. Therefore, the expression of SVSII mRNA reappeared in the AIT 
tumor may be due to the up-regulated autocrine and paracrine peptide growth factors. The 
positive expression of SVSII in the AIT tumor probably represents the dysregulation of 
SVSII mRNA expression in androgen-independent tumor. 
4.5 Gene Therapy 
The concept of gene therapy involves the insertion of a gene sequence into cells 
leading to the replacement of a defective gene, or insertion of a gene sequence that can 
shut down the function of an abnormally regulated gene [Naitoh and Belldegrun, 1998]. 
Although conceptually appealing, the efficacy of gene therapy has been limited by the 
inefficient vector systems that currently are being used to deliver genes to the cell. 
Liposomes, retroviruses, and adenoviruses have been used in early gene therapy 
trials to deliver the genetic information. However, the utility of these vectors is limited by 
a number of factors such as the low transfection efficiency, lack of target specificity, 
potential for random insertion of the gene into the genome, inability to induce long-term 
gene expression, and their immunogenicity, which interferes with their ability to deliver 
the gene to the target [Naitoh et al., 1998]. To overcome these limitations, Dr. Verma has 
worked on the creation of new vectors based on the lentivirus family [Kafri et a l , 1997]. 
The lentiviruses (which include the HIV-1) are RNA viruses that are unique in 
their ability to achieve stable, efficient incorporation into the host genome [Naldini et al., 
1996]. However, problems with wild-type lentiviruses include selective infectivity 
towards CD4+ cells and may result in immunodeficient disease (such as AIDS). To 
circumvent these problems, Dr. Verma and his associates modified HIV by deleting 
almost all of the native viral genome and by replacing the capsular proteins on the surface 
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of the viron with proteins that are derived from the vesicular stomatitis virus, which has a 
higher affinity for a wide variety of epithelial cell types pSIaldini et al., 1996]. Although 
lentiviral vectors appear to have promise as a safe and effective gene therapy delivery 
vehicle, a method still needs to be developed to confer better target specificity for both 
gene delivery and gene expression [Naitoh et al., 1998]. 
The target-specific gene therapy for prostate cancer is based on a recombinant 
adenoviral vector that expresses therapeutic genes under control of a tissue-specific 
promoter (a novel PSA promoter) exclusively found in prostate cells [Dannull and 
Belldegrun, 1997]. Based on this approach, several studies have optimised the regulation 
ofPSA promoter. [Pang et al., 1997; Dannull and Belldegrun, 1997; Segawa et al., 1998; 
Cleutjens et al., 1997a and b; Gotoh et al., 1998]. On the other hand, a specific 
therapeutic gene must be chosen that is capable of altering the biological behaviour of the 
cancer cell in order to slow down its growth, reduce invasive potential, induce apoptosis 
or even completely eradicate the tumor cell [Dannull and Belldegrun, 1997]. Caspase-7, 
apoptosis-associated protease, is proteolytically activated in every model of apoptosis. 
Transfer of caspase-7 mediated by adenovirus may offer another approach for the 
treatment of prostate cancer [Marcelli et al., 1999]. 
In present study, I have shown that PSP94 expresses and secretes by the rat lateral 
prostate. This protein is prostate-specific as it is not found in the non-prostatic tissues in 
rat. Moreover, PSP94 is an androgen dependent secretory protein in the rat lateral 
prostate. However, the promoter region of rat or mice PSP94 genes needs further 
characterisation in order to find out whether the promoter of PSP94 is another prostate-
specific promoter for gene therapy approaches. 
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Chapter 5: Conclusions 
1. The mRNA and protein expressions of PSP94 are specifically and mainly expressed 
in the lateral lobe (LP) of rat prostate, moderately in the dorsal lobe (DP), weakly in 
the coagulating gland (CG), negative in the ventral lobe (VP) and seminal vesicle 
(SV). However, no PSP94 mRNA is detected in non-prostatic tissues. 
2. The mRNA expression ofPSP94 is under androgen regulation as shown by its down-
regulation after castration. Among PSP94, probasin and SVSII, the sensitivity to 
androgen ablation is observed with the following decreasing order: SVSII > PSP94 > 
probasin. Moreover, the results of Westem blotting show that the protein synthesis of 
PSP94 in LP is also under androgen regulation. 
3. Besides androgen, the mRNA expressions ofPSP94 and probasin in the castrated LP 
are also regulated by glucocorticoid (DEX) and progesterone (MPA). In contrast, 
SVSII mRNA expression in the castrated LP is solely regulated by androgen and is 
not affected by glucocorticoid and progesterone. 
4. The mRNA expression of PSP94, probasin and SVSII is also examined in the lesions 
of prostatic intraepithelial neoplasia (PIN) induced by sex steroids in the rat lateral 
prostate. The mRNA expressions of these secretory proteins are down-regulated in 
both low-grade and high-grade PINs. 
5. By RT-PCR, a newly identified form (300 bp) ofPSP94 PCR product is detected in 
the Dunning R3327-H and AIT tumors. The probasin mRNA is weakly expressed in 
Dunning R3327-H but absent in AIT. The mRNA expression of SVSII is weakly 
detected in both Dunning R3327-H and AIT tumors. 
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